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ABSTRACT 
The recent identification of TMPRSS2:ETS gene fusions highlighted the 
importance of chromosomal rearrangement and fusion gene development in 
prostate tumourigenesis. We previously reported a recurrent translocation, t(4;6), 
in prostate cancer (PCa) with the breakpoints identified at 4q22 and 6q15 in the 
LNCaP cell line. A small deletion adjacent to the 6q15 breakpoint was found, 
which is consistent with the frequently lost chromosome region previously 
reported and detected by our micro-array analysis. Here I accessed the 
prevalence of the t(4;6)(q22;q15) and the 6q15 deletion and also looked for 
relevant candidate tumour suppressor genes (TSGs) in PCa. Using fluorescence 
in situ hybridisation (FISH) analysis, t(4;6)(q22;q15) was detected in 78 of 667 
clinical, localised PCa samples. Statistical analysis showed it was not 
independently associated with patient outcome but occurred more frequently in 
high clinical T stage, high tumour volume specimens and in those with high 
baseline PSA (prostate-specific antigen) (P=0.001, 0.001 and 0.01 respectively). 
We hypothesised that both t(4;6)(q22;q15) and the 6q15 deletion contribute to 
the inactivation of TSGs at 6q15, which are associated with PCa development 
and progression. Therefore I investigated the TSGs located in this region. Using 
FISH analysis, this deletion was confirmed in 46% (13 in 28) of the PCa 
samples. Using Exon array to systematically detect inactivated genes in this 
region, four candidate genes, CNR1, PNRC1, GJA10 and BACH2 were identified 
with common down-regulation. The real-time PCR analysis validated these exon 
array results. However, with additional controls and clinical cancer samples, only 
two genes (CNR1 and BACH2) still showed significant down-regulation. CNR1 
protein expression was absent in 76.8% (43 in 56) of PCa cases whereas its 
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expression was shown in 83.9% (26 in 31) of benign prostatic hyperplasia (BPH) 
samples as demonstrated by immunohistochemistry (IHC) analysis (p<0.001). In 
contrast, cytoplasmic expression of BACH2 was slightly less in the examined 
PCa cases (14.0%, 12 in 86) compared with BPH samples (6.9%, 2 in 29). 
However, nuclear expression of BACH2 was significantly higher in prostate 
cancer cases (45.3%) than it was in BPH samples (10.3%) (p=0.001). Five of the 
43 PCa samples without CNR1 expression were selected for sequencing and one 
of the five samples had insertion in the CNR1 genomic DNA. The cellular 
function study of PCa cell lines indicated that the CNR1 might function as a 
tumour suppressor involved in cell proliferation and invasion. In conclusion, 
both t(4;6)(4q22;6q15) and the 6q15 deletion are frequent events and the gene 
CNR1 is a candidate TSG at this deletion region in PCa.  
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1 INTRODUCTION 
1.1 Cancer 
1.1.1 Definition and classification of cancer 
Cancer is a collection of diseases that share common features. The two main 
characteristics of cancer are uncontrolled proliferation of the cells within a tissue 
type and the ability of these cells to invade from the original site and migrate to 
distant sites (Alison, 2002). Tumours can be divided, according to their cellular 
behaviour, into two major types: benign or malignant. Benign growths tend to be 
localised without invading surrounding tissue and histologically similar to the 
cell from which they arose. In contrast, malignant tumours are invasive, 
dissimilar to the parent tissue and become life threatening by spreading to other 
parts of the body (Alison, 2002).  
 
Cancer arises from many specialised cell types. By classification of the cellular 
origin, cancers can be divided into four main categories: (1) Carcinomas arise in 
the epithelium and account for 90% of human cancers; (2) Sarcomas are cancers 
of the supporting/connective tissues; (3) leukaemias and lymphomas are 
originated from the blood and lymph glands respectively; (4) Blastomas arise 
from the outer cell layer of the early embryo. However, not all tumours fit into 
the major classifications (Alison, 2002). For example, melanomas derive from 
melanocytes, the pigmented cells of the skin and the retina (Weinberg, 2007). 
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Cancer is believed to be a monoclonal growth with accumulated genetic 
alterations. At the molecular level, six fundamental features (hallmarks) define 
malignant cells: self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis and tissue invasion and 
metastasis (Hanahan and Weinberg, 2000). In recent years, deregulation of 
microRNA, suppressed cancer-related inflammation and increased genomic 
instability have been suggested as additional hallmarks of cancer (Colotta et al., 
2009; Negrini et al., 2010). 
1.1.2 Epidemiology of cancer  
Cancer is a major cause of morbidity in the UK, with 297, 991 new cases 
diagnosed in 2007 (http://info.cancerresearchuk.org/cancerstats/index.htm). 
There are more than 200 different types of cancer, but more than half of the cases 
in the UK were from four major sites: breast (16%), lung (13%), colorectal 
(13%), and prostate cancer (12%). The risk of developing cancer increases with 
age. Nearly three quarters of cancer cases are diagnosed in individuals aged 60 
and over, whereas less than 1% of all cases occur in children aged 0-14 years. 
Other risk factors related to cancer development include gender, ethnicity, family 
history, and lifestyle (http://info.cancerresearchuk.org/cancerstats/index.htm). 
1.1.3 Aetiology of cancer 
1.1.3.1 Genetic factors  
Genetic factors associated with cancer are either germ-line mutations or somatic 
alterations, which cause cancer by eventually affecting two important classes of 
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genes: proto-oncogenes and tumour suppressor genes (Bower and Wasman, 
2006).  
 
Proto-oncogenes are genes coding for proteins that regulate cell growth, cell 
division, survival and differentiation. A proto-oncogene becomes an oncogene as 
a result of genetic alterations, such as mutations, gene amplifications or 
chromosomal translocations. Upon activation, oncogenes can cause cells to 
survive and proliferate instead of undergoing apoptosis (Croce, 2008). According 
to their different functions, products of oncogenes can be classified into five 
groups: growth factors (e.g. platelet-derived growth factor beta polypeptide, 
PDGFB); growth factor receptors (e.g. epidermal growth factor receptor, EGFR); 
signal transducers activated by growth factor binding to receptor (e.g. PI-3 and 
RAS/MAP kinase pathway); transcription factors (e.g. v-myc myelocytomatosis 
viral oncogene homolog, c-Myc); apoptosis regulators (e.g family members of B-
cell CLL/lymphoma 2, BCL2) (Croce, 2008; Alison, 2002).  
 
In contrast to oncogenes, the products of tumour suppressor genes have either a 
repressive effect on the regulation of the cell cycle or promote apoptosis; 
sometimes they do both. Thus tumour suppressor genes cause cancer by loss of 
their function, in most cases, through inactivation of both alleles (Knudson, 
1971). In hereditary cancer syndromes, patients carrying one inactivated tumour 
suppressor gene in their germ line have a normal phenotype, but will develop 
cancer if the second gene is lost due to somatic mutation, loss of heterozygosity 
(LOH) or epigenetic modification. Tumour suppressor genes can be classified 
broadly into three groups according to their functions: (1) Gatekeepers include 
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all direct inhibitors of cell growth (suppressing proliferation, inducing apoptosis 
or promoting differentiation) such as adenomatous polyposis coli (APC), 
retinoblastoma 1 (Rb) and tumour protein p53 (TP53) (van Heemst et al., 2007). 
(2) Caretakers refer to the tumour suppressors that act indirectly to suppress cell 
growth by maintaining the integrity of the genome or repairing DNA (e.g. MSH2, 
ATM protein kinase and TP53) (van Heemst et al., 2007). (3) Landscapers are 
cancer susceptibility genes that act by modulating the microenvironment in 
which cancer cells grow. The landscaper effect was first found in the juvenile 
polyposis syndrome (JPS) wherein the initiating lesions appeared to not occur in 
tumour cells but in the surrounding stromal cells. Loss of function of landscapers 
in stromal cells would induce abnormal growth of the adjacent epithelia (e.g. 
germline mutation of PTEN and DPC4 in JPS) (Howe et al., 1998; Kinzler and 
Vogelstein, 1997; Kinzler and Vogelstein, 1998; Lengauer et al., 1998; Lynch et 
al., 1997; Macleod, 2000; Olschwang et al., 1998).  
 
MicroRNAs (miRNAs), a class of non-coding small RNAs of 19-25 nucleotides 
in length, regulate the translation of about 30% of the protein coding genes 
through binding to complementary sequences in the 3' UTRs of target mRNAs 
(Lewis et al., 2005), therefore miRNAs directly or indirectly affect most cellular 
pathways. The differential expression of miRNAs has been identified between 
tumours and normal tissue, indicating the association of miRNAs with 
tumourigenesis. So far a number of putative oncogenic and tumour-suppressive 
miRNA have been proposed (Medina and Slack, 2008). As an example of 
oncogenic miRNA, miR-17-92 cluster (13q31.3) frequently is over-expressed in 
B-cell lymphomas and other malignancies and acts cooperatively with c-Myc to 
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accelerate tumour development by increasing the tumour resistance to apoptosis 
(Medina and Slack, 2008; Ventura and Jacks, 2009). Regarding tumour-
suppressive activity, lower expression of the let-7 microRNA family has been 
implicated in lung cancer initiation (Yanaihara et al., 2006) and correlated with a 
poor prognosis (Takamizawa et al., 2004). Let-7 performs its tumour suppressor 
role through regulating the oncogenes and proteins involved in the cell cycle, 
such as RAS, HGMA2, myc, CDK6 and CDC25 (Johnson et al., 2007; Johnson et 
al., 2005; Mayr et al., 2007; Sampson et al., 2007).  
1.1.3.2 Environmental factors  
The development of malignancy frequently is linked to environmental factors, 
which usually are divided into three groups: chemical, physical and biological 
factors. Certain kinds of cancers are associated with specific exposure to 
chemical carcinogens. Tobacco, particularly cigarette smoking, is the single 
greatest cause of cancer deaths in the UK. It accounts for more than a quarter 
(29%) of all deaths from cancer and 90% of deaths from lung cancer. Polycyclic 
aromatic hydrocarbons in the tar are carcinogenic. Other chemical agents, such 
as asbestos, wood, dust, soot, arsenic, aflatoxin , also are responsible for certain 
forms of human cancers (Neal and Hoskin, 2009).  
 
The major physical carcinogen is radiation, which may either be ionising, like X-
rays from medical imaging, -particles from radon and -rays from cosmic 
radiation and isotope decay, or non-ionising like ultraviolet light from the sun. 
The physical carcinogen can cause direct damage to the genome, such as DNA 
strand breaks or point mutations. Skin and mucosal surfaces, which are exposed 
to the external environment, are most prone to physical carcinogenic influences.  
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Viruses, as biological factors, have been implicated as carcinogens. The 
integration of the virus genome with the infected host genome may lead to 
deregulation of oncogenes or inactivation of tumour suppressor genes. As a 
consequence, the normal cell can be malignantly transformed. For example, 
hepatitis B virus has been associated with hepatoma, Epstein-Barr virus (EBV) 
with nasopharyngeal carcinoma, B-cell and Burkitt‘s lymphomas and human 
papilloma virus (HPV) with cervical cancer (Damania, 2007). 
1.1.3.3 Immune and endocrine factors 
There is evidence that immunosuppression is related to development of some 
types of cancer. For example, the incidence of non-Hodgkin‘s lymphoma and 
Kaposi‘s sarcoma is increased significantly in patients with acquired immune 
deficiency syndrome (AIDS) (Caceres et al., 2010; Gaidano et al., 1996). 
Similarly, transplant recipients receiving drugs to induce immunosuppression 
have an increased incidence of Kaposi‘s sarcoma, non-Hodgkin‘s lymphoma and 
skin cancer (Neal and Hoskin, 2009).  
 
Over-stimulation of receptors for hormones by endogenous or exogenous 
hormones can lead to excessive cell proliferation and sometimes result in 
malignancy. For instance, chronic severe iodine deficiency causes a rise in 
thyroid-stimulating hormone, leading to goitre and, in some cases, follicular 
carcinoma (Franceschi, 1998). 
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1.1.4 Multi-stage carcinogenesis 
The development of cancer is a complex, multi-step process, which can be 
divided broadly into three sequential phases: (1) tumour initiation, (2) tumour 
promotion and (3) tumour progression (Trosko and Ruch, 1998). In the first 
phase, a cancer stem cell becomes initiated by acquiring irreversible genetic 
alterations leading to partial escape from homeostatic control of growth. The 
promotion phase refers to the process during which the initiated cell clonally 
expands and gives rise to a population of initiated cells. Finally, one of the 
initiated cells acquires additional genetic changes to transform into the malignant 
cell with the new properties of invasion and metastasis (Moolgavkar and 
Luebeck, 2003; Trosko and Ruch, 1998).  
1.2 Genomic instability in cancer 
1.2.1 Genomic instability in cancer 
Genomic instability is a common feature of cancer cells and is present in all 
stages of cancer, from precancerous lesions through to disseminated disease. 
Underlying genomic instability might accelerate the accumulation of these 
mutations in oncogenes and tumour suppressor genes (Geigl et al., 2008). 
Genomic instability refers to a series of spontaneous genomic changes occurring 
at a rate higher than in normal cells (Raptis and Bapat, 2006). There are various 
forms of genomic instability, including chromosomal instability (CIN), 
microsatellite instability (MIN) and CpG island methylator phenotype (CIMP) 
(Geigl et al., 2008). The majority of human malignant tumours are characterised 
by CIN, defined as gain or loss of whole chromosomes or fractions of 
chromosomes with an increased rate. CIN can be classified as numerical and 
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structural instabilities. It has been suggested that CIN may represent an early 
event during carcinogenesis and might therefore be involved in tumour initiation 
(Coleman and Tsongalis, 1999, Geigl et al., 2008). MIN refers to the expansion 
or contraction of the number of oligonucleotide repeats present in microsatellite 
sequences. Currently, genomic instability is best characterised for colorectal 
cancer. CIN and MIN occur in approximately 85% and 15% of colorectal cancer 
respectively (de la Chapelle, 2003) and their occurrence usually is mutually 
exclusive in colorectal cancer cell lines (Abdel-Rahman et al., 2001). In 
colorectal cancer, about 10% of MIN-tumours occur sporadically and in most 
cases, this phenotype overlaps with CIMP, which is characterised by extensive 
promoter methylation (Weisenberger et al., 2006). In fact, some colorectal 
cancers display none of CIN, MIN or CIMP. It might be because of the limitation 
of the detection method used, which might not detect subtle genomic changes 
(Mao et al., 2008), or it is possible that other, as yet unknown, forms of 
instabilities might exist (Geigl et al., 2008). 
1.2.2 Mechanisms of genomic instability 
In hereditary cancers, the presence of MIN is linked to mutations in DNA repair 
genes. Germline mutation in one of the mismatch repair genes (i.e. MLH1, 
MSH2, MSH6 and PMS2) leads to MIN and causes hereditary nonpolyposis 
colorectal cancer, which occurs in approximately 5% of all colorectal cancers (de 
la Chapelle, 2003; Geigl et al., 2008). Biallelic germline mutations in the DNA 
base excision repair gene, MYH, result in increased GC to TA transversion 
frequencies and account for hereditary MYH-associated polyposis colorectal 
cancer (Al-Tassan et al., 2002). In sporadic colorectal cancers, MIN is found in 
most tumours with mutations in the B-Raf oncogene.  
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Compared with MIN, CIN is linked to more complex mechanisms. Numerical 
CIN appears to arise as a result of chromosome segregational defects, which 
have been shown to be caused by several factors, including multi-polar spindles, 
centrosome amplification, abnormal kinetochore-spindle interactions, premature 
chromatid separation and abnormal cytokinesis (Gollin, 2004; Gollin, 2005). 
Structural CIN results from chromosome breakage and rearrangement due to 
defects in cell cycle checkpoints, the DNA damage response and loss of telomere 
integrity. Human papillomavirus interferes with these processes, causing CIN 
and tumour formation in some of the epithelial cells that it infects (Feldser et al., 
2003; Gollin, 2004; Holland and Cleveland, 2009).  
 
Currently it still is unclear whether genomic instability is the primary driving 
force for tumourigenesis, or whether the acquisition of genomic instability is a 
more passive secondary consequence, which occurs during the malignant 
process. However, it has been proposed that different cancers follow alternative 
pathways of initiation, thus the role of genomic instability in carcinogenesis may 
vary depending on the tumour type or nature of the transformed cell (Bayani et 
al., 2007).  
1.3 Chromosomal aberrations in cancer 
1.3.1 Classification of chromosomal aberrations 
Chromosomal aberration reflects an abnormal number of chromosomes or a 
structural abnormality in one or more chromosomes. Aneuploidy occurs when 
individual whole chromosomes are lost (monosomy) or extra whole 
chromosome(s) are gained (trisomy, tetrasomy, etc.) from the normal set of 
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chromosomes (46 chromosomes in human beings). Polyploidy arises when cells 
possess complete extra sets of chromosomes (triploidy, tetraploidy, etc.). It has 
been suggested that polyploidy cells are genetically unstable and precede the 
formation of aneuploid cells (Ganem et al., 2007; Margolis et al., 2003). 
Although it is clear today that aneuploidy is a common genetic feature of solid 
human tumours (Weaver and Cleveland, 2006), its role in malignant 
transformation remains unclear (Ricke et al., 2008).  
 
Structural chromosome abnormalities initiate when there are double strand 
breakages (DSB) in chromosomes, leading to loss, gain or abnormal 
rearrangement of one or more chromosomes. Structural abnormalities include 
deletion, amplification, ring chromosome, translocation, insertion, inversion and 
isochromosome, etc. (Figure 1.1). Unlike aneuploidy, structural abnormalities, 
especially deletions, amplifications and translocations, are an established cause 
of cancer (Holland and Cleveland, 2009).  
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Figure 1.1 Numerical and structural changes leading to chromosomal 
aberrations. 
Adapted from (Albertson et al., 2003; Czepulkowski, 2001). 
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1.3.2 Deletion and amplification in cancer 
Deletion is one of the most frequent genetic alterations detected in cancer cells. It 
can appear in the early stages of carcinogenesis, since deletion has been detected 
in normal cells (Deng et al., 1996). Non-random deletions detected in certain 
regions have been widely interrogated to identify tumour suppressor genes. For 
example, deletions involving regions of chromosome 10 occur in the vast 
majority (>90%) of human glioblastoma multiforme as well as other cancers 
including prostate, renal, small cell lung, and endometrial carcinomas (Eagle et 
al., 1995; Herbst et al., 1994; Morita et al., 1991; Peiffer et al., 1995; Petersen et 
al., 1997; Ransom et al., 1992; Rempel et al., 1993; Trybus et al., 1996). PTEN 
was identified as the tumour suppressor gene located at 10q23−24 (Steck et al., 
1997). Neuroblastomas are characterised by hemizygous 1p deletions. CHD5, 
which was mapped to the smallest region of consistent deletion in a 2-Mb region 
of 1p36.31, was identified as the tumour suppressor (Fujita et al., 2008). Deletion 
of tumour suppressor loci, containing bona fide tumour suppressor genes, such as 
17p13/TP53 and 9p21/ p16INK4a, has been reported in various cancers and these 
changes have contributed to the gene inactivation (Khayat et al., 2009; Kohno 
and Yokota, 2006; Park et al., 1996).  
 
DNA amplification also is a frequent event in tumour cells, in which it plays a 
major role in oncogene activation, by causing an enhancement of gene 
expression (Albertson, 2006). Typical examples are amplification of oncogenes, 
ERBB2, N-myc and EGFR. ERBB2 belongs to the epidermal growth factor 
receptor family. Amplification of ERBB2 at 17q21 occurs in 10–35% of breast 
cancer cases and is linked to poor prognosis for patients with these tumours 
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(Ross and Fletcher, 1998; Slamon et al., 1987; Slamon et al., 1989). The 
increased expression of ERBB2 in tumours led to the development of a therapy 
based on a specific antibody, Trastuzumab, directed against the extracellular 
domain of ERBB2 (Carter et al., 1992). N-myc belongs to the MYC proto-
oncogene family and is fundamental in the development of the peripheral and 
central nervous systems. Amplification of N-myc has been reported to be present 
in 20% of neuroblastomas and associated with more aggressive disease (Pession 
and Tonelli, 2005; Savelyeva and Schwab, 2001). Amplification of EGFR occurs 
in 40% of gliomas and commonly is observed in malignant gliomas (Brandes et 
al., 2008; Vogt et al., 2004).  
 
In recent years, miRNA has drawn great attention as more and more studies have 
shown that miRNAs are involved in the initiation and progression of cancer 
(Garzon et al., 2009). It has also been shown that miRNAs are frequently located 
in minimal regions of loss of heterozygosity and minimal regions of 
amplification (Calin et al., 2004). For example, miR-143 and miR-145 are 
located at 5q33, which frequently is deleted in myelodysplastic syndromes (Calin 
et al., 2004). The miRNA cluster 17-92 is located at 13q31, a region commonly 
amplified in lymphomas (Ota et al., 2004). Therefore miRNAs are now 
becoming the target candidates, together with tumour suppressors or oncogenes, 
to be searched for in recurrent deletion/amplification regions. 
1.3.3 Chromosomal translocation and fusion genes 
Chromosomal translocations have a causal effect in haematological 
malignancies. In 1960, Nowell and Hungerford reported the first consistent 
chromosomal abnormality, a small marker chromosome (Philadelphia 
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chromosome), which presents in 90% of chronic myelogenous leukaemias 
(CML) (Capdeville et al., 2008). Philadelphia chromosome was characterised as 
a reciprocal translocation t(9;22), which creates a fusion gene, BCR-ABL, 
encoding a chimeric protein with increased tyrosine kinase activity (Warmuth et 
al., 1999) and abnormal localisation (McWhirter and Wang, 1991). It has been 
shown that BCR-ABL is essential for the development of CML (Bruns et al., 
2009). Another important component of translocation events was the t(8;14), 
responsible for Burkitt‘s lymphoma. The fusion of the oncogene c-Myc, located 
at the breakpoint region of chromosome 8q24, with the 5‘ region of the 
immunoglobulin heavy chain (IGH) gene results in abnormal timing and levels 
of c-Myc expression (ar-Rushdi et al., 1983; Dalla-Favera et al., 1982). 
Accordingly, chromosomal translocation can play a causal role in malignancy 
through the generation of fusion genes. It can either cause juxtaposing of 
promoter/enhancer elements from one gene with the intact coding region of 
another gene, or cause recombining of the coding regions of two different genes.  
 
Fusion genes have been causally implicated in sarcomas. Sarcomas have at least 
50 different histological subtypes. Chromosomal translocations are present in 
about one fourth of sarcomas diagnosed, but gene fusions occur much more often 
in some subtypes than in others (Mertens et al., 2009). For example, almost all of 
Ewing sarcomas, myxoid liposarcomas and synovial sarcomas harbour chimeric 
genes involving Ewing sarcoma breakpoint region 1 (EWSR1), DNA-damage-
inducible transcript 3 (DDIT3) and synovial sarcoma X breakpoint 1, 2 or 4 
(SSX1, SSX2 or SSX4) genes, respectively, whereas no gene fusion has so far 
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been reported in osteosarcoma, conventional chondrosarcoma or 
leiomyosarcoma (Mertens et al., 2009; Mitelman et al., 2010).  
 
Largely due to technical difficulties and the complexity of carcinoma karyotypes, 
cytogenetic analyses of carcinomas have lagged behind those of haematological 
malignancies and sarcomas (Edwards, 2010). It is now clear that carcinomas also 
have chromosomal abnormalities that result in the formation of fusion genes. The 
first example found in epithelial tumours was in papillary thyroid carcinoma 
(Pierotti et al., 1992). The fusion gene joined the RET proto-oncogene, encoding 
a tyrosine kinase receptor, with the coiled-coil domain containing 6 (CCDC6) 
gene. So far, about ten fusions of RET and five of NTRK1 (neurotrophic tyrosine 
kinase, receptor, type 1) have been found, which occur in up to 50% of papillary 
thyroid carcinomas. Unlike the fusion genes in haematological malignancies, 
which are generated by chromosomal translocation, the most prevalent fusion 
gene, CCDC6/H4-RET, is generated by inversion of a large section of 
chromosome, inv(10)(q11q21) (Pierotti et al., 1992). Since the initial findings in 
thyroid cancers, other gene fusions have been discovered in less well-known 
carcinomas, such as the CRTC1-MAML2 and CRTC3-MAML2 fusions in 
mucoepidermoid carcinoma, the ETV6-NTRK3 fusion in secretory breast cancer 
(a rare form of breast cancer) and translocations of Xp11.2, fusing the TFE3 
gene, in a subset of renal cell carcinomas (Edwards, 2010; Mitelman et al., 
2007).  
 
It was not until the identification of highly recurrent fusion genes in prostate and 
lung cancer that the pivotal role of fusion genes in common epithelial cancer was 
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recognised. The fusion of an androgen-responsive gene, transmembrane protease, 
serine 2 (TMPRSS2) with ETS transcription factor family genes has been 
commonly found in prostate cancer and in some cases of prostatic intraepithelial 
neoplasia (PIN) (Tomlins et al., 2005; Clark et al., 2008; Perner et al., 2007; 
Shah and Chinnaiyan, 2009). The most prevalent fusion gene, TMPRSS2-ERG, 
was caused by either inversion or by interstitial deletion, as the two genes are 
about 3 Mb apart on chromosome 21 (Prensner and Chinnaiyan, 2009; Rabbitts, 
2009). A variety of other fusions mostly are formed by chromosome 
translocations. More detail of fusion genes in prostate cancer is illustrated in 
section 1.6, regarding the genetic alterations in prostate cancer.  
 
Recurrent gene fusions have also been reported in non-small cell lung cancer 
(NSCLCs). The fusion between the anaplastic lymphoma kinase gene (ALK) and 
the echinoderm microtubule-associated protein-like 4 gene (EML4), which was 
created by an inversion of chromosome 2p, has been detected in a subset of 
NSCLCs (Soda et al., 2007). Another tyrosine kinase ROS (highly expressed in 
NSCLCs) also becomes part of a fusion protein in lung tumours, fusing with the 
transmembrane portions of either SLC34A2 or CD74, to create a chimeric kinase 
(Rikova et al., 2007).  
 
The identification of fusion genes in prostate and lung cancer indicates that there 
are more undefined fusion genes in common epithelial cancers. With new 
technologies in sequencing, microarrays analysis and bioinformatics, it is a 
promising time for gene fusion discovery and characterisation of recurrent gene 
fusions in major epithelial cancers (Edwards, 2010). 
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1.4 Technologies for the detection of chromosomal 
aberrations 
Chromosomal aberrations characterise various cancers and have been commonly 
studied in genetic research. The identification of chromosomal aberrations 
largely depends on available techniques. From low resolution banding techniques 
to molecular cytogenetic methods and more recent high-resolution microarray 
techniques, the detection of chromosomal aberrations has been constantly 
improved. Especially, the very recent introduction of a new generation of DNA 
sequencers opens a new era for the systematic discovery of chromosomal 
rearrangements and genomic alterations (Barrett, 2010). 
1.4.1 Banding technology 
Karyotyping is a classical cytogenetic tool to identify chromosomal aberrations in 
cell metaphases (Mitelman, 1995). It usually involves the use of dyes to stain 
individual chromosomes and produce a pattern of alternated dark and light bands 
for each chromosome. Darkness or lightness of bands depends on chromosomal 
condensation. In classic G-banding techniques, with Giemsa as the dye mixture, 
light bands appear to be early replicating, guanosine/cytosine (GC) and gene-rich, 
whereas the dark ones are late replicating, adenosine/thymine (AT) rich and gene-
poor regions. Other alternative banding methods have also been developed. 
However all banding methods fall into two principal groups: (1) bands distributed 
along the whole chromosome, such as G-, Q- (similar banding pattern to G-
banding), and R-banding (reverse band pattern of G-banding); (2) a restricted 
number of bands with staining on specific chromosome structures, including C-
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banding (reveal constitutive heterochromatin), T-banding (visualise telomeric), 
and NORs (show nucleolus organising regions) (Mitelman, 1995).  
 
Banding techniques were used to identify the first translocations in human cancer, 
which is the Philadelphia chromosome in CML (Nowell and Hungerford, 1960). 
However, as banding methods have low resolution and require good quality 
metaphases, they are no longer commonly used for the analysis of genetic 
alterations. 
1.4.2 Molecular cytogenetic technology 
1.4.2.1 Fluorescence in situ hybridisation (FISH) 
FISH is a relatively simple and reliable method, which is routinely applied for the 
study of molecular cancer cytogenetics. It allows the identification and 
localisation of genetic alterations by using specific DNA probe(s) with 
incorporated reporter molecules (Price, 1993). In brief, the DNA probes are 
hybridised to chromosomal loci containing the complementary sequences. Then 
the reporter molecules are detected under a fluorescence microscope. The reporter 
molecule can be a protein, such as biotin or digoxigenin, or a fluorescent 
molecular such as rhodamine or fluoroisothiocyanate. The reporter molecule, as 
labelled nucleotides is incorporated into the probe by nick translation or primer 
extension (Price, 1993).  
 
The FISH technique has been used intensively in both basic research and clinical 
diagnosis for detecting specific translocations, gene amplifications and deletions. 
Recently, the application of the FISH method on paraffin-embedded tissue 
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microarrays has been optimised (Lu et al., 1999; Summersgill et al., 2008). This 
combination of methods enables the detection of specific genetic alterations on a 
large number of clinical samples in parallel. Therefore, it is becoming a promising 
approach to be applied widely in clinical research. 
1.4.2.2 Multiplex fluorescence in situ hybridisation (M-FISH) and 
Spectral karyotyping (SKY) 
The development of M-FISH and SKY technology provides an accurate 
overview of the chromosomes present in a tumour, so that they have been used to 
detect translocations not recognisable by traditional banding analysis (Bayani 
and Squire, 2004). M-FISH use fluorescent dyes that label each chromosomal 
DNA in a different colour combination. As different chromosomes have unique 
spectral characteristics, they are hybridised with varying amounts of the dyes 
(Kearney, 2006). The slight variations of colour are detected by computer and 
the different ratios of colour combinations are translated to a pseudocolour. 
Therefore, each chromosome has one colour. If translocation occurs, more than 
one colour will appear on a chromosome. Spectral karyotyping (SKY) is a 
similar technique to M-FISH. The only difference between M-FISH and SKY is 
the imaging system used to discriminate the fluorophore combination (Bayani 
and Squire, 2004). 
 
Due to the limited resolution, M-FISH and SKY, however, cannot detect 
translocation breakpoints accurately. In addition, metaphases are required for 
these techniques; therefore M-FISH and SKY are used mostly on cell lines rather 
than on clinical samples.  
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1.4.2.3 Comparative genomic hybridisation (CGH) 
CGH is another molecular cytogenetic approach, which detects DNA copy 
number changes. Equal amounts of control and test DNA (e.g. tumour DNA), that  
are differentially fluorophore labelled, are hybridised simultaneously to normal 
metaphases. The ratio of the colours on each chromosomal segment reflects the 
ratio of test DNA to control DNA on that segment. The decreased and increased 
ratios of fluorescent intensities for the test DNA probes represent the deletion 
(losses) and amplification (gains) of the chromosomal regions in the cancer 
genome, respectively (Kallioniemi et al., 1992). The CGH technique does not 
require metaphase spreads but has low resolution. It scans the entire genome to 
detect gains and losses of DNA sequences at a megabase level of resolution.  
1.4.3 Microarray technology 
1.4.3.1 Array Comparative genomic hybridisation  
Based on CGH technology, array CGH was developed. Instead of human 
metaphases, array CGH uses an array of cloned DNAs or synthesised 
oligonucleotides immobilised on a solid surface to achieve the higher resolution 
(Solinas-Toldo et al., 1997). Currently a commercialised CGH array can consist of 
42 million probes distributed uniformly across the entire human genome, allowing 
detection of DNA copy number variations down to ~500 bp resolution 
(http://www.roche.com). Array CGH can find the breakpoints of unbalanced 
rearrangements but does not detect balanced rearrangements, such as reciprocal 
translocations.  
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1.4.3.2 Single nucleotide polymorphism genotyping (SNP) arrays  
SNP array is a new generation of micro-array technique, which apply SNPs 
probes on array chips. SNPs are the most frequent genetic variation in the human 
genome (Dutt and Beroukhim, 2007). According to the NCBI SNP databases, the 
total number of SNPs currently known is around 10 million, thus the average 
overall frequency of SNPs is approximately one per 300 bp. Although SNPs are 
not evenly distributed across the whole genome, they are still the most powerful 
markers to detect genomic alterations. Among the different proposed platforms, 
Affymetrix Human Mapping arrays allow genome-wide studies using 25 
nucleotide long probes and the latest SNP6.0 array chips provide very high 
coverage, that is, the median distance between probes is 1.7 Kb 
(www.invitrogen.com). SNP array has been widely used to detect genome-wide 
genotyping, loss of heterozygosity and DNA copy number changes (Dutt and 
Beroukhim, 2007). 
1.4.4 Next generation sequencing technology 
Next generation of DNA sequencing technology has been developed recently and 
it has provided a different route to systematic discovery of genome 
rearrangements. The new sequencers typically sequence very large numbers of 
DNA fragments simultaneously. In most published work, two instruments, the 
Roche 454 and the Illumina (formerly Solexa)1G, were applied. Briefly, the next 
generation of DNA sequencers work by amplifying individual DNA molecules in 
droplets or bound to glass, respectively, then sequencing them by adding 
nucleotides sequentially, monitoring the addition by light emission or 
fluorescence (Mardis, 2008). So far, DNA sequencing is used to discover 
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genome rearrangements in two main ways. Pieces of genome or cDNA can 
simply be sequenced at random and compared to the reference genome and 
transcriptome. This has worked quite well when applied to cDNA  (Guffanti et 
al., 2009; Maher et al., 2009), but will not detect genomic fusion without a 
fusion transcript. The second way is the paired end read approach, which 
fragments the genome to a defined size and sequences just the ends. The paired 
end approach is very well suited to discovering genome rearrangements 
(Campbell et al., 2008). 
 
The sequencing-based methods are probably already superior for the discovery 
of genome rearrangements, but the molecular cytogenetic tools will remain 
essential for some time yet because of the analysis simplicity (Edwards, 2010). 
1.5 Human prostate cancer 
1.5.1 Prostate histology 
Prostate develops from the urogenital sinus and is comprised of three major 
prostatic zones: the peripheral zone, the central zone and the transition zone, 
which take up 70%, 25% and 5% of the prostatic volume, respectively (McNeal, 
1981). The vast majority of prostate cancers are adenocarcinomas (malignant 
cancer of epithelia originating in glandular tissue). Approximately 75% of 
prostate adenocarcinomas develop in the peripheral zone and 15% in the 
transition zone. Benign prostate hyperplasia (BPH) commonly arises in the 
central zone. The prostate gland is mainly constituted by two distinct cell types: 
basal cells and luminal cells. The basal cells form a layer along the basement 
membrane of each duct, and the luminal cells form a layer above the basal cells. 
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The presence of an intact basal cell layer distinguishes the non-cancerous from 
the cancerous gland.  
1.5.2 Epidemiology  
1.5.2.1 Incidence of prostate cancer in the UK  
Prostate cancer is the most common cancer in men in the UK. Each year about 
36,000 new cases are diagnosed with prostate cancer in the UK. Over the last 30 
years, the incidence of prostate cancer has increased dramatically, although much 
of the increase is due to increased detection through widespread use of the PSA 
test. The incidence of prostate cancer is strongly related to age. More than half of 
prostate cancer cases are diagnosed in men aged over 70 years 
(www.cancerresearchuk.org). 
1.5.2.2 Mortality and survival of prostate cancer patients in the UK 
Prostate cancer is the second most common cause of cancer death in men in the 
UK, following lung cancer. In 2008 there were 10,168 deaths in the UK from 
prostate cancer (http://info.cancerresearchuk.org/cancerstats/).  
 
Survival rates for prostate cancer have been successfully improved over 30 years. 
For men diagnosed with prostate cancer in England, the relative five-year 
survival rate was raised from 31% in 1971–1975 to 77% in 2001-2006 
(http://info.cancerresearchuk.org/cancerstats/) This may reflect the detection of a 
greater proportion of latent, earlier, slow-growing tumours in more recent time 
periods, which would be expected to have a beneficial effect on survival rates. 
There may also have been genuine improvements in survival due to more 
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effective treatment, both for early, aggressive prostate cancers and for advanced 
cases. 
 
Survival from prostate cancer is strongly related to the stage of the disease at 
diagnosis. For localised prostate cancer, five-year relative survival for patients in 
England is 90% or more in 1999-2002, but for the metastatic cancer, five-year 
relative survival is lower, at around 30% (http://info.cancerresearchuk.org/cancer 
stats/).  
1.5.2.3 Risk factors 
Prostate cancer is caused by multiple factors. Epidemiological studies of 
potential genetic, environmental and social issues have provided some clues to 
these underlying factors. The strongest known risk factor of prostate cancer is 
age. According to post-mortem results, approximately 80% of men by age 80 
were shown to have cancer cells in their prostate (Sakr et al., 1996). Although 
prostate cancer can be found in men as young as age 30, prostate cancer 
incidence in men under the age of 40 is extremely rare (Powell et al., 2010). 
Ethnicity is another significant risk factor. The rate of prostate cancer differs by 
as much as 90-fold between populations. The lowest rates are usually in Asian 
men while the highest rates are in African-American population (Gronberg, 
2003). Migration studies have shown that when Japanese people move from 
Japan to the USA, the incidence of prostate cancer in these people increases; 
however, the increase is only to about 50% of the rate for white people and to 
25% of that for African-American people in the USA, indicating the real 
difference between ethnic populations (Reviewed by Gronberg, 2003). Family 
history plays an important role in the incidence of prostate cancer. 
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Approximately 5-10% of all prostate cancer patients have a family history of the 
disease (Bratt, 2002). Men with a family history of prostate cancer have higher 
risk and those whose families have an increased risk of breast cancer are also at 
higher risk of prostate cancer. The association between prostate cancer and breast 
cancer in the same family may be explained, in part, by the suggested increase in 
the risk of prostate cancer among men with BRCA1/2 mutations, which are main 
risk factors in hereditary breast cancer (Gayther et al., 2000; Mitra et al., 2010). 
 
Other risk factors include diet, sexual behaviour, alcohol consumption, exposure 
to ultraviolet radiation and occupational exposure. Red and processed meats have 
been reported as having a strong association with significantly increased risk of 
prostate cancer or death from prostate cancer (Rodriguez et al., 2002; Walker et 
al., 2005). The foods containing lycopenes and selenium probably have a 
protective effect while diets high in calcium may increase risk (McMichael, 
2008).  
1.5.3 Screening 
Prostate cancer is incurable when diagnosed at a late stage. An accurate method 
for early detection therefore is highly desirable. However, no single, effective 
screening test for early prostate cancer is available at the moment. Serum PSA 
measurement alone is used in the USA for men over 50, or men over 45 thought 
to be at high risk of prostate cancer. In general, a PSA value less than 4 ng/mL is 
considered as normal; levels above 10 ng/mL indicate high risk; values between 
4 and 10 ng/mL are the most ambiguous. Men in this range may benefit most 
from refinements in the PSA test, e.g. the PSA density (total serum PSA per 
cubic centimetre of prostatic volume), PSA velocity (change in PSA value 
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overtime) and percentage of free (non-protein-bound) PSA (Alison, 2002; 
McNeal, 1988). 
 
The PSA test alone is not recommended for screening in the UK. There are three 
main reasons: 1) around 15% of men with a normal PSA level have prostate 
cancer (Thompson et al., 2004); 2) about two-thirds of men with an elevated 
PSA level do not have prostate cancer; 3) there is uncertainty about the best way 
to treat early prostate cancer (http://www.cancerhelp.org.uk/type/prostate-
cancer/). A randomized European study of prostate cancer screening recently 
reported that PSA-based screening reduced the rate of death from prostate cancer 
by 20% but was associated with a high risk of over-diagnosis (Schroder, et al., 
2009). 
 
A few new biomarkers discovered have shown some clinical value for detecting 
prostate cancer. Of these novel biomarkers, including human kallikrein 2 (hK2), 
urokinase-type plasminogen activator receptor (uPAR), prostate-specific 
membrane antigen (PSMA), early prostate cancer antigen (EPCA), prostate 
cancer antigen 3 (PCA3), alpha-methylacyl-CoA racemase (AMACR) and 
glutathione S-transferase pi (GSTP-1) hypermethylation, the most promising is 
the PCA3 test (Nogueira et al., 2010; Berney, 2010). PCA3 (9q21-22) is a 
prostate-specific non-coding mRNA, which is over-expressed 60–100 times in 
95% of prostate cancers and prostate metastatic specimens than in benign 
prostate tissue (de Kok, et al., 2002). It has been shown that use of PCA3 in 
combination with PSA significantly increased diagnostic accuracy (Aubin et al., 
2010). Although not approved by the FDA (USA Food and Drug Administration) 
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for prostate cancer detection, a commercial PCA3 test is available (Bostwick 
Laboratory, Glen Allen, VA, USA). Additional clinical research trials are 
required to provide further guidelines for widespread application of the urinary 
PCA3 test (Nogueira et al., 2010). 
1.5.4 Diagnosis and tumour grade 
The PSA test and digital rectal examination are routine initial tests for the 
diagnosis of prostate cancer, but prostate cancer can only be confirmed by 
biopsy. Systematic transrectal core biopsy, with guidance by transrectal 
ultrasound, is the most common urologic procedure used to obtain the tissue 
specimen. For grading adenocarcinoma of the prostate, the Gleason method is the 
one in most widespread usage (Gleason, 1966; Gleason and Mellinger, 1974). 
This system relies on the architectural assessment of tumour growth according to 
histological grades (grades 1-5). The grades 1, 2 and 3 represent tumours that 
most closely resemble normal prostate glands, and grade 4 and 5 tumours show 
increasingly abnormal glandular architecture (Lotan and Epstein, 2010). The 
Gleason score is the sum of the two most common grades. For example, if the 
most common tumour pattern was grade 3, and the next most common tumour 
pattern was grade 4, the Gleason score would be 3+4 = 7. Gleason score ranges 
from 2 to 10, with 2 being the least aggressive and 10 the most aggressive. For 
Gleason score 7, a Gleason 4+3 is a more aggressive cancer than a Gleason 3+4.  
1.5.5 TNM system for tumour stage 
The TNM System is the staging system most commonly used in prostate cancer 
Table 1.1. The TNM system separately assesses the tumour (T), lymph nodes 
(N) and secondary cancer or metastases (M).  
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Table 1.1 TNM Staging for Prostate Cancer* 
STAGE DEFINITION 
T1 Clinically inapparent tumour, not detected by digital rectal examination 
nor visible by imaging 
T2 Confined within the prostate 
T3 Tumour extends through the prostate capsule but has not spread to other 
organs  
T4 Tumour is fixed or invades adjacent structures other than seminal 
vesicles 
  
STAGE DEFINITION 
NX Regional lymph nodes can not be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
  
STAGE DEFINITION 
MX Distant metastasis can not be assessed 
M0 No distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bones 
M1c Metastasis at other site(s) 
* Adapted from CRUK webpage, http://www.cancerhelp.org.uk, with modifications 
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1.5.6 Clinical management 
The latest detailed guidelines for clinical treatment of prostate cancer are 
published in the website of the National Institute for Health and Clinical 
Excellence (http://www.nice.org.uk/Guidance/CG58). In brief, prostate cancer 
cannot be cured when it has metastasised. Immediate hormonal therapy is 
recommended for patients with metastatic disease, which could extend their lives 
by several years. Prostate cancer can be cured when treated early. Patients 
diagnosed with locally advanced prostate cancer should be given dose-escalated 
radiotherapy or a combination of radiotherapy and adjuvant hormonal therapy. 
For the large group of patients diagnosed with apparently localised prostate 
cancer of low-to-intermediate risk, the choice of treatment (active monitoring, 
radical prostatectomy, or any type of radiotherapy) is adapted according to 
tumour characteristics and the patient‘s life expectancy. Because most cases of 
prostate cancer have an indolent course during the first 10 to 15 years, they even 
can be left without active treatment (Albertsen et al., 2005; Johansson et al., 
2004). Men with a life expectancy of less than 10 years should be monitored 
actively as the first step in the treatment. The main difficulty that clinicians face 
is the small number of men diagnosed with localised prostate cancer who will 
have cancer progression and ultimately die if not treated. This progression is 
possible because of future random mutations in the tumour, or some aggressive 
cells that are already present but undetectable (Klein, 2009).  
1.5.7 Prognostic factors 
Prognostic factors provide information about the natural history (outcome) of the 
cancer in an individual and also can be used to estimate probable survival years 
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of patients after treatment. Generally, patients with a high tumour burden have a 
poorer prognosis, whereas patients with a low tumour burden will do much 
better. The prognosis is not linked strongly to the chosen treatment (Damber and 
Aus, 2008). For patients with localised prostate cancer, prognostic risk factors, 
which include clinical T stage, serum concentration of PSA, and biopsy grade or 
Gleason score, are commonly used (Humphrey, 2004; Montironi et al., 2006). 
For patients with stage N1 disease, the median survival is 8 years (Aus et al., 
2003), better than for those with distant metastasis. For patients with distant 
metastases, the prognosis is poor, with an average survival of 24-48 months. 
More metastases on bone scan, raised serum PSA concentrations and high 
concentrations of bone-turnover markers indicate poorer prognosis. After 
treatment of patients with stage M1 disease, the PSA nadir after castration 
provides prognostic information; the lower the PSA, the better the prognosis. 
Circulating tumour cell (CTC) number has been shown to be the most accurate 
and independent predictor of overall survival in castration-resistant prostate 
cancer (de Bono et al., 2008; Scher et al., 2009). So far, there are no other 
informative risk factors to aid in the prognosis and treatment decisions to be 
taken for patients. Efforts to identify prostate cancer prognosticators must 
continue. 
1.6 Genetic alterations in prostate cancer 
As previously illustrated, cancer is caused by an accumulation of genetic 
alterations, which cause inactivation of tumour suppressor genes and/or over-
expression of oncogenes. With emerging genetic and genomic technologies, 
extensive studies have been applied to investigate genetic alterations occurring in 
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prostate cancer. So far, the identification of germline variations and somatic 
alterations of prostate cancer have improved our understanding of molecular 
mechanism of prostate cancer initiation and progression.  
1.6.1 Germline variations in prostate cancer 
In the last decade, linkage analyses largely have been undertaken to unravel 
common germline mutations, which account for families with a significantly 
increased risk of prostate cancer. Several strong candidate genes, such as the 
ribonuclease L 2,5-oligoisoadenylate synthase-dependent gene (RNAseL, 
formally termed hereditary prostate cancer 1 [HPC1]) at 1q25, elaC homolog 2 
gene (ELAC2/HPC2) at 17p11 and the macrophage scavenger receptor 1 gene 
(MSR1) at 8p22, have been reported to be associated with prostate cancer. 
However, most of the studies have not been well replicated (Schaid, 2004). So 
far, no gene has been identified for prostate cancer, which is equivalent to the 
breast cancer gene BRCA1 or the adenomatous polyposis coli gene APC in colon 
cancer with respect to frequency or penetrance. Therefore it is believed that 
much of the genetic basis of prostate cancer arises from multiple, low-risk genes. 
 
In contrast to linkage analysis, which is best suited to studying rare variants with 
high penetrance, genome-wide association studies (GWAS) provide greater 
power to detect small to modest effects on disease risk (Jorgenson and Witte, 
2007). In recent years, GWAS in prostate cancer have revealed over a dozen 
highly replicated, independent germline loci for the disease (Table 1.2) (Duggan 
et al., 2007; Eeles et al., 2008; Gudmundsson et al., 2007a; Gudmundsson et al., 
2008; Haiman et al., 2007b; Thomas et al., 2008a; Witte, 2007; Yeager et al., 
2007). Among all the loci, three regions, including 8q24, 10q and 17q, have 
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received the most attention. The association of 8q24 with prostate cancer was 
first identified through linkage and admixture studies (Amundadottir et al., 2006; 
Freedman et al., 2006) and has also been confirmed through GWAS (Eeles et al., 
2008). At least three distinct prostate cancer susceptibility regions have been 
identified within a ~ 1 Mb segment of 8q24 (Eeles et al., 2008; Gudmundsson et 
al., 2007a; Haiman et al., 2007b). A meta-analysis suggests that the SNPs within 
8q24 may result in a 25-50% increased risk of prostate cancer (Cheng et al., 
2008). SNPs in the 8q24 region have also been associated with colorectal, breast, 
ovarian and bladder cancer (Ghoussaini et al., 2008; Haiman et al., 2007a; 
Kiemeney et al., 2008; Zanke et al., 2007). No known genes reside within the 
8q24 region, but the oncogene MYC is approximately 200 Kb downstream. 
Although no evidence of association between risk alleles in the 8q region and 
expression of MYC in prostate or colorectal cancer has been found (Pomerantz et 
al., 2009b), recent functional studies have described possible mechanisms by 
which SNP rs6983267 increases cancer risk. It has been shown that, in colorectal 
cancer cells, rs6983267 differentially binds transcription factor 7-like 2 
(TCF7L2), which is the main transcriptional effector of Wnt signalling, and the 
partner for -catenin coactivation, while it physically interacts with MYC 
(Pomerantz et al., 2009a). Whether other 8q24 risk loci also interact with MYC, 
and the mechanisms underlying the association of these loci with prostate cancer 
risk, remains unknown. 
 
Two risk alleles were identified on chromosome 10. rs10993994 lies 2 bp 
upstream of the transcription start site of the β-microseminoprotein gene 
(MSMB). This risk allele has been shown to down-regulate MSMB expression by 
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approximately 70% (Buckland et al., 2005). MSMB encodes β-
microseminoprotein (PSP94), which is one of the most abundant proteins in the 
prostate. MSMB is a tumour suppressor and loss of its expression has been 
demonstrated to result in unregulated cell growth and tumourigenesis in prostate 
cancers (Whitaker et al., 2010). 
 
Two distinct loci on chromosome 17 (17q12 and 17q24) have been identified to 
be associated with prostate cancer and the corresponding variants increase the 
prostate cancer risk by approximately 20% independently (Eeles et al., 2008; 
Gudmundsson et al., 2007b; Sun et al., 2008; Thomas et al., 2008a). The 
chromosome 17q12 prostate cancer risk variant rs4430796 decreases the risk of 
type 2 diabetes (T2D) by approximately 10%, which is consistent with the 
finding that there is an inverse association between T2D and prostate cancer 
(Gudmundsson et al., 2007b). rs4430796 locates in intron 4 of the HNF1 
homeobox B gene, HNF1B. It might suggest that there is a common mechanism 
underlying both prostate cancer and T2D, such as in a hormonal or metabolic 
pathway, or HNF1B has pleitropic effects across different tissue (Gudmundsson 
et al., 2007b).   
 
Because of the fact that many risk loci were identified in a few years, it is 
possible that, with larger cohorts of prostate cancer samples, more alleles 
associated with the risk of developing prostate cancer and with the clinical 
behaviour of prostate cancer will be identified in the near future. It is challenging 
to identify the causal variants underlying the associations, because typically there 
are many strongly correlated variants in a given region and also most of the 
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variants do not lie within coding regions of the genome (Varghese and Easton, 
2010). However, it is plausible to believe that, with more risk loci being 
discovered, our knowledge of the mechanisms of carcinogenesis will be 
expanded considerably in the near future (Manolio, 2010). 
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Table 1.2 Common susceptibility loci for prostate cancer identified through 
GWAS* 
Locus SNP Allele 
(-/+) 
Nearby genes and 
potential function 
Reference 
2p15 rs721048 G/A EHBP1: endocytic 
trafficking 
 
(Gudmundsson et al., 2008) 
3p12 rs2660753 C/T Intergenic 
 
(Eeles et al., 2008) 
6q25 rs9364554 C/T SLC22A3: elimination 
of drugs and toxins 
 
(Eeles et al., 2008) 
7q21 rs6465657 T/C LMTK2: endosomal 
membrane trafficking 
 
(Eeles et al., 2008) 
8q24 (region 2) 
 
rs16901979 C/A Intergenic (Haiman et al., 2007b) 
8q24 (region 3) 
 
rs6983267 T/G Intergenic (Haiman et al., 2007b) 
 (Eeles et al., 2008) 
8q24 (region 1) rs1447295 C/A Intergenic (the 
oncogene MYC is 200 
kb downstream) 
 
(Gudmundsson et al., 2007a) 
(Haiman et al., 2007b) 
(Eeles et al., 2008) 
10q11 rs10993994 C/T MSMB: tumour 
suppressor properties 
 
(Thomas et al., 2008a) 
(Eeles et al., 2008) 
10q26 rs4962416 T/C CTBP2: antiapoptotic 
activity 
 
(Thomas et al., 2008a) 
11q13 rs7931342 T/G Intergenic 
 
(Thomas et al., 2008a) 
(Eeles et al., 2008) 
17q12 rs4430796 G/A HNF1B: tumour 
suppressor properties, 
epithelial differentiation 
 
(Gudmundsson et al., 2007b) 
(Thomas et al., 2008a) 
(Eeles et al., 2008) 
17q24 rs1859962 T/G Intergenic (Gudmundsson et al., 2007b) 
(Eeles et al., 2008) 
19q13 rs2735839 A/G KLK2 and KLK3: serine 
protease that affects 
PSA concentrations, 
androgenic 
(Eeles et al., 2008) 
Xp11 rs5945619 T/C NUDT10 and NUDT11: 
apoptosis, DNA repair, 
stress response 
(Gudmundsson et al., 2008) 
(Eeles et al., 2008) 
* Adapted from (Dianat et al., 2009; Varghese and Easton, 2010). 
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1.6.2 Epigenetic alterations in prostate cancer 
Somatic epigenetic alterations are an increasingly recognised
 
phenomenon in the 
development of human cancers, including prostate
 
cancer (Jones and Baylin, 
2002; Jones and Baylin, 2007; Bastian et al., 2004). During prostatic 
carcinogenesis, epigenetic
 
changes appear to be the earliest somatic changes
 
yet 
recognised
 
in human prostate cancer, linking the appearance
 
of epigenetic 
alterations to prostate cancer initiation.  
 
Hypermethylation of glutathione S-transferase (GSTP1) is one of the most 
frequently observed epigenetic alterations, occurring in 72–100% of clinical 
specimens in more than 50 independent analyses (Bastian et al., 2004). GSTP1 
(11q13) encodes an enzyme responsible for detoxifying
 
electrophiles and 
oxidants (Lee et al., 1994). Loss of GSTP1 function likely
 
occurs at the initiation 
of prostatic carcinogenesis, with GSTP1
 
methylation evident in some 5–10% of 
proliferative inflammatory
 
atrophy (PIA) lesions, the earliest prostate cancer 
precursors,
 
and in more than 70% of prostatic intraepithelial neoplasia
 
lesions 
(Nakayama et al., 2003) (Brooks et al., 1998). 
 
A recent review summarised the genes that frequently are methylated in prostate 
cancer (Phe et al., 2010). Since then, frequent methylation of a few more genes 
has been identified in prostate cancer (Table 1.3). The methylation of paired-like 
homeodomain 2 (PITX2) gene has been reported as a prostate specific antigen 
recurrence predictor in patients with post-radical prostatectomy prostate cancer 
(Banez et al., 2010; Schatz et al., 2010). B-cell CLL/lymphoma 2 (BCL2) gene 
was found to be silenced frequently in prostate cancer due to aberrant promoter 
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methylation, possibly indicating a future role of apoptosis-targeted therapy in 
prostate cancer (Carvalho et al., 2010).The methylation of homeobox D3 
(HOXD3) has been identified to distinguish low-grade prostate cancers from 
intermediate and high-grade ones and may have prognostic value when 
considered together with pathological stage (Kron et al., 2010). 
 
It is now clear that epigenetic regulation plays an important role in the 
development and progression of prostate cancer; however, the relative 
importance of the individual genes identified still needs to be clarified. 
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Table 1.3 Genes that are frequently methylated in prostate cancer * 
Gene Location Name 
GSTP-1 11q13 Glutathione S-transferase P1 
CDKN2A 9p21 Cyclin-dependent kinase inhibitor 2 A (p16) 
CCND2 12p13 Cyclin D2 
p14b   
MGMT 10q26 O-6-methylguanine DNA methyltransferase 
ASC 16p11.2 Apoptosis-associated Speck-like protein containing a 
CARD 
AR Xq12 Androgen receptor 
ESR1 6q25.1 Oestrogen receptor 1 
ESR2 14q23.2 Oestrogen receptor 2 
RARβ 3p24 Retinoic acid receptor β 
EDNRB 13q22 Endothelin receptor type B 
RASSF1A 3p21.3 Ras association domain family protein 1 isoform A 
MDR1 7q21.12 Multidrug resistance receptor 1 
CDH13 16q23.3 Cadherin 13 
APC 5q21-q22 Familial adenomatous polyposis 
TIMP3 22q12.3 TIMP metallopeptidase inhibitor 3 
CDH1 16q22.1 E-cadherin 
CD44 11p13 CD44 molecule 
RARRES1 3q25.32 Retinoic acid receptor responder (tazarotene induced) 1 
LAMA3 18q11.2 α-3 laminin 
LAMB3 1q32 β-3 laminin 
LAMC2 1q25-q31 γ-3 laminin 
CAV 1 7q31.1 Caveolin 1 
PTGS2 1q25.2-q25.3 Prostaglandin endoperoxide synthase 2 
RUNX3 1p36 Runt-related transcription factor 3 
WIF1 12q14.3 WNT inhibitory factor 1 
COX2 1q25.2-q25.3 Cyclo-oxygenase 2 
* Adapted from (Phe et al., 2010) with modifications. 
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1.6.3 Somatic DNA alterations 
1.6.3.1 Somatic DNA copy number changes in prostate cancer 
Various technologies have been used to detect somatic DNA copy number 
alterations in prostate cancer, including conventional cytogenetic evaluation of 
chromosomal aberrations, DNA polymorphism analysis for detecting LOH, CGH 
and microarray approaches (aCGH and SNP array) for genome-wide 
investigation of segmental copy number changes.  
 
A number of chromosomal regions have been identified for their frequent 
alterations in prostate cancer. Table 1.4 lists the chromosomal deletions detected 
by conventional cytogenetic analysis.  
 
Application of genome-wide approaches, including CGH, aCGH and SNP array, 
to investigate somatic DNA copy number changes has identified more, and 
confined, regions with gain and loss in prostate cancer. Sun et al. performed a 
combined analysis of 41 studies (including 872 prostate tumours), which applied 
CGH/aCGH approaches to detect DNA copy number variations reported before 
April 2006 (Sun et al., 2007). Eight deletions and five gains in prostate tumour 
genomes were defined as being frequently altered regions since they were 
observed in more than 10% of the examined tumours. In addition, three deletions 
and three gains were found in more than 10% of advanced tumours (Table 1.5)  
 
Since April 2006, ten more studies have performed aCGH or SNP array analysis 
in a total number of 238 prostate tumours to examine the genome-wide DNA 
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copy number alterations.  In each study, the frequent gain/loss regions (at least in 
more than 10% of examined prostate tumours) were described. All the frequent 
loss/gain regions revealed by the previous 41 studies have been confirmed by at 
least one of the ten studies. Table 1.6 and Table 1.7 list the gain/loss regions, 
which have been reported in at least two of the ten studies. One gain region on 8q 
and seven loss regions on 6q, 8p, 10q, 13q, 16q, 17p and 17q respectively were 
reported by more than five of the ten studies. 
 
Chromosome 8q is the most commonly gained region in prostate cancer. It has 
been suggested that 8q gains are associated with prostate cancer progression and 
poor prognosis (Ribeiro et al., 2006b; El Gammal et al., 2010; Holcomb et al., 
2009). c-MYC is the well-defined oncogene located at 8q24. The c-MYC protein 
is a nuclear transcription factor that regulates cell proliferation, autophagy, and 
apoptosis. Over-expression of c-MYC has been identified in the majority of 
clinical prostate cancers and high-grade PIN samples (Gurel et al., 2008). Other 
genes on chromosome 8q have also been implicated as potential targets of 
amplification. Amplification of EIF3S3 (8q23) has been identified to be 
associated with advanced stage in prostate cancer. A recent study reported a 
target gene, TCEB1 (8q21.11), that promotes invasion of prostate cancer cells 
and is involved in development of hormone-refractory prostate cancer (Jalava et 
al., 2009).  
 
Chromosome 8p is the region most commonly lost in prostate cancer. Allelic loss 
on 8p also has been demonstrated in many prostate tumours by LOH analysis 
(Crundwell et al., 1996; Deubler et al., 1997; Oba et al., 2001). Several genes 
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located on chromosome 8p have been examined as candidate tumour 
suppressors, with one of the most promising being NKX3.1. NKX3.1 encodes a 
prostate restricted homeobox protein that is involved in the regulation of prostate 
development (Shen and Abate-Shen, 2003). The NKX3.1 protein is expressed in 
normal prostate epithelium and often is decreased in PIN lesions and in prostate 
tumour cells (Bethel et al., 2006). 
 
Other strong candidate tumour suppressors and oncogenes corresponding to the 
loss/gain regions are detailed in Table 1.8. It is notable that loss of 6q14-6q21 
was one of the most frequent genetic alterations in prostate cancer; however, no 
known strong candidate genes have yet been identified in this region.  
 
Our team recently identified differences in the somatic genomic alterations in 
prostate cancers from two different ethnic populations, suggesting that genetic 
changes might be induced by specific environmental and/or genetic risk factors 
(Mao et al., 2010). 
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Table 1.4 Chromosomal deletions detected by cytogenetic analysis*  
Band No. of 
cases 
No. of 
studies 
Reference 
1q12 5  2 (Carvalho-Salles et al., 2000) (Qi et al., 1996) 
 
3p13 2  2 (Gibas et al., 1985) (Jones et al., 1994) 
 
7q22 6  5 (Atkin and Baker, 1985) (Azar et al., 1997) 
(Lundgren et al., 1988) (Lundgren et al., 1992) 
(Milasin and Micic, 1994) 
 
8p21 3  2 (Lundgren et al., 1992) (Webb et al., 1996) 
 
10q24 10 3 (Atkin and Baker, 1985) (Lundgren et al., 1992) 
 
16q22 2  2 (Webb et al., 1996) (Zitzelsberger et al., 1996)  
 
17p11 3  3 (Konig et al., 1998) (Molenaar et al., 1996)  
(Teixeira et al., 2000) 
* Data were collected primarily from the Mitelman Database of Chromosome 
Aberrations and Gene Fusions in Cancer (Mitelman et al., 2010). Only the 
chromosomes with at least two cases showing deletions and reported in at least 
two studies are listed. 
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Table 1.5 Frequently altered chromosomal regions in prostate cancer 
detected by CGH/aCGH analysis reported before April 2006  
 Band Peak Peak 
frequency 
(%) 
Tumour related genes 
Loss  
2q21.2-2q22.3* 
 
2q22.2 12.42 TTL, ERCC3, BIN1 
4q21.3-4q31.1* 
 
4q27-4q28.1 7.55 MAD2L1, SYNPO2, MAPK10 
 
5q13.1-5q21.3 5q15 13.06 APC, MCC 
 
6q14.1-6q21 
 
6q15 22.24 FOXO3A, GOPC, MAP3K7 
8p21.3-8p21.1 8p21.3 34.09 WRN, WHSC1L1, FGFR1, LZTS1, 
TUSC3, MSR1, NKX3.1, DLC1 
 
10q23.1-10q25.3 
 
10q23.2 11.76 PTEN, TNFRSF6, SUFU, FGFR2 
 
12p13.32-
12p11.23* 
 
12p13.1 6.02 CDKN1B, RECQL, CCND2 
13q14.13-13q22.2 
 
13q21.33 28.04 RB1, FOXO1A, LCP1, RFP2, 
DLEU1, DLEU2, KLF5 
 
15q21.1-15q25.3* 15q23 6.66 TCF12, BUB1B, THBS1 
 
16q13-16q24.3 16q22.1 17.85 ERCC4, CYLD, CBFB, CDH1, 
ATBF1, CDH11, CBFA2T3, 
FANCA, RBL2 
 
18q12.1-18q23 18q21.33-
18q22.1 
12.80 SERPINB5, SMAC, SMAD4, 
MALT1, DCC 
 
Gain 
1q24.1-1q42.3* 1q32.2 7.46 SIL, ABL2 
 
3q23-3q26.33 3q26.1 10.24 GMPS, PIK3CA, MLF1, SKIL, 
CCNL1, ECT2 
 
4q21.21-4q27* 4q26 6.99 NFKB1 
 
7q11.21-7q33 7q21.11 12.48 CDK6, SMOH, TIF1, HIP1, ABCB1, 
MET 
 
8q21.3-8q24.3 8q22.2 25.09 CBFA2T1, WISP1, MYC 
 
9q32-9q34.2* 9q33.3 8.07 ABL1, SET 
 
17q24.1-17q25.3 17q24.1 11.65 MAFG, BCAS3 
 
Xq11.1-Xq23 Xq11.1 10.86 AR 
* Regions with altered copy number frequencies below 10% in all tumours but above 
10% in advanced tumours. 
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Table 1.6 Frequently observed regions of chromosomal loss in prostate 
cancer detected by aCGH/SNP array analysis reported after April 2006. 
Chro. Band Reference 
2 2q14.2 (Watson et al., 2009) (Saramaki et al., 2006) 
 2q31.1 (Watson et al., 2009) (Saramaki et al., 2006) 
 2q22.2 (Saramaki et al., 2006) (Liu et al., 2006) 
3 3p12.2 (Liu et al., 2006) (Kobayashi et al., 2008) 
 3q26.33 (Kim et al., 2007) (Liu et al., 2006) 
4 4p16.3-4p16.1 (Holcomb et al., 2009) (Saramaki et al., 2006) (Holcomb et al., 
2008) 
 4q28.2-4q31.1 (Saramaki et al., 2006) (Liu et al., 2006) (Saramaki et al., 2006) 
(Kobayashi et al., 2008) 
5 5p15.32-5q15.2 (Holcomb et al., 2008) (Watson et al., 2009) 
 5q12.3-5q13.2 (Ishkanian et al., 2009) (Holcomb et al., 2009) 
 5q13.2-5q13.3 (Kim et al., 2007) (Ishkanian et al., 2009) (Kobayashi et al., 
2008) 
 5q14.2 (Watson et al., 2009) (Holcomb et al., 2009) 
 5q23.1 (Holcomb et al., 2009) (Liu et al., 2006) 
6 6q14-6q21 (Saramaki et al., 2006) (Holcomb et al., 2009) 
(Ishkanian et al., 2009) (Watson et al., 2009) (Jiang et al., 2008) 
(Kobayashi et al., 2008) (Holcomb et al., 2008) (Kim et al., 
2007) (Liu et al., 2006) (Paris et al., 2006) 
8 8p23.3-8p12 (Kim et al., 2007) (Paris et al., 2006) (Kobayashi et al., 2008) 
(Holcomb et al., 2008) (Watson et al., 2009) (Holcomb et al., 
2009) (Saramaki et al., 2006) (Liu et al., 2006) 
10 10q23.31 (Kim et al., 2007) (Ishkanian et al., 2009)  (Holcomb et al., 
2008) (Watson et al., 2009) (Liu et al., 2006) 
12 12q13.13 (Watson et al., 2009) (Jiang et al., 2008) 
13 13q14.13-13q21.31 (Kim et al., 2007) (Ishkanian et al., 2009)  (Holcomb et al., 
2008) (Watson et al., 2009) (Liu et al., 2006) (Saramaki et al., 
2006) 
16 16q12.2-16q24.1 (Kim et al., 2007) (Ishkanian et al., 2009)  (Holcomb et al., 
2008) (Watson et al., 2009) (Liu et al., 2006) (Saramaki et al., 
2006) (Kobayashi et al., 2008) (Holcomb et al., 2008) 
(Holcomb et al., 2009) 
17 17p13.1-17q13.1 (Ishkanian et al., 2009)  (Watson et al., 2009) (Liu et al., 2006) 
(Holcomb et al., 2009)  (Saramaki et al., 2006) (Jiang et al., 
2008) 
 17q21.31 (Kim et al., 2007) (Ishkanian et al., 2009)  (Watson et al., 2009) 
(Liu et al., 2006) (Holcomb et al., 2009) 
18 18q21.2-18q21.33 (Kim et al., 2007) (Watson et al., 2009) (Saramaki et al., 2006) 
(Kobayashi et al., 2008) 
21 21q21.3 (Saramaki et al., 2006) (Holcomb et al., 2008) 
 21q22.2 (Ishkanian et al., 2009) (Watson et al., 2009) (Holcomb et al., 
2009) 
22 22q11.2 (Saramaki et al., 2006) (Ishkanian et al., 2009) (Watson et al., 
2009) (Holcomb et al., 2009) 
 22q13.33 (Saramaki et al., 2006) (Holcomb et al., 2009) 
Note: Cytobands that were found in more than five of the ten studies are 
indicated in bold. 
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Table 1.7 Frequently observed regions of chromosomal gain in prostate 
cancer detected by aCGH/SNP array analysis reported after April 2006. 
Chro. Band Reference 
1 1q21.2-1q43 (Holcomb et al., 2009) (Holcomb et al., 2008) (Saramaki et al., 
2006) (Liu et al., 2006) 
2 2p23.3 (Kim et al., 2007) (Holcomb et al., 2008) 
 2p25.1 (Kim et al., 2007) (Holcomb et al., 2009) 
3 3q26.32 (Kim et al., 2007) (Liu et al., 2006) (Paris et al., 2006) 
 3q26.2 (Paris et al., 2006) (Liu et al., 2006) (Kobayashi et al., 2008) 
 3q25.1-3q25.2 (Jiang et al., 2008) (Kobayashi et al., 2008) 
 3q29 (Saramaki et al., 2006) (Holcomb et al., 2008) 
5 5p15.33 (Holcomb et al., 2008) (Saramaki et al., 2006) (Liu et al., 2006) 
 5q35.3 (Holcomb et al., 2008) (Liu et al., 2006) 
7 7p21.3-7p13 (Kobayashi et al., 2008) (Kim et al., 2007) (Holcomb et al., 2009) 
 7q21.2-7q33 (Liu et al., 2006) (Holcomb et al., 2009)  (Kobayashi et al., 2008) 
 7q36.1 (Kim et al., 2007) (Kobayashi et al., 2008) 
8 8q21.13-8q24.3 (Kim et al., 2007) (Paris et al., 2006) (Kobayashi et al., 2008) 
(Holcomb et al., 2008) (Watson et al., 2009) (Holcomb et al., 2009) 
(Saramaki et al., 2006) (Liu et al., 2006) (Ishkanian et al., 2009) 
(Jiang et al., 2008) 
9 9q33 (Kim et al., 2007) (Watson et al., 2009) (Holcomb et al., 2008) 
(Holcomb et al., 2009)  
11 11q13.4-11q13.5 (Paris et al., 2006) (Holcomb et al., 2008) (Holcomb et al., 2009) 
(Liu et al., 2006) 
16 16p13.3 (Holcomb et al., 2008) (Saramaki et al., 2006) 
17 17q25.3 (Paris et al., 2006) (Holcomb et al., 2008) (Saramaki et al., 2006) 
21 21q22.3 (Saramaki et al., 2006) (Watson et al., 2009) 
X Xq12-Xq13.1 (Holcomb et al., 2009) (Jiang et al., 2008) 
 Xq28 (Holcomb et al., 2008) (Saramaki et al., 2006) 
Note: Cytobands that were found in more than five of the ten studies in bold. 
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Table 1.8 Summary of the most frequently reported loss/gain regions, and 
associated key genes, in prostate cancer. 
Band No. of 
studies 
Key Gene 
Loss   
6q14-6q21 10  
8p23.3-8p12 9 NKX3.1 (8p21) 
10q23.31 5    PTEN (10q23) 
13q14.13-13q21.31 6    KLF5 (13q21) 
16q12.2-16q24.1 9  ATBF1 (16q22) 
17p13.1-17q13.1 6       P53 (17p13) 
17q21.31 5  
Gain   
8q21.13-8q24.3 10  c-MYC (8q24) 
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1.6.3.2 Fusion genes in prostate cancer 
The first fusion gene reported in prostate cancer was TPC-HPR in the LNCaP 
cells caused by chromosome translocation, t(6; 16)(p21; q22) (Veronese et al., 
1996). As this fusion was an isolated example from one cell line and therefore of 
unknown wider significance, it attracted little attention (Edwards, 2010). One of 
the most important recent findings in prostate cancer is the identification of 
recurrent gene fusions involving the ETS family of transcription factor genes 
(Tomlins et al., 2005). Initially, androgen-responsive gene TMPRSS2 was 
identified as being able to fuse with ERG (12q23) and ETV1 (12q22), leading to 
the over-expression of these two genes in many prostate tumours. Additional 
ETS gene fusions including ETV4 (17q21) and ETV5 (3q27) were discovered 
shortly after. ETS fusions in prostate cancer exhibit a variety of 5‘ binding 
partners that drive over-expression of the ETS transcription factors. So far, ten 5′ 
binding partners have been identified (Table 1.9). TMPRSS2-ERG is the most 
common of the known fusions, accounting for approximately 90% of all the 
fusions, followed by TMPRSS2-ETV1. Other fusions feature prostate-specific 
genes (KLK2, C15orf21, CANT1, SLC45A3), endogenous retroviral elements 
(HERV_K_22q11.23, FLJ35294), a fatty-acid chain ligase (ACSL3), a DEAD 
box helicase (DDX5) and a housekeeping gene (HNRPA2B1). With the exception 
of HNRPA2B1, C15ORF21, and DDX5, all the other 5‘ partners are androgen-
responsive. 
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Table 1.9 The 5′ binding partners of ETS family genes in prostate cancer 
5‘-fusion 
partners 
Oncogenic ETS transcription factors 
ERG ETV1 ETV4 ETV5 
TMPRSS2-
ETS  
 
TMPRSS2
*
 
 
TMPRSS2
* 
 
TMPRSS2
* 
 
TMPRSS2
* 
 
Other 
androgen- 
inducible 
 
SLC45A3
*
 
 
SLC45A3
*
, 
HERV-K
*
, 
FLJ35294 
CANT1
*
, KLK2
*
 
 
SLC45A3
*
 
 
Androgen- 
repressed 
 
 
 
C15orf21* 
 
 
 
 
 
Androgen-
irrelevant 
 
 
HNRPA2B1 
ACSL3 
DDX5 
 
 
 
* Prostate specific gene 
   
 64 
Recent studies have revealed part, if not all, of the mechanisms underlying 
androgen-induced TMPRSS2-ERG fusion. First of all, androgen receptors (AR) 
bind to multiple intronic regions near break sites in TMPRSS2 and ERG genes 
and juxtapose the translocation loci by triggering intra- and interchromosomal 
interactions. AR then promotes site-specific DNA double-stranded breaks 
(DSBs) at the translocation loci by recruiting multiple enzymatic activities, 
including that of topoisomerase II beta (TOP2B) in the case of intrinsic androgen 
signaling and other nucleases (including activation-induced cytidine deaminase 
(AID) and the LINE-1 repeat-encoded ORF2 endonuclease) in the case of 
exogenous genotoxic stress. Under regulation of DSB repair machinery, DSBs 
are recombined and the TMPRSS2-ERG fusion gene is generated (Mani et al., 
2009; Lin et al., 2009; Haffner et al., 2010). 
 
Although TMPRSS2-ERG fusion occurs in 50-80% of prostate cancer patients, 
the role of the fusion in prostate carcinogenesis is still unclear. Over-expression 
of ERG and ETV1 has been shown to contribute to cellular invasiveness in 
benign prostate epithelial cells (Tomlins et al., 2008) (Cai et al., 2007). 
However, TMPRSS2-ERG fusion is insufficient for the initiation of 
carcinogenesis in mouse models (Tomlins et al., 2008). Therefore it has been 
suggested that over-expression of ERG needs to cooperate with other early 
genomic alterations in prostate cancer, such as loss of the tumour suppressor 
PTEN, to induce an invasive phenotype (Tomlins et al., 2008). 
 
Clinically, the association of TMPRSS2:ERG gene rearrangement with Gleason 
score, aggressive disease, and prognosis is unclear, as multiple studies with 
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conflicting findings have been described (Yoshimoto et al., 2008; Rajput et al., 
2007; Demichelis et al., 2007; Attard et al., 2008; Gopalan et al., 2009). 
However, it has been shown that TMPRSS2-ERG fusions generated by 
intrachromosomal deletions tend to correspond with worse prognoses than do 
those created by inversions (Attard et al., 2008). Furthermore, prostate cancer 
with two or more copies of the 3′ ERG region showed much worse clinical 
behaviour than those lacking this amplification (Attard et al., 2008). 
 
Recent transcriptome sequencing analysis revealed many more fusion genes and 
chromosomal alterations occurring in prostate cancer cells. It has been shown 
that a particular cancer cell line or tissue can harbour multiple gene fusions 
(Maher et al., 2009). With application of next generation sequencing technology, 
there is no doubt that more and more fusion events will be discovered in prostate 
cancer, which will improve our understanding of genetic causes of prostate 
cancer development and further contribute to clinical prostate cancer diagnosis 
and treatment. 
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2 MATERIALS AND METHODS 
2.1 Cell lines and culture conditions 
Six prostate cancer cell lines: LNCaP, DU145, PC3, VCaP, 22RV1 and MDA 
PCa 2b, four immortalised prostate cell lines: PNT1A, PNT2, PNT2C2 and 
RWPE, and the human embryonic kidney (HEK) 293 cell line were stored in 
liquid nitrogen. All the cell lines were thawed at 37 °C immediately after 
removal from liquid nitrogen. The suspension was then mixed with 10 mL 
relevant culture media, pelleted by centrifugation at 1,200 g for 5 mins and re-
suspended in relevant media prior to transfer into tissue culture flasks. With the 
exception of MDA PCa 2b and HEK293 cells, which were maintained in high 
glucose DMEM media (Gibco), all prostate cancer and immortalised cells were 
maintained in RPMI-1640 media (Gibco). Both DMEM and RPMI-1640 were 
supplemented with 10% foetal bovine serum (FBS) and 1% 
penicillin/streptomycin (CRUK). Cells were grown in incubators containing 5% 
CO2 at 37 C and split at 80% confluence by trypsinisation. 
2.2 Primary tissue samples and tissue microarray 
(TMA) construction 
2.2.1 Clinical fresh frozen samples 
15 fresh clinical prostate cancer and 23 BPH specimens were collected from 
Barts and The London Hospital by the Orchid tissue bank. All samples were 
freshly frozen in dry ice immediately after removal from the patients and stored 
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in liquid nitrogen prior to use. The collection of these specimens was approved 
by the Local Ethical Committee. 
2.2.2 Formalin-fixed paraffin embedded (FFPE) clinical 
samples 
A large number of formalin-fixed and paraffin embedded (FFPE) clinical 
samples were used to construct six batches of tissue microarrays (TMAs), 
including a total of 1182 prostate cancer samples, 50 BPH and 16 non-prostate 
non-malignant samples. 
 
The first TMA contained 16 cases of non-prostate non-malignant controls from a 
variety of human tissue types (Table 3.1). The second TMA was constructed 
from 34 benign prostate hyperplasia (BPH) samples collected from the Barts and 
The London Hospital following transurethral resection of prostate (TURP) 
specimens. The third comprised two TMAs constructed from 68 archival 
anonymous prostate cancer samples from radical prostatectomy specimens and 6 
morphologically non-malignant prostate samples obtained from the Barts and 
The London Hospital. These three batches of TMAs were constructed in 
35x22x4 mm blocks of paraffin wax using a manual tissue microarrayer 
(Beecher Instruments, Sun Prairie, WI, USA). Triplicate cores of 1 mm diameter 
were taken from each sample. The fourth batch included three TMAs containing 
124 archival anonymous prostate cancer radical prostatectomy specimens 
collected from Whipps Cross Hospital (London, UK). This batch of TMAs was 
constructed in 35x22x4 mm blocks of paraffin wax. Triplicate cores of 0.6 mm 
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diameter were taken from each sample. The collection of these specimens was 
approved by the Local Ethical Committee. 
 
The fifth batch comprised 24 TMAs constructed from a large cohort of 808 cases 
of TURP prostate cancer specimens. These samples were provided by the 
Transatlantic Prostate Group, which represents a collaboration between Barts and 
The London Hospital, (London, UK), Royal Marsden Hospital, (London, UK) 
and Memorial Sloan-Kettering Cancer Centre, (New York, USA). All the 
patients were managed conservatively without initial treatment except early 
hormone management. Clinical outcome data were available for all cases. The 
median follow-up time was 121 months (8–203 months) and more than 80% of 
the men were diagnosed after the age of 65. The 10-year survival rate of the 
patients was 50% and 17% of the patients died due to prostate cancer (Cuzick et 
al., 2006). TMAs were constructed using a manual tissue microarrayer into 
35x22x7 mm paraffin wax blocks. Up to four tumour cores of 0.6 mm diameter 
were taken from each prostate sample. Ethical approval was obtained from the 
Northern Multi-Research Ethics Committee for the collection of the cohort and 
followed by Local Research Ethics Committee approval at individual 
collaborating hospitals.  
 
A pathologist (D. Berney) examined all samples and graded each cancer 
specimen with Gleason scores. The samples on the fourth batch of TMAs were 
also centrally reviewed by pathologists (D. Berney, C. S. Foster and V. Reuter) 
in the Transatlantic Prostate Group (TAPG).  
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The sixth batch comprised three TMAs with 182 prostate cancer and 10 BPH 
cases obtained from the Changhai Hospital, The Second Military Medical 
University (Shanghai, China). The TMA was constructed in 35x22x7 mm 
paraffin wax blocks. 1.5 mm diameter cores were taken from each sample. 
Collection of this batch of specimens was approved by local ethics committee.  
2.3 Fluorescence in situ hybridisation (FISH) 
2.3.1 FISH probe preparation 
2.3.1.1 DNA extraction from bacterial artificial chromosomes (BACs) 
Thirteen BAC clones, including RP11-18N21, RP11-681L8, RP11-240J11, 
RP11-111J1, RP11-595C20, RP1-214H13, RP1-44N23, RP1-154G14, RP11-
104N3, RP1-102H19, RP1-249N8, RP1-72A23 and RP3-322A2, were obtained 
from the Wellcome Trust Sanger Institute (Hinxton Hall, Cambridge, UK). 
Details of the BACs can be seen in Table 2.1.  
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Table 2.1 Location and length of BAC clones. 
Chr. Location BAC clone Region Length 
 (bps) 
Antibiotic 
 
 
4 
 
 
 
Distal 4q  
RP11-18N21 98,354,298-
98,515,689 
63,210  Chloramphenicol 
 
RP11-681L8 98,513,689-
98,622,889 
161,392  Chloramphenicol 
  
RP11-240J11 98,832,380-
98,895,589 
109,201  Chloramphenicol 
 
 
 
6 
 
 
 
Proximal 
6q 
RP11-111J1 87,249,921-
87,344,749  
97,534 Chloramphenicol 
 
RP11-595C20 87,344,650-
87,442,183  
59,031 Chloramphenicol 
 
RP1-214H13 87,576,952-
87,635,982 
94,829  Kanamycin  
 
 
 
6 
 
 
 
6q15 
Deletion 
RP1-44N23 90,814,536-
90,843,275 
28,740 Kanamycin  
 
RP1-154G14 91,251,386-
91,352,280 
100,895 Kanamycin  
 
RP11-104N3 91,549,094-
91,609,835 
60,742 Chloramphenicol 
 
6 
 
6q15 
Deletion 
RP1-44N23 90,814,536-
90,843,275 
28,740 Kanamycin  
 
RP1-154G14 91,251,386-
91,352,280 
100,895 Kanamycin  
 
6 
 
Distal 
CNR1 
RP1-102H19 88,009,641-
88,111,280 
101,640 Kanamycin  
 
RP1-249N8 88,688,904-
88,750,812 
61,908 Kanamycin  
 
6 
 
Proximal 
CNR1 
RP1-72A23 89,632,912-
89,781,452 
148,540 Kanamycin  
 
RP3-322A2 90,145,402-
90,277,901 
132,499 Kanamycin  
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The method for BAC DNA extraction was modified based on a standard Qiagen-
Tip method without organic extractions or columns. To initiate single clone 
culture, BAC clones were cultured on the lysogeny broth (LB) agar containing 
chloramphenicol (20 µg/mL) or kanamycin (25 µg/mL) (Sigma) and incubated 
overnight at 37 °C in an incubator. A single isolated bacterial colony was 
inoculated into 5 mL LB media supplemented with 12.5 g/ml chloramphenicol 
or kanamycin. The bacteria were then cultured for 12 h on an oscillating 
incubator shaking at 225-300 rpm at 37 C. 1.5 mL of bacterial culture was 
harvested by centrifugation for 5 mins at 10,000 rpm in a tabletop centrifuge. 
The bacterial pellet was re-suspended in 150 μL P1 solution (Table 2.2) and 
lysed with 150 μL of P2 solution. The bacterial lysis solution was mixed gently 
by inverting the tube 4 times and left at RT for 5 mins until the cell suspension 
cleared. 150 μL of P3 neutralisation solution was added slowly and the tube was 
gently inverted 4 times before being placed on ice for 10 mins. The tube was 
then centrifuged at 13,000 rpm for 20 mins. The supernatant was transferred to a 
fresh tube and centrifuged again at 13,000 rpm for 5 mins. The supernatant was 
then mixed with 0.8-volume ice-cold isopropanol at -20 C for 15-30 mins (or 
overnight). The BAC DNA was ultimately precipitated after spinning the tube at 
13,000 rpm for 15 mins. The DNA pellet was washed with 0.5 mL fresh 80% 
ethanol and then centrifuged at 13,000 rpm for 5 mins. The supernatant was 
carefully aspirated off and the DNA pellet was left to air-dry at RT before 
dissolving in 30 μL Tris-EDTA (TE) buffer. The concentration and quality of the 
DNA was assessed by spectrophotometer ND-1000 (Nanodrop, USA) as well as 
running a 1% agarose gel (Invitrogen, Paisley, UK). 
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Table 2.2 Solutions for plasmid extraction 
Buffer Ingredient  Concentration 
P1 Tris 
EDTA 
RNase A 
50 mM (pH 8) 
10 mM 
100 g/ml 
P2 NaOH 
SDS 
0.2N 
1% 
P3 KOAc 3M (pH 5.5) 
 
2.3.1.2 BAC DNA amplification 
BAC DNA was amplified before labelling. The amplification was achieved using 
the GenomiPhi amplification V2 kit (GE Healthcare) following the 
manufacturer‘s guidelines. Briefly, BAC DNA was heated to 55 C for 5 mins 
and then centrifuged at 13,000 rpm for 10 mins. 1 μL BAC DNA (10 ng -1 g) 
was taken from the top of the supernatant and then added to 9 μL sample buffer 
before heating at 95 ºC for 3 mins. After cooling on ice for 5 mins. 1 μL 
polymerase and 9 μL reaction buffer were added to DNA/sample buffer mix and 
kept at 30 ºC for 1.5 h for amplification. The polymerase was then inactivated at 
65 ºC for 10 mins. A DNA smear should be seen after running 1 μL of amplified 
DNA on a 1% agarose gel, to confirm the amplification. 10 μL of amplified 
DNA was purified using standard phenol/chloroform extraction. Simply, 90 μL 
1x TE (10 mM TrisHCl pH75/1 mM EDTA) was added to 10 μL DNA. Then 
100 μL (1 volume) 1:1 phenol/chloroform was added and mixed before being 
centrifuged at 13,000 rpm for 1-2 mins. The top aqueous phase was transferred to 
100 μL (1 volume) chloroform followed by spinning at 13,000 rpm for 1-2 mins. 
The aqueous phase was then transferred and mixed with 5 μL  (1/20 volume) 4 
M NaCl and 100 μL isopropanol (2.5 volume ethanol). After incubation at -20 C 
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for 20 mins, the DNA was precipitated by centrifugation at 13,000 rpm for 20 
mins. The DNA pellet was washed with 1 volume fresh 80% ethanol and 
centrifuged at 13,000 rpm for 10 mins. The supernatant was discarded and the 
DNA pellet was left to air-dry at RT before dissolving in 15 μL TE. The 
concentration of DNA was determined by the Nanodrop technique. 
2.3.1.3 BAC DNA labelling 
300 ng amplified DNA was added to distilled water to reach the final volume of 
24 μL.  20 μL random primer (BioPrime labelling kit, Invitrogen) was added and 
the tube was heated up to 95 ºC for 5 mins before cooling on ice for 10 mins. 
Probes for FISH analysis were labelled either by Biotin or digoxigenin (DIG). 
For biotinylated probes, 5 μL of 10 x dNTP (BioPrime labelling kit, Invitrogen) 
was added to DNA/primer mix, whereas for DIG labelled probes, 1.75 μL DIG-
11-dUTP (pH 7.5, Roche) and 5 μL special DIG 10x dNTP (1 mM dATP, dGTP, 
dCTP, and 0.65 mM dTTP) was used. After 1 μL Klenow (BioPrime labelling 
kit, Invitrogen) was added, the tubes were incubated in a water bath at 37 ºC for 
3 h. This was followed by the addition of 5 μL stop buffer (BioPrime labelling 
kit, Invitrogen). All labelled probes were cleaned up using Microspin G50 
columns (GE Healthcare, UK). Briefly, G50 columns were spun at 3,500 rpm for 
1 min and then washed twice with 200 μL 1x TE at 3,500 rpm. DNA was added 
to the centre of the column and spun at 3,500 rpm for 2 mins. The concentration 
of DNA was then measured (expect ~90-150 ng/l). 30 μL Cot-1 DNA (1 g/l) 
and 1 μL salmon sperm (10 g/l) were added and the DNA was precipitated by 
adding 4 l 4 M NaCl and 222 μL 100% ethanol and spinning at 13,000 rpm for 
10-20 mins. The pellet was rinsed with 100-200 μL fresh 80% ethanol and air 
dried before being dissolved in 20 μL H2O.  
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2.3.1.4 Preparation of metaphase slides 
Slides (HV Skan Ltd) were immersed in acetic acid over night and then washed 
with distilled water prior to use. The slides were stored in fresh distilled water at 
4 ºC prior to use.  
 
Metaphase slides were prepared from human lymphocytes. Briefly, 0.5 mL of 
fresh blood collected from a male or female healthy donor was mixed to 10 mL 
of cell culture medium containing phytohaemagglutinin in a small cell culture 
flask and incubated at 37 ºC for 72 h. Colcemid (Invitrogen) was added into the 
flask for 2-4 h at a final concentration of 0.04 L/mL, in order to maintain 
lymphocytes in metaphase. Lymphocytes subsequently were pelleted through 
centrifugation and then re-suspended in 10 mL of 0.075 M potassium chloride 
(KCl), which is a hypotonic solution used to enlarge cells for adequate spreading 
of metaphase chromosomes. After 10 mins incubation at 37 ºC, 10 mL of 
fixation solution, acetate/methanol (1:3, v/v), was added drop-wise to the pellet. 
Cells were pelleted through centrifugation for 6 mins at 1,000 rpm. This step was 
repeated twice before final re-suspension of the pellet into a small volume of fix 
solution. The lymphocyte suspension was then dropped on pre-cleaned slides and 
left to air-dry. The slides were kept at - 20 ºC until further use.  
2.3.2 FISH analysis 
2.3.2.1 Confirmation of BAC clone location and probe labelling 
efficiency 
The location of BAC clones and probe labelling efficiency was examined by 
FISH hybridisation (as described below) to normal human lymphocyte 
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metaphase slides, prepared as described above. Subsequently, the probes 
producing sharp FISH signals in the correct regions were applied for FISH 
analysis on TMAs. 
2.3.2.2 Hybridisation and post-hybridisation washes 
4 µm TMA sections were cut onto SuperFrostPlus glass slides (VWR 
International, Poole, UK) and baked at 65 C over night. TMA slides were 
dewaxed in Xylene at 55 C three times, each for 7 mins, followed by washing in 
100% ethanol twice, 3 mins each. Then the tissue was fixed with boiling ethanol 
and washed twice in H2O, 3 mins each. The slides were washed in pre-treatment 
buffer (SPoT-light tissue pre-treatment kit, Zymed, South San Francisco, CA, 
USA) at  98 C for 15 mins and digested with pepsin solution (Digest All-3, 
Invitrogen, Paisley, UK) for 4.5 mins at 28 C. Then the slides were washed in 
water twice, 3 mins each, and air-dried. For each slide, 300 ng probes (1.5 μL) 
were needed and they were mixed with 1 μL COT-1/sperm (10 g/ μL COT-1, 2 
g/ μL sperm) and 9.6 μL hybridisation buffer (Table 2.3). Each slide was co-
denatured with 13 μL such probe/hybridisation buffer mix at 98 C for 7 mins at 
37 C overnight for hybridisation.  
 
Table 2.3 FISH Hybridisation buffer 
Components Volume 
DI formamide 600 μL  
dextran sulphate 120 mg 
20x SSC 120 μL  
EDTA (500 mM, pH 8) 028 μL  
Salmon sperm (10 mg/ml) 40 μL  
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2.3.2.3 Post-hybridisation wash and hybridisation signal detection 
by adding fluorescent antibodies 
The cover slip was removed from the slide before it was rinsed 3 times in 2x 
SSC at 42 C. The slide was then washed twice in 50% formamide/2x SSC at 42 
C, 4 mins each. After the slide was washed twice in 2x SSC at 42 C, 5 mins 
each, it was washed in SSCT (4x SSC, 0.5% Tween) once at RT. 
 
Before adding fluorescent antibodies, the slide was incubated with 200 μL 
SSCTM (05 g Marvel milk powder dissolved in 10 mL SSCT, then the mix 
solution was filtered by 045 m filter) at 37 C for 15 mins. The slide was 
washed in SSCT for 3 mins at RT. For each slide, 200 μL SSCTM with 1 μL 
Streptavidin-Cy3 conjugate (Sigma-Aldrich, Poole, UK) and 200 μL SSCTM 
with 1 μL anti-DIG-FITC (Roche, Welwyn Garden City, UK) were required. The 
slide firstly was incubated with 200 μL streptavidin-Cy3/SSCTM and then with 
200 μL anti- DIG-FITC/SSCTM under the same conditions at 37 C for 10 mins. 
The slide was washed by phosphate buffered saline (PBS) solution twice, 5 mins 
each, and shortly dehydrated in 70% ethanol. 20 μL Vectashield anti-fade 
containing DAPI (Vector labs, Burlingame, CA, USA) was mounted on each 
slide and a 22x50 mm cover slip was placed on the top. Slides were stored at 4 
C before scanning. 
2.3.2.4 Re-hybridisation 
For some slides, that needed to be re-hybridised with different probes, the 
previous signal was removed first. Briefly, the cover slip was removed by 
soaking in SSCT for 5 mins and then the slide was washed in 2x SSC twice with 
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agitation, each for 10 mins. After being washed in 2x SSC at 68 C for 2 mins, 
the slide was soaked in 70% formamide/2x SSC at 68 C for 4 mins to remove 
hybridised probes. The slide was washed in 2x SSC for 2 mins at RT and then in 
water for 3 mins. The slide and probes were co-hybridised and incubated as 
illustrated in 2.3.2.1. 
2.3.2.5 Image scanning and analysis   
All the TMA slides were scanned at 40x magnification with seven 0.5 µm z-
stacks using an Ariol SL-50 system (Applied Imaging, San Jose, CA, USA) with 
an upright fluoresence microscope (Olympus BX61). Images were then stored 
for future analysis. 
 
Evaluation of the FISH results in each core was performed in a double blind 
manner. A minimum of 50, and in most cases (80%), out of 100 cells with both 
green and red signals in a continuous tissue area were counted. FISH signal co-
localisation was defined as a red and a green signal overlapping or separated by a 
distance of less than one signal-diameter. For FISH signal break-apart assay, 
chromosome split was defined as a red and a green signal separated by a distance 
of more than two signal-diameters. Cores with high background or very weak 
signals that affected the signal assessment were excluded from analysis. Cases 
with less than 50 scorable cells were excluded from data interpretation. 
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2.4 Genomic DNA sequence analysis 
2.4.1 Genomic DNA extraction from FFPE prostate cancer 
specimens 
Twelve 10 µm slices of paraffin-embedded tissue sections of each prostate 
cancer sample were cut onto mega twinfrost slides (MAD-1400-02A, CellPath, 
UK) using a microtome (LEICA, UK). The first and last sections of each sample 
were stained with haematoxylin and eosin (H&E). A pathologist (L.Y. Xue) 
examined the H&E sections and marked the tumour area on the first section after 
confirming that the last sections of each sample had a similar size of tumour 
tissue area as with the first sections. Tumour tissues from each sample were 
macro-dissected using scrapers and directly collected in 1.5 mL micro-tube 
containing 1 mL xylene. The tubes were kept for 10 mins at 65 °C and then the 
supernatants were discarded after centrifugation at 13,620 g for 5 mins. The 
procedure was repeated three times and the last round of centrifugation was 
performed at maximum speed. The pellet was washed in a descending series of 
ethanol dilutions (100%, 95% and 75%). Every change was preceded by 
homogenisation and centrifugation at maximum speed for 5 mins. The pellet was 
washed in 1 mL of Tris-NaCl-EDTA (TNE) buffer followed by centrifuging at 
maximum speed for 5 mins. A volume of 490 µL of lysis solution (440 µl TNE, 
50 µL of 10% SDS) and 10 µL of proteinase K (25 mg/mL) (0.5 mg/mL) was 
added to the pellet and vortexed for 5 s, followed by an overnight incubation at 
55 °C. 10 µL of proteinase K (25 mg/mL) was added on the second day and the 
third day followed by overnight incubation at 55 °C. After incubation, 5.2 µl of 
RNase A (10 mg/ml) (final concentration, 100 µg/mL) was added to each tube 
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followed by incubation at 37 °C for 1 h. Following the addition of another 10 µL 
of proteinase K (25 mg/mL), the samples were incubated at 55 °C for 1.5 h. The 
genomic DNA was then purified using phenol (Sigma) and chloroform (Fluke). 
Briefly, an equal volume of phenol/chloroform (1:1, v/v) was added to each 
reaction tube. The samples were then vortexed at slow speed for 5-10 s and 
centrifuged at 4,000 rpm for 15 mins. The aqueous phase was transferred into a 
new 1.5 mL tube. The phenol/chloroform extraction was repeated once. The 
equal volume of chloroform was then added and the aqueous phase (upper layer) 
was transferred into a 1.5 mL tube after repeating the vortex and centrifuging 
step. Equal volume of isopropanol and 1/10 volume of 3 M NaOAc (pH5.2, 
Invitrogen) were added. The tube was kept at -80 °C for 30 mins, and then 
centrifuged at 13,000 rpm at 4 °C for 10 mins. The pellet was washed by 1 mL of 
70% ethanol. After centrifugation at 13,000 rpm at 4 °C for 5 mins, ethanol was 
removed and the pellet was left to air dry at RT. DNA was dissolved in distilled 
water and the concentration was measured using a Nanodrop.  
2.4.2 Polymerase chain reaction (PCR) analysis  
All primers applied were ordered from Sigma. PCR reactions with genomic 
DNA template, extracted from paraffin-embedded samples, were all performed 
using Phusion DNA polymerase (Finnzymes), 5x GC buffer (Finnzymes) and 
dNTP (10 mM each) (Invitrogen). Primer sequences, PCR working conditions 
(temperature and time of annealing and extension) and expected sizes in 
reference human genome are listed in Table 2.4. All reactions were preceded by 
initial heating at 98 C for 2 mins and ended with heating at 72 C for 10 mins. 
Each reaction was 35 cycles with denaturing at 98 C for 10 s. PCR products 
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were purified using a PCR purification kit (Qiagen) according to manufacturer‘s 
instruction. The concentration of each purified sample was tested using a 
Nanodrop and then the concentration was adjusted to around 100 ng/µL. 
Sequence analysis service was provided by the Genome Centre (William Harvey 
Research Instititute, Queen Mary). The BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystem) was applied. Briefly, the sequencing 
reaction mix was made as described in Table 2.5. The reaction was performed in 
a thermo-fast 96-well semi-skirted plate (ABgene) under the following 
conditions: 96 ºC for 30 s, 50 ºC for 15 s and 60 ºC for 1 min for 25 cycles and 4 
ºC for 2 mins. Unincorporated Big Dye was removed through the following 
procedures: 30 µL of 96% Ethanol: 7.5 M Ammonium Acetate (27.9:2.1, v/v) 
was added to each sample well. The plate was sealed with a new PCR seal and 
inverted 5 to 10 times to mix. Then the plate was spun at 4,388 rpm at 4 °C for 
35 mins. The supernatant was tipped off immediately onto tissue paper. The plate 
was inverted on fresh tissue paper and then spun again at 1,246 rpm for 30 s. 100 
μL of chilled 70% ethanol was added to each well. Then the plate was spun at at 
4,388 rpm at 4 °C for 6 mins. The supernatant was tipped off immediately and 
the plate was spun upside down on tissue paper at 1,246 rpm for 30 s. The plate 
was left to air dry for 10 mins. 10 µL of distilled H2O was added to each well to 
re-suspend the amplified PCR products. 8 μL of highly deionised formamide 
(Applied Biosystem) was added to each well before the plate was sealed. The 
plate was pulse-centrifuged to at 4,388 rpm and placed assembly on the 
ABI3730xl machine for sequencing. Table 2.6 lists the sequencing primers for 
the gene CNR1. PCR products, which could not generate sequencing data, were 
cloned into a T-vector (Invitrogen) according to the manufacturer‘s instructions 
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and sequenced with a T7 promoter primer and M13 reverse primer. The detailed 
procedure for cloning is described in the plasmid construction section, 2.7.3. 
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Table 2.4 PCR primers for CNR1 sequencing and breakpoint mapping 
No. 
PCR 
Primer 
Sequence Condition 
Expected 
size 
Genome 
position 
1 Full fwd 5'-GAGGTTATGAAGTCGATCCTAG 
ATGGC 
65°C-30s 72°C-1.5 mins 1415bp 21268-22692 
 full rvs 5'-TCACAGAGCCTCGGCAGACGTG   
2 P1 fwd 5‘- CCTTCCTACCACTTCATCG 55°C-30 s 72°C-1 min 681bp 21724-22404 
 P1 rvs 5‘- CGTCTTAATGAGCTTGTTCA   
3 P2 fwd 5'-CCTGTGGGTCACTTTCTCAGTC 60°C-30 s 72°C-1 min 897bp 21219-22115 
 P2 rvs 5'-CCGATCCAGAACATCAGGTAG   
4 P3 fwd 5'-TGGCCTATAAGAGGATTGTCACC 61°C-30 s 72°C-1 min 787bp 21938-22724 
 P3 rvs 5'-TCTTTTCCTGTGCTGCCAG   
5 P4 fwd 5'- AAGTCTCTCTCGTCCTTCAAG 56°C-30 s  72°C-30 s 286bp 21523-21808 
 P4 rvs 5'- CGTGGAAGTCAATGAAGC   
6 P2 fwd 5'-CCTGTGGGTCACTTTCTCAGTC 58°C-30 s 72°C-30 s 590bp 21219-21808 
 P4 rvs 5'- CGTGGAAGTCAATGAAGC   
7 P6 fwd 5'- AAGGGTAAGACCTGGCAGAGTTG 64°C-30 s 72°C-15 s 134bp 742-875 
 P8 rvs 5'- AAACACCGACGCACGATTCG    
9 P10 fwd 5'-GCTTCCTCAGTTCTCACTAGCTC 60°C-30 s 72°C-20 s 337bp 20619-20955 
 P10 rvs 5'-TCAGTGTGTGAATCCAGGAAGG   
10 P11 fwd 5'-ACGCCATCCCTGAACTTTG 60°C-30 s 72°C-20 s 229bp 21010-21238 
 P11 rvs 5'-CTGAGAAAGTGACCCACAGG   
11 P12 fwd 5'-TTCTCACCATTCGGCTTATTTG 60°C-30 s 72°C-30 s 396bp 21173-21569 
 P12 rvs 5'-CCACACTGGATGTTCTCCTC   
12 P13 fwd 5'-AGCTTTCATTCCCTGCTGAA 60°C-30 s 72°C-25 s 345bp 3459-3804 
 P13 rvs 5'-GAAAAATCAGCAAAGCAGGC   
13 P14 fwd 5'-TTGCAAGTGCTTTGGTCAAC 61°C-30 s 72°C-15 s 192bp 10860-11051 
 P14 rvs 5'-TCTGCATAATTCAAAGCCCC   
14 P15 fwd 5'-ACAAGAGCCTGAGGGTCAGA 61°C-30 s 72°C-15 s 293bp 18607-18900 
 P15 rvs 5'-TCTCATCACTGCTCACCAGG   
15 P16 fwd 5'-GCAGCTACATCCCCCAAAGCCT 67°C-30 s 72°C-15 s 152bp 13681-13833 
 P16 rvs 3'-GGCAGGAAAACTGCTCTCTGCAT   
16 P17 fwd 5'-TCTGGGTGCAGTGCTTGCTC 64°C-30 s 72°C-15 s 163bp 15330-15493 
 P17 rvs 3'-TGGACTGGTGACACTGAGCCT   
17 P18 fwd 5'-GTGGGAGGGGCTGGTCAGGA 69°C-30 s 72°C-15 s 174bp 16768-16941 
 P18 rvs 3'-TGGCCCTGAGTGACTTGCTGC   
18 P19 fwd 5'-GAGCAGCAAGTCACTCAGG  59°C-30 s 72°C-20 s 317bp 16919-17236 
 P19 rvs 5'-CCTTAGGTTCCCTGTTCATCTG   
19 P20 fwd 5'-CAGACAGATGAACAGGGAACC  59°C-30 s 72°C-25 s 353bp 17211-17564 
 P20 rvs 5'-TGAACCAGTTCTGCACACC    
20 P21 fwd 5'-CTGGTTCAGAAGCCCAGAC 58°C-30 s 72°C-30 s 407bp 17557-17964 
 P21 rvs 5'-AAGGGATCTAGCCTGGAGAG   
21 P22 fwd 5'-TCTCCAGGCTAGATCCCTTG 60°C-30 s 72°C-25 s 354bp 17946-18300 
 P22 rvs 5'-GAACACCCTTTCTGGGCTC    
22 P23 fwd 5'- TCTGTTTGGGTATTCTGGGAG  59°C-30 s 72°C-2 mins 3381bp 18264-21645 
 P23 rvs 5'-GAGGGACAGGACTGCAATG    
23 P24 fwd 5'-GAGCAGCAAGTCACTCAGG  58°C-30 s  72°C-3 mins 4726bp 16919-21645 
 P24 rvs 5'-GAGGGACAGGACTGCAATG    
24 P25 fwd 5'-GAGCAGCAAGTCACTCAGG  58°C-30 s  72°C-3 mins 4691bp 16919-21610 
 P25 rvs 5'-GGTTCAGGACCATGAAACACTC    
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Table 2.5 BigDye sequencing reaction mix 
Components Volume 
PCR product 4 L (100 ng) 
Sequencing primer 1 L 
BigDye Terminator Master Mix v 3.1 0.5 L 
Better buffer 3.5 L 
DMSO 0.5 L 
 
 
Table 2.6 Sequence of the primers for CNR1 sequencing 
No. Sequence 
1 5'- AAGTCTCTCTCGTCCTTCAAG  
2 5'- ACCGCAAAGATAGCCGCAAC  
3  5'- TCTGTTCATCGTGTATGCG  
4 5'- ATGCTCTGCCTGCTGAACTC  
5 5'- TCTCCCGCAGTCATCTTCTC  
6 5'-GAGGTTATGAAGTCGATCCTAGATGGC 
7 5'-TCACAGAGCCTCGGCAGACGTG 
8 5‘- CCTTCCTACCACTTCATCG 
9 5‘- CGTCTTAATGAGCTTGTTCATC     
10 5‘- CCTCTGCTTGCAATCATGG 
11 5‘– ACACGTGGAAGTCAATGAAGC       
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2.4.3 Genome walking assay 
The Genome walking assay was performed mainly according to the  
GenomeWalker universal Kit user manual (Clontech) with slight alterations. All 
genome walking related primers and their sequences are listed in Table 2.5. First 
of all, 2.5 µg of genomic DNA from each sample was digested with 80 units of 
blunt-end restriction enzymes, PvuII, DraI, StuI and EcoRV (Promega), 
respectively, in 100 µL reaction volumes in 0.5 mL tubes at 37 ºC for 2 h. The 
tubes were vortexed at slow speed for 5-10 s before returning to 37 ºC overnight 
(16-18 h). The genomic DNA was then purified using phenol and chloroform as 
described in 2.4.1 with slight alteration. Briefly, an equal volume (100 µL) of 
phenol was added to each reaction tube followed by vortexing at slow speed for 
5-10 s and centrifuging at 13,000 rpm for 1 min at room temperature (RT). The 
aqueous phase was transferred into a 0.5 mL tube. An equal volume (100 µL) of 
chloroform was then added to the tube. Following vortexing and centrifuging 
again, the aqueous phase was transferred into a 0.5 mL tube. 2.5 volumes (250 
µL) of ice-cold 100% ethanol and 1/10 volume (10 µL) of 3 M NaOAc were then 
added and the tube was placed at -20 ºC for at least 20 mins. The tube was then 
centrifuged at 13, 000 rpm for 20 mins at 4 ºC and the DNA pellet was washed 
twice with 500 µL 80% of ice-cold ethanol. The pellet was air dried before 
dissolving in 20 µL of sterilised deionised water. Following the digestion and 
purification steps, 4 µL genomic DNA from each tube was ligated to 1.9 µL 
adaptors (25 µM) in 8 µL reaction volume using 0.5 µL T4 DNA ligase (6 
units/µL) (Promega). The adaptors were made through annealing two primers, 
AL and AS (Table 2.7). 25 µM AL and AS primers were mixed in 100 µL 
sterilised deoinised water before they were denatured at 98 ºC for 2 mins in a 
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PCR machine. The primers were annealed after the machine was switched off 
and the temperature in the PCR block was gradually dropped down over 1 hr. 
After the ligation of genomic DNA and adaptor at 16 ºC overnight, the reaction 
was stopped through incubation at 70 ºC for 5 mins.   
 
The primary and secondary nested PCRs were then carried out. For primary 
PCR, 1 µL of each library was used as a template; 1 µL adaptor-binding primer 1 
(AP1) (10 µM) and 1 µL gene-specific primer were used as a primer pair. The 
PCR reaction was performed in a 50 µL volume under the following two-step 
cycle parameters: 98 ºC-25 s, 72 ºC-3 mins for 7 cycles; 98 ºC-25 s, 67 ºC-3 mins 
for 32 cycles and 67 ºC for an additional 7 mins after the final cycle. 5 µL of the 
primary PCR products were analysed on a 1.5% agarose/EtBr gel. For the 
secondary nested PCR, 1 µL of the primary PCR product was used as the 
template; 1 µL adaptor-binding primer 2 (AP2) (10 µM) and 1 µL gene-specific 
nested primer were used as a primer pair. The PCR reaction was performed in 50 
µL volume under the following two-step cycle parameters: 98 ºC-25 s, 72 ºC-3 
mins for 5 cycles; 98 ºC-25 s, 67 ºC-3 mins for 24 cycles and 67 ºC for an 
additional 7 mins after the final cycle. 5 µL of the secondary PCR products were 
analysed on a 1.5% agarose gel.  
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Table 2.7 Primers for genome walking analysis 
Genome walking primers Short name Sequence 
Adaptor 
related 
primers 
Adaptor long AL 5'-GTAATACGACTCACTATAGGGCACGCGTGGT 
CGACGGCCCGGGCTGGT 
 
Adaptor short AS 5'-[Phos]ACCAGCCC[Amine]-3' 
 
Adaptor primer 1 AP1 5'-GTAATACGACTCACTATAGGGC-3' 
 
Nested adaptor 
primer 2 
 
AP2 5'-ACTATAGGGCACGCGTGT 
 
Gene 
specific 
primers 
CB1 down-stream 
breakpoint primer 1 
 
CB1DBP1 5'-GTTCAGGACCATGAAACACTCTATGTC 
CB1 down-stream 
breakpoint nested 
primer 2 
 
CB1DBP2 5'-TCATTCTCCTTGAAGGACGAGAGAGAC 
CB1 up-stream 
breakpoint primer 1 
 
CB1UBP1 5'-CTATCATGCTATCAGGCTGGTAAACCACT 
CB1 up-stream 
breakpoint primer 2 
CB1UBP2 5'-AACTCCTGATTATACGACGTGATGAGG 
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2.5 DNA methylation analysis 
Genomic DNA from 10 BPH and 48 prostate cancer samples, which were 
extracted from macro-dissected clinical fresh frozen materials, were available in 
our group. These 58 DNA samples were sent to the Molecular Epidemiology 
Laboratory, Wolfson Institute of Preventive Medicine (http://www.wolfson.qmu 
l.ac.uk/ems/research/Molecular_Epidemiology_Laboratory.html), for CNR1 
methylation analysis.  
2.5.1 Bisulfite conversion 
120 – 300 ng of genomic DNA from each sample was used in the bisulfite 
conversion reactions, where unmethylated cytosines were converted to uracil 
with the EpiTect Bisulfite kit (Qiagen) according to manufacturer‘s instructions. 
Briefly, DNA was mixed with water, DNA protect buffer and bisulfite mix and 
then the conversion was run in a thermocycler (Biometra, Goettingen, Germany) 
at the recommended cycle conditions. Converted DNA was purified and eluted 
into a total 40 µl Buffer EB and further diluted into 20 µl aliquots of 100 cell-
equivalents/µl (the cell genome-equivalents of DNA calculations assumed 6 pg 
DNA per diploid cell).  
2.5.2 PCR and Pyrosequencing 
Primer set with reverse biotin-labelled primer at the 5‘ end was used to amplify 
the bisulfite converted DNA. Primers for the gene amplification CNR1 F 5‘ – 
GTTTAGTTTAGGGGTTGGTTG – 3‘, BCNR1 R 5‘ – B-
CTTCCTTCTCCACTTCTTTTCC – 3‘ and the pyrosequencing CNR1 S 5‘ – 
GAGTTTTGTAGGGAGT -3‘ were designed using PyroMark Assay Design 
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software version 2.0.1.15 (Qiagen); The size of the amplicons was restricted to a 
maximum of 210 bp. The primers were located in promoter or first exon CpG 
islands identified by MethPrimer (http://www.urogene.org/methprimer/index1.ht 
ml), depending on where the design of the assay allowed for optimal primers. 
Due care was taken to avoid any primer overlapping CG dyads to prevent 
amplification biases. PCRs were performed using a converted genomic DNA 
genome-equivalent of 200 to 400 cells employing the PyroMark PCR kit 
(Qiagen). Briefly, 12.5 µl master mix, 2.5 µl Coral red, 5 pmol of each primer, 7 
µl of water and 2 µl sample were mixed for each reaction and run at thermal 
cycling conditions: 95 °C for 15min and then 45 cycles: 30 sec at 94 °C; 30 sec 
at 56 °C; 30 sec at 72 °C and a final extension for 10 min at 72 °C. The correct 
amplified DNA was confirmed by the QiaExel capillary electrophoresis 
instrument (Qiagen). A standard pyrosequencing sample preparation protocol 
was applied (Tost and Gut, 2007). 3 µl streptavidin beads (GE Healthcare, UK), 
37 µl PyroMark binding buffer (Qiagen), 20 µl PCR product and 20 µl water 
were mixed and incubated for 10 min on a shaking table at 1300 rpm. Using the 
Biotage Q96 Vacuum Workstation, amplicons were separated, denatured, 
washed and added to 45 µl annealing buffer containing 0.33 µM of 
pyrosequencing primer. Primer annealing was performed by incubating the 
samples at 80 °C for 2 min and allowed to cool to room temperature prior to 
pyrosequencing. PyroGold reagents were used for the pyrosequencing reaction 
and the signal was analysed using the PSQ 96MA system (Biotage, Uppsala, 
Sweden). Target CGs were evaluated by instrument software (PSQ96MA 2.1), 
which converts the pyrograms to numerical values for peak heights and 
calculates proportion of methylation at each base as a C/T ratio. All runs 
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contained standard curves, which comprised a range of control methylated DNA 
(0%, 25%, 50%, 75%, and 100%) to allow standardised direct comparisons 
between different primer sets. For the standard curves a total of 300 ng of 
unmethylated (Qiagen) and hypermethylated DNA (Millipore, Billerica, MA, 
USA) were mixed to obtain the different ratios of DNA methylation and then 
bisulfite converted as described above. 
2.6 RNA expression analysis 
2.6.1 Total RNA extraction 
2.6.1.1 Total RNA isolation from cell lines 
Total RNA was extracted using TRIzol® reagent (Invitrogen) according to the 
manufacturer‘s recommendations. 1 mL TRIzol was used per 5 x 105 cells for 
lysis. The lysate was incubated at RT for 5 mins to permit the complete 
dissociation of nucleoprotein before 0.2 mL chloroform per 1 mL of TRIzol was 
added. Tubes were shaken vigorously for 15 s and incubated 2-3 mins at RT 
before centrifugation at 11,900 g for 15 mins at 4 °C. The aqueous phase (about 
60% volume) was transferred to a fresh tube, and 0.5 mL of isopropanol was 
added per 1 mL of TRIzol. The tube was incubated for 10 mins at RT before 
centrifugation at 11,900 g for 10 mins at 4 °C. The supernatant was removed and 
the pellet was washed with 1.5 mL 75% ethanol. RNA was dissolved in 50 μL 
RNase-free water and stored at -80 °C. 
2.6.1.2 Total RNA isolation from fresh frozen sliced tissues 
Slides were washed with RNaseZap (Ambian, Applied Biosystem) to remove 
RNases and then rinsed with diethylpyrocarbonate (DEPC) water before being 
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left to air-dry. Ten 15 µm slices of fresh frozen tissue sections of each clinical 
sample were cut onto the pre-treated slides. The slides were placed in a plastic 
slide box, which was kept on dry ice. The first and the last sections of each 
sample were stained with H&E. A pathologist (LY Xue) examined the H&E 
sections and marked the tumour or BPH area on the first section after confirming 
that the last section of each sample had a similar size of tumour or BPH tissue 
area as the first sections. Tumour or BPH tissue from each sample were macro-
dissected using scrapers and directly collected in a 1.5 mL micro-tube containing 
1 mL TRIzol (Invitrogen). Tissue was homogenised with a syringe. Following 
homogenisation, the same procedure was performed as detailed in 2.5.1.1 
2.6.1.3 Residual DNA removal and RNA quantification 
In order to remove the residual genomic DNA from RNA samples, DNase I 
(Ambion, Applied Biosystems) treatment was applied following the 
manufacturer‘s instructions. 1 μL (2 U) DNase I was used to treat ≤ 10 g RNA 
in 50 μL volume with DEPC-treated water. After incubation at 37 °C for 30 
mins, RNA was purified using phenol/chloroform to inactivate the DNase I as 
illustrated in 2.3.1.2. To reduce the volume, and also to improve the RNA 
quality, RNA was re-precipitated by adding 1/10 volume of 3 M NaOAc (pH 5.2, 
Gibco, Invitrogen) and 2.5 volumes of 100% ethanol to the samples. Following 
incubation at -20 °C for 20 mins, RNA was precipitated by centrifugation at 
12,000 g for 20 mins at 4 °C. The RNA pellet was washed by 80% ethanol and 
re-suspended in RNase-free water. The quality and quantity of RNA were 
assessed using the spectrophotometer ND-1000 and Agilent 2100 Bioanalyser 
(Agilent Technologies). 
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2.6.2 Affymetrix Exon array 
Affymetrix GeneChip® Human Exon 1.0 ST Array was applied to investigate 
expression variations of whole transcripts. The experiment was performed by 
Sharon James following the manufacturer‘s protocol as described below. This 
protocol can be downloaded from Affymetrix website 
(http://www.affymetrix.com/Auth/support/downloads/manuals/wt_sensetarget_la
bel_manual.pdf). Figure 2.1 shows the whole transcript sense target labelling 
assay schematic. 
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Figure 2.1 Whole transcript sense target labelling assay schematic 
Adapted from Affymetrix GeneChip® Whole Transcript Sense Target Labelling 
Assay Manual. 
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2.6.2.1 rRNA reduction 
2.6.2.1.1 Preparation of dilutions of poly-A RNA controls 
GeneChip® Poly-A RNA Control Kit was used for this step.  2 μL of Poly-A 
RNA Control Stock was added to 38 μL of Poly-A Control Dil Buffer to make 
the first dilution (1:20). After mixing and spinning, 2 μL of the first dilution was 
added to 98 μL Poly-A Control Dil Buffer to make the second dilution (1:50). 
Then 2 μL of the second dilution was added to 98 μL of Poly-A Control Dil 
Buffer to make the third dilution (1:50). 2 μL of the third dilution was added to 1 
g of total RNA for each reaction to finally make up the total RNA/Poly-A RNA 
Control Mix.  
2.6.2.1.2 rRNA reduction 
For rRNA reduction, the RiboMinus
TM 
Human/Mouse Transcriptome Isolation 
Kit (Invitrogen) was used. First of all, 54 μL betaine (5 M) and 126 μL 
hybridisation buffer were mixed to give a total volume of 180 μL hybridisation 
buffer with betaine for a single total RNA sample. Then 3 μL of total RNA/Poly-
A RNA Control Mix and 20 μL of hybridisation buffer with betaine were mixed 
with 0.8 μL of RoboMinus probe (100 pmol/μL) in a 0.2 mL strip tube and 
incubated at 70 °C for 5 mins. The tube was then placed on ice while magnetic 
beads were prepared. 50 μL of bead suspension was transferred to a 1.5 mL non-
stick RNase-free tube. After spinning and placing on the magnetic stand for 1 
min, the supernatant was gently aspirated off and discarded. The beads were then 
washed by 50 μL of RNase-free water and placed on the magnetic stand for 1 
min before the supernatant was discarded. This washing step was repeated twice, 
once with 50 μL of RNase-free and once with 50 μL of the hybridisation buffer. 
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The beads were finally re-suspended in 30 μL of the hybridisation buffer with 
betaine, and kept at 37 °C for 1-2 mins. After beads preparation, ice-cold 
hybridised sample (prepared previously) was transferred to the tube containing 
the beads and incubated at 37 °C for 10 mins. The tube was placed on the 
magnetic stand for 1-2 mins to obtain the rRNA-probe pellet. The supernatant 
was transferred to a 1.5 mL non-stick, RNase-free tube and left on ice while the 
beads were washed in 50 μL of hybridisation buffer with betaine and incubated 
at 50 °C for 5 mins. The beads were than placed on the magnetic stand for 1 to 2 
mins. Finally, the supernatant was combined with the supernatant, which was left 
on ice. The total volume of the rRNA-reduced sample was approximately 100 
μL. 
2.6.2.2 RNA concentration 
The GeneChip® IVT cRNA Cleanup Kit was required for measurement of the 
RNA concentration. 350 μL of cRNA binding buffer was added to each rRNA-
reduced sample from the previous step and vortexed for 3 s. 250 μL of 100% 
ethanol was added to each reaction and flicked to mix well. The sample was then 
applied to the IVT cRNA Cleanup Spin Column sitting in a 2 mL collection tube. 
Following centrifugation for 15 s at ≥ 8,000 g, the flow-through was discarded 
and the IVT cRNA Cleanup Spin Column was transferred to a new 2 mL 
collection tube.  The 500 μL of cRNA Wash Buffer was added and then the tube 
was centrifuged for 15 s at ≥ 8,000 g, the flow-through again was discarded. The 
tube was centrifuged at ≤ 25,000 g for 15 s with the cap left open. After 
transferring to a new 1.5 mL collection tube, 11 μL of RNase-free Water was 
directly added to the membrane of the IVT cRNA Cleanup Spin Column and 
then centrifuged at ≤ 25,000 g for 1 min. The eluted rRNA-Reduced Total 
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RNA/Poly-A RNA Controls Mix was approximately 9.8 μL. The quality of 
rRNA-Reduced Total RNA/Poly-A RNA was checked using the Agilent 2100 
Bioanalyser. 
2.6.2.3 First-strand cDNA synthesis 
The GeneChip® WT cDNA Synthesis Kit was used for first strand DNA 
synthesis. The T7- (N)6  primer was diluted in RNase-free water to a 500 ng/ μL 
working solution and mixed with the concentrated rRNA-reduced sample. After 
the mixture was mixed well and spun, it was incubated at 70 °C for 5 mins 
followed by 4 °C for at least 2 mins. The sample was stored on ice until further 
use. The First-Cycle, First-Strand Master Mix was prepared as shown in Table 
2.8 below. 5 μL of the First-Cycle, First-Strand Master Mix was added to the 
tube containing the Concentrated rRNA-Reduced Total RNA/Poly-A RNA 
controls/ T7- (N)6 Primers Mix giving a total reaction volume of 10 μL. The tube 
was then incubated sequentially at 25 °C for 10 mins, 42 °C for 60 mins, 70 °C 
for 10 mins and 4 °C for at least 2 mins before immediately continuing to the 
First-Cycle, Second-Strand cDNA synthesis. 
 
Table 2.8 First-Cycle, First-Strand Master Mix 
      Component Volume in 1 reaction 
5 x 1
st
 Strand Buffer 2 μL 
DTT, 0.1 M 1 μL 
dNTP Mix, 10 mM              0.5 μL 
RNase Inhibitor              0.5 μL 
SuperScript
TM
 II 1 μL 
Total Volume 5 μL 
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2.6.2.4 First-cycle, Second-Strand cDNA synthesis 
The GeneChip® WT cDNA Synthesis Kit was also used in this procedure. 2 μL 
of 1 M MgCl2 was mixed with 112 μL of RNase-free water first. Then the First-
Cycle, Second-Strand Master Mix was prepared as described in Table 2.9 below. 
10 μL of the First-Cycle, Second-Strand Master Mix was mixed with the reaction 
tube from the First-Strand cDNA Synthesis Reaction for a total reaction volume 
of 20 μL. The tube was incubated in a thermal cycler at 16 °C for 120 mins 
without a heated lid and at 75 °C for 10 mins with a heated lid before being 
cooled for at least 2 mins at 4 °C. 
 
Table 2.9 First-Cycle, Second-Strand Master Mix 
Component Volume in 1 Rxn 
MgCl2, 17.5 mM    4 μL 
dNTP Mix, 10 mM 0.4 μL 
DNA Polymerase I 0.6 μL 
RNase H 0.2 μL 
RNase-free Water 4.8 μL 
Total Mix Volume 10.0 μL 
 
2.6.2.5 First-cycle, cRNA synthesis and cleanup 
The GeneChip® WT cDNA Amplification Kit and the GeneChip® Sample 
Cleanup Module were used for this step. In a separate tube, the IVT Master Mix 
was assembled at RT as listed in Table 2.10 below.  
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Table 2.10 First-Cycle, cRNA Synthesis 
Component Volume in 1 Reaction 
10x IVT Buffer   5 μL 
IVT NTP Mix 20 μL 
IVT Enzyme Mix   5 μL 
Total Volume 30 μL 
 
30 μL of the IVT Master Mix to each First-Cycle cDNA Synthesis Reaction 
sample from the previous step was transferred to a final volume of 50 μL and 
briefly spun in a centrifuge before incubation at 37 °C for 16 h. 50 μL of RNase-
free water was added to each IVT reaction to a final volume of 100 μL and then 
350 μL of cRNA Binding Buffer was added to each sample. The tube was 
vortexed for 3 s before 250 μL 100% ethanol was added. The sample was then 
applied to the IVT cRNA Cleanup Spin Column sitting in a 2 mL collection tube.  
500 μL of cRNA Wash Buffer was added and the tube was centrifuged for 15 s at 
≥ 8,000 g. The flow-through was discarded, 500 μL of 80% (v/v) ethanol was 
added to wash again and then the tube was centrifuged at the same speed for 15 s 
before discarding the flow-through. After spinning at ≤ 25,000 g for 5 mins with 
the column cap open, the IVT cRNA Cleanup Spin Column was transferred to a 
new 1.5 mL collection tube and 12 μL of RNase-free water was added directly to 
the membrane. The tube was centrifuged at 25,000 g for 1 min. The eluted cRNA 
is approximately 10.5 μL. The cRNA yield was determined by Nanodrop ND-
100.  
2.6.2.6 Second-cycle, first-strand cDNA synthesis 
The GeneChip® WT cDNA Synthesis Kit was used in this step. cRNA was first 
mixed with the Random Primers as listed in Table 2.11 below. The tubes were 
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flick-mixed and spun down before being incubated at 70 °C for 5 mins and 25 °C 
for 5 mins. After cooling at 4 °C for at least 2 mins, 12 μL of the Second-Cycle, 
First-Strand cDNA Synthesis Master Mix, as described in Table 2.12, was 
transferred to the Second-Cycle, cRNA/Random Primers Mix for a total reaction 
volume of 20 μL. After mixing and centrifuging, the tubes were incubated 
sequentially at 25 °C for 10 mins, 42 °C for 90 mins, 70 °C for 10 mins and 4°C 
for at least 2 mins. 
 
Table 2.11 Second-Cycle, cRNA/Random Primers Mix 
Component Volume in one reaction 
cRNA, 8 μg Variable 
Random Primers (3 μg/ μL ) 1.5 μL 
RNase-free water Up to 8 μL 
Total Volume 8 μL 
 
Table 2.12 Second-Cycle, First-Strand cDNA Synthesis Master Mix 
Component Volume in one reaction 
5 x 1
st
 Strand Buffer       4 μL 
DTT, 0.1 M      2 μL 
dNTP+dUTP, 10 mM 1.25 μL 
SuperScript
TM  
II 4.75 μL 
Total Volume    12 μL 
 
2.6.2.7 Hydrolysis of cRNA and cleanup of single-stranded DNA 
For this step, the GeneChip® WT cDNA Synthesis Kit and the GeneChip® 
Sample Cleanup Module were used. First of all, 1 μL of RNase H, 2 U/μL was 
added to each of the samples. The samples were then incubated sequentially at 
37 °C for 45 mins, 95 °C for 5 mins and 4 °C for 2 mins. 80 μL of RNase-free 
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water and 370 μL of cDNA Binding Buffer were added to each sample. After 
vortexing for 3 s, the entire sample (the total volume is 471 μL) was applied to a 
cDNA Spin Column sitting in a 2 mL collection tube and spun at ≥ 8,000 g for 1 
min. The flow-through was discarded and the columns were placed in 1.5 mL 
collection tubes. After 15 μL of the cDNA Elution Buffer was directly added to 
the column membrane, the columns were incubated at RT for 1 min and 
centrifuged at ≤ 25, 000 g for 1 min. The cDNA elution step was repeated. The 
yield of single-stranded DNA was determined by NanoDrop ND-1000. 
2.6.2.8 Fragmentation of single-stranded DNA 
The GeneChip® WT Terminal Labeling Kit was used in this step. The 
fragmentation mix was prepared as described in Table 2.13 below and added to 
each sample. The samples were incubated at 37 °C for 60 mins, 93 °C for 2 mins, 
4 °C for at least 2 mins. After being flick-mixed and spun down, 45 μL of each 
sample was transferred to a new tube. The remainder of the samples was used for 
size analysis using Agilent 2100 Bioanalyser. The range in peak size of the 
fragmented samples should be approximately 40 – 70 nt.  
 
Table 2.13 Fragmentation mix of Single-Stranded DNA 
Component Volume/Amount in one reaction 
Single-Stranded DNA    5 μg 
10x cDNA Fragmentation Buffer 4.8 μL 
UDG, 10 U/μL    1 μL 
APE 1, 1,000 U/ μL     1 μL 
RNase-free Water Up to 48 μL 
Total Volume 48 μL 
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2.6.2.9 Labelling of fragmented single-stranded DNA 
The GeneChip® WT Terminal Labeling Kit was used in this step. The labelling 
reaction was prepared as listed in Table 2.14 below. After adding the labelling 
reagents, the fragmented DNA samples were flick-mixed and spun down. The 
samples were then incubated at 37 °C for 60 mins, 70 °C for 10 mins and 4 °C 
for at least 2 mins.  
 
Table 2.14 Labelling Master Mix 
Component Volume/Amount in one reaction 
Fragmented Single-Stranded DNA 45 μL 
5x TdT Buffer 12 μL 
TdT   2 μL 
DNA labelling Reagent, 5 mM   1 μL 
Total Volume 60 μL 
 
2.6.2.10 Preparation of the hybridisation cocktail 
The hybridisation cocktail was prepared in a 1.5 mL RNase-free tube as shown 
in Table 2.15 below. At this point, samples were consigned to the Affymetrix 
operator (Mrs T.Chaplin), who was in charge of performing hybridisation, 
washing, staining, and scanning of the samples on chips. 
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Table 2.15 Hybridisation Cocktail 
Component Volume for a single 
49 format array 
Final concentration or 
Amount 
Fragmented and labelled DNA target 
 
~ 60 μL ~ 5 μg 
Control Oligonucleotide B2 
 
3.3 μL 50 pM 
20x Eukaryotic Hybridisation 
Controls (bioB, bioC, bioD, cre) 
 
10 μL 1.5, 5, 25 and 100 pM, 
respectively 
Herring Sperm DNA (10 mg/mL) 
 
2 μL 0.1 mg/mL 
Acetylated BSA (50 mg/mL) 
 
2 μL 0.5 mg/mL 
2x Hybridisation Buffer 
 
100 μL 1x 
DMSO 
 
14 μL 7% 
RNase free H2O 
 
Up to 200 μL  
Total Volume 200 μL  
 
2.6.2.11 Hybridisation, washing, staining and scanning 
The Affymetrix Exon 1.0 ST Array chips were stored at 4 °C. Prior to use, they 
were equilibrated to RT while the hybridisation cocktail was heated at 99 °C for 
5 mins, cooled down to 45 °C for 5 mins and then centrifuged at maximum speed 
for 1 min. Subsequently, the samples were added to the chip and incubated at 45 
°C for 16 h in a hybridisation oven at 60 rpm. After overnight hybridisation, the 
hybridisation cocktail was removed and replaced by Non-stringent Wash Buffer. 
Once placed in a GeneChip® 450 Fluidics wash station, chips were washed to 
remove non-hybridised probes and stained with Streptavidin Phycoerythrin 
(SAPE) to localise the biotiylated targets using the protocol EukGE_WS2v5. In 
the end, chips were scanned using the GeneChip® 3000 scanner.  
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2.6.3 Exon array data analysis 
2.6.3.1 Bioinformatics analysis 
Microarray analysis generates large sets of data and, therefore, requires the use 
of bioinformatics and additional analytical tools. For global analysis of 
expression alterations, raw Exon array data were statistically analysed by Phil 
East (bioinformatics software specialist, CRUK). First of all, probe level 
intensities were background corrected using the anti-genomic probe groups and 
then quantile normalised. Core level probeset and gene level signal estimates, 
along with probeset detection p-values (DABG), were generated using Iter-plier. 
Quantification was further carried out using apt-1.10.0 from Affymetirx with a '-
a' option of 'quant-norm.pm-gcbg.iter-plier'. For each of the pairwise 
comparisons, probesets displaying a greater than 0.05 detection p-value in more 
than half of the samples, in both conditions, were removed from the analysis. In 
addition, entire transcript clusters were removed if more than half the member 
probesets had a detection p-value above 0.05 across one condition. This step was 
implemented since it is impossible to infer a translocation event against an 
unexpressed transcript. Once filtered each probeset was scaled to its 
corresponding gene level intensity estimate to remove any gene effect present in 
the comparison. Scaled probesets displaying differential behaviour were detected 
via Anova analysis using a 0.05 fdr (false discovery rate) threshold. T-statistics 
were moderated using empirical Bayes shrinkage to increase statistical power. 
The analysis was then carried out using the Limma package from Bioconductor 
(Gentleman et al., 2004). Finally, transcript clusters with differential probesets 
were inspected visually for expression profiles indicative of translocations. 
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2.6.3.2 Exon array data analysis with commercial software 
2.6.3.2.1 Integrated Genomic Browser (IGB) 
IGB is an interactive software programme which can be used to visualise and 
explore genome-scale data sets from multiple data sources. All data viewed in 
IGB, regardless of its source, were organised into distinct genomes and 
chromosomes. IGB was downloaded from the Affymetrix website 
(www.affymetrix.com/partners_programs/ developer/ tools/download_igb.affx). 
The Exon array data text file generated via ExACT software, (beta test software, 
Affymetrix) was uploaded to IGB. The expression variations of the probes 
representing individual genes were visualised in the browser.  
2.6.3.2.2 Ingenuity Pathway Analysis (IPA) 
In order to identify biologically relevant pathways, Ingenuity Pathway Analysis 
(IPA version 4.0), a web-based application (www.Ingenuity.com) that enables 
building signalling networks from gene expression data, was applied. According 
to the introduction from IPA website (www.Ingenuity.com), IPA is based on 
IPKB (Knowledge Base database), which is currently the largest curated 
database containing millions of computable relationships between genes, 
proteins, drugs and diseases. IPA‘s curation is performed by PhD-level scientists 
that manually curate the data and assess their quality. IPA‘s knowledge base 
ontology contains 12 major branches, ~580, 000 classes, as well as pathway 
interaction domains. IPA‘s biological process relationships describe the impact 
of gene on the process (for example, increases apoptosis or decreased migration 
etc), and has more than 15,000 gene-to-disease associations. 
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A data set containing Affymetrix probe identifiers and their corresponding ‗fold 
change‘ values was uploaded in Excel. Each probe identifier was mapped to its 
corresponding object in the IPK base. To build a network, IPA searches the 
IPKB for interactions between focus genes/proteins and all other gene objects 
stored in the Knowledge base (‗Focus genes‘ show direct interaction with other 
genes in the knowledge base). It then generates a set of networks with a 
maximum of 35 genes, and computes a score for each network. The score shows 
the likelihood that a gene is placed in a network due to random chance (for 
example, a score of 2 gives a 99% confidence that the focus genes are not being 
generated by random chance). In addition, IPA‘s Global Functional Analysis 
feature provides an overview of biological functions associated with a set of 
dysregulated genes/proteins, with functions displaying a p-value <0.05 being 
significant. The significance values for these analyses are calculated using the 
right-tailed Fisher‘s Exact test. 
2.6.4 Synthesis of complementary DNA 
1 μg of total RNA and 1.5 μL of random hexamers (50 μM) were co-denatured at 
70 °C for 5 mins. 6 μL of M-MLV RT 5x synthesis buffer (Promega, UK), 10 μL 
of dNTPs (2.5 mM each) and 2 μL of M-MLV RT RNase H minus, Point mutant 
(200 U/μL) (Promega) were added and then the reactions were incubated for 1 h 
at 42 °C followed by 5 mins at 95 °C. Following the addition of 2 μL of RNase H 
(1 U/μL) (Promega), tubes were placed back at 42 °C for 10 mins and 
subsequently stored at -20 °C. 
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2.6.5 Real-time quantitative reverse transcription PCR 
(qRT-PCR) analysis 
2.6.5.1 cDNA quality confirmation using β-actin control PCR 
Following the cDNA synthesis, a standard PCR using β-actin primers (Forward 
sequence: 5‘-GCGGGAAATCGTGCGTGCGTGACATT-3‘; Reverse sequence: 
5‘-GATGGAGTTGAAGGTAGTTTCGTG-3‘) (Sigma) was performed. β-actin 
is a commonly used housekeeping gene for PCR-based techniques and Western 
blotting. Here, β-actin was used as a positive control to determine the quality of 
the cDNA synthesised by checking for the presence or absence of PCR product.  
 
For each sample, the PCR reaction was performed in 25 µL volume. A mixture 
of 2 µL of cDNA, 2.5 µL 10X buffer (Invitrogen), 0.5 µL of dNTPs (10 mM), 
0.75 µL of MgCl2 (50 mM, Invitrogen), 1 µL of each β-actin primer (10 µM 
each, Sigma), 0.2 µL of Taq DNA polymerase (5 U/µL, Invitrogen) and 17.05 
µL of molecular biology-grade water was used. The PCR was carried out under 
the following conditions: 95 ºC-1 min; 95 ºC-30 s, 62 ºC-30 s and 68 ºC-90 s for 
35 cycles; 72 ºC for an additional 1 min after the final cycle. PCR products were 
analysed on a 1.5% agarose/EtBr gel and bands of 250 bp were expected. 
 
2.6.5.2 Real-time quantitative reverse transcription PCR 
Relative expression of genes, which were selected from Exon array data, was 
determined using either Taqman-based or SYBR-Green based real-time 
quantitative reverse transcription PCR analysis.  
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2.6.5.2.1 Taqman-based gene expression detection 
Taqman gene expression probes were ordered from Applied Biosystems (ABI) 
(Table 2.16 and Table 2.17) and the qRT-PCR reactions were performed using 
an ABI 7900 Real Time PCR System (Applied Biosystems, ABI) keeping the 
default settings for baselines and thresholds. The housekeeping gene (GAPDH) 
was used as an endogenous control. The standard reaction volume (20 μL) and 
cycling conditions were applied to assess all Taqman probes in MicroAmp fast 
optical 96-well reaction plates (Applied Biosystem). The reaction mix is listed in 
Table 2.18. The cycling conditions were as follows: 2 mins at 50 °C, 10 mins at 
95 °C, 40 cycles of 15 s at 95 °C and 1 min at 60 °C. All measurements were 
performed in triplicate and a no template control (NTC) was included to detect 
any possible contamination. 
 
Each probe generated an expression curve from which the cycle threshold (Ct) 
values were extracted. For each triplicate, a mean Ct value was calculated, 
making sure to remove any aberrant values. Each target mRNA was normalised 
against the housekeeping gene by subtracting the Ct value of GAPDH from the Ct 
value of the target probe (∆Ct). This compensates for the variability in the 
amount of starting material. To ensure that results processed on different plates 
were comparable to a unique calibrator (positive control, P129), the ∆Ct for the 
control sample was subtracted from the ∆Ct for the target sample (∆∆Ct). Fold 
change compared with control was calculated by 2
-∆∆Ct
. 
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Table 2.16 ABI Taqman gene expression probes ordered for target 
validation 
Probes ordered from www.appliedbiosystems.com 
Gene Name Assay ID Interrogated 
sequence (Refseq) 
Exon boundary 
CNR1 Hs00275009_s1 NM_033181.2 2-2 
PNRC1 Hs00199095_m1 NM_006813.1 1-2 
GJA10 Hs01087606_s1 NM_032602.1 1-1 
ARMCX1 Hs01849556_s1 NM_016608.1 4-4 
SRD5A2  Hs00936406_m1 
Hs03003722_m1 
NM_000348.3 2-3 
4-5 
KRT23 Hs01119993_m1 
Hs01119997_m1 
NM_015515.3 3-4 
8-9 
UNC5C Hs01031779_m1 NM_003728.2   9-10 
GAPDH Hs99999905_m1 NM_002046.3 3-3 
 
  
∆Ct = ∆Ct target - ∆Ct housekeeping gene 
∆∆Ct = (∆Ct target - ∆Ct housekeeping gene)sample – (∆Ct target - ∆Ct housekeeping gene)control 
Expression fold change =2
-∆∆Ct
 
   
 108 
Table 2.17 Custom TaqMan® Gene Expression Assays 
 
Gene 
name 
Interrogated 
sequence 
(Refseq) 
Forward 
primer 
Reverse 
primer 
Reporter 
sequence 
Exon 
boundary 
SRD5A2 NM_000348.3 GGCACTG
GCCTTGTA
CGT 
 
AGCCGCC
GGCTTCA
G 
CTCTCCGTG
TGCTTCC 
 
1-1 
KRT23 NM_015515.3 AGGTGTGC
TGGGATG
AAAGG 
 
GGTATCTT
TCTAATCT
TGCCGTG
AAGT 
CTGGAAGT
GGAAGGTA
AAT 
 
1-2 
 
Table 2.18 Reaction mix for Taqman Real-time quantitative reverse 
transcription PCR 
 
Component Volume for one reaction 
2x Universal PCR Master Mix 10 μL 
20x ABI probe/primer mix   1 μL 
cDNA   1 μL 
Water   8 μL 
 
2.6.5.2.2 SYBR-Green based detection 
To ensure that primers are specific for the target sequence, free of internal 
secondary structure, and to avoid complementation at 3′-ends, primers for 
SYBR-Green gene expression analysis were designed using the online software 
Primer3 (http://frodo.wi.mit.edu/primer3/) . In addition, primers were designed to 
ensure that the amplicon length was approximately 80–120 bp to optimise the 
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efficiency of qPCR and also the primers span different exons to avoid 
amplification from residual genomic DNA. The primers were ordered from 
Sigma and the SYBR® Green PCR Master Mix was purchased from Applied 
Biosystems, ABI (Table 2.19).  Prior to the detection of gene expression, a 
standard curve for each primer pair was created by performing qRT-PCR on a 
serial of five-fold serial dilutions of a cDNA template (1, 1/5, 1/25, 1/125, 1/625, 
1/3125). Ct values (>8 and <35) were plotted against log10 of the dilution factor. 
The amplification efficiency was assessed using the slope of the regression line 
in the standard curve. A slope of – 3.3 indicates 100% PCR amplification 
efficiency and 10-fold increase of products for every 3.3 cycles. The specificity 
of the primers was determined through dissociation peak and further confirmed 
on a 1.5% agarose gel with a single band at the correct size. Primers, which had a 
PCR efficiency and R
2 
values (correlation coefficiency) >98% and that also 
demonstrated specificity, were applied for further analysis.  
 
The SYBR-Green qRT-PCR reactions were performed on a ABI PRISM 96-well 
optical plate using an ABI 7500 Real Time PCR System (Applied Biosystems, 
ABI). The housekeeping gene (-actin) was used as an endogenous control. The 
standard reaction volume (20 μL) was applied as listed in Table 2.20. The 
cycling conditions were as follows: 2 mins at 50 °C, 10 mins at 95 °C, 50 cycles 
of 15 s at 95 °C, 1 min at 60 °C, 15 s at 95 °C, 1 min at 60 °C and 15 s at 95 °C. 
All measurements were performed in triplicate and a no template control (NTC) 
was included to detect any possible contamination. The threshold cycle (Ct) data 
were determined using default threshold settings. The qRT-PCR data analysis 
was the same as illustrated 2.2.6.2 
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Table 2.19 SYBR Green gene expression primers 
Target gene Primer Sequence 
CNR1 Forward 5'-AAGACCCTGGTCCTGATCCT 
Reverse 5'-CGCAGGTCCTTACTCCTCAG 
CNR2 Forward 5'-ATCATGTGGGTCCTCTCAGC 
Reverse 5'-GATTCCGGAAAAGAGGAAGG 
β-actin Forward 5'-AGAAAATCTGGCACCACACC 
Reverse 5'-AGAGGCGTACAGGGATAGCA 
SULF Forward_1 5'-AGAGCGTGGAAGGACCATAA 
Reverse_1 5'-TTATGGTCCTTCCACGCTCT 
SULF Forward_2 5'-GAAGGAGAAGAGACGGCAGA 
Reverse_2 5'-CAGAAAGATCCCAGGTTCCA 
PTGIS Forward_1 5'-CATCCCCTGGTTGGGGTATG 
Reverse_1 5'-CGTCGTAGGAGTGTGGGTC 
PTGIS Forward_2 5'-CACGAGGATGAAGGAGAAGC 
Reverse_2 5'-GTCCAGGAGAACGGTGACAT 
 
 
Table 2.20 Reaction mix for SYBR Green Real-time quantitative reverse 
transcription PCR 
Component Volume for one reaction 
2x SYBR® Green PCR Master Mix 10 μL 
Forward primer (10 μM) 0.6 μL 
Forward primer (10 μM) 0.6 μL 
cDNA 1 μL 
Water 7.8 μL 
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2.7 Protein expression analysis  
2.7.1 Western blot analysis 
2.7.1.1 Total protein isolation from cell lines 
Media was removed before cells were washed with cold PBS. 100 µl of lysis 
buffer (1% Triton X-100 and 1x protease inhibitor cocktail (Roche) in PBS) was 
applied to 1 well of a 6-well plate. Cells were scraped and centrifuged at 1000 
rpm for 2 mins. The supernatant was stored at – 80 °C.  
2.7.1.2 Total protein isolation from clinical fresh frozen tissue 
All clinical fresh frozen samples were cut onto slides and marked with tumour or 
BPH area before being macro-dissected to 2 mL tubes as illustrated in 2.5.1.2. 
500 μL of lysis buffer was added to each tube. Tissue was homogenised using a 
homogeniser. The tissue was then sonicated on ice with 2x 10 s pulses. The tubes 
were centrifuged at 14,000 rpm for 15 mins at 4 °C. Supernatants were 
transferred to pre-chilled 1.5 mL tubes and kept at – 80 °C prior to use. 
2.7.1.3 Protein quantification 
Protein concentrations of whole cell extracts were quantified in duplicate, using 
the Bradford Protein Assay (BioRad) in a 96-well microplate (Greiner Bio-One). 
Protein was quantified by diluting the whole cell extract (1:10) in double distilled 
H2O, adding 190 µl of 1x BioRad reagent (5x) diluted in distilled H2O. In 
addition, 10 µl of 0.1, 0.2, 0.3, 0.4, 0.5, 0.8, 1 mg/ml of bovine serum albumin 
(BSA; Sigma-Aldrich) were added to 190 µL 1x BioRad reagent respectively. 
After incubation at RT for 5 mins, absorbance of samples at 595 nm was 
measured using an Opsys MR 96-well microplate reader (DYNEX). A standard 
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curve of absorbance versus concentration was constructed for the different 
concentrations of BSA and the protein concentration in each sample was 
calculated using this graph.  
2.7.1.4 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and protein detection 
30 µg of protein from each sample was used for Western-blot analysis. The 
protein was combined with SDS-PAGE loading buffer and reducing buffer and 
then heated to 100 °C for 5 mins before separation by electrophoresis. The Bio-
Rad mini-PROTEAN Tetra gel electrophoresis system was used (Bio-Rad 
Laboratories Ltd).  Depending on the molecular weight of the protein of interest, 
different concentrations of resolving gel were prepared: 7.5-8% gels were cast 
for high molecular weight proteins (i.e. more than 100 kD) and 10-12% gels for 
lower molecular weight proteins (i.e. 20-100 kD) (Table 2.21). After the 
resolving gel was loaded in between the gel plates, double distilled water was 
overlaid to exclude air. Once set, water was poured off and the stacking gel was 
added. The desired comb was inserted to form wells within the stacking gel. 
Once set, the gel was transferred into a Bio-Rad reservoir tank filled with 1x 
Tris-Glycine-SDS PAGE buffer (National Diagnosis). The protein samples and 
15 µL spectra multicolour broad range protein ladder (Fermentas) were loaded.  
The gel was run at 100 V for protein stacking and 120 V for protein separation. 
Then proteins were transferred onto a PVDF membrane at 0.25 mA for 90 mins 
in a transfer tank filled with 1x Tris-Glycine electroblotting buffer (National 
Diagnosis) and surrounded by an ice-box. 
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Table 2.21 SDS-Polyacrylamide Gel Formulations 
 Resolving gel Stacking gel 
 7.5% 10% 12% 15% 5% 
Acrylamide/Bisacrylamide (40%) 2.85 mL  3.8 mL    4.5 mL    5.7 mL 625 µL 
Tris-HCl (1.5M, pH 8.8) 3.75 mL 3.75 mL 3.75 mL 3.75 mL — 
Tris-HCl (1M, pH 6.8) — — — — 625 µL 
SDS (10%) 170 µL 170 µL   170 µL 170 µL   50 µL 
H2O (MiliQ) 8.15 mL 7.17 mL 6.472 mL 5.27 mL    3.67 mL 
TEMED   10 µL   10 µL     10 µL   10 µL     5 µL 
Ammonium persulphate (1.5%)  100 µL 100 µL   100 µL 100 µL  25 µL 
 
After the proteins were transferred, the membrane was blocked with 5% (w/v) 
non-fat milk and 0.01% Tween-20 in PBS (PBST) for 1 h at RT. The membrane 
was incubated with primary antibody, which was diluted in 10% bovine serum 
albumin (BSA) in PBST, overnight at 4 °C before being washed with PBST for 
10 mins at RT. After the secondary antibody, which was diluted in PBST, was 
added to the membrane and incubated for 50 mins, the membrane was washed 
three times with PBST, 10 mins per wash. Protein was detected by 
chemoluminescent detection of the horseradish peroxidase-conjugated secondary 
antibody using the enhanced chemiluminecence (ECL) Western Blotting 
Detection Reagent (Amersham Biosciences). Signal was visualised with Super 
RX Fuji Medical X-Ray Film (Fujifilm) developed in a Curix 60 Developer 
(Agfa, Middlesex, UK). 
2.7.2 Immunohistochemistry (IHC) 
2.7.2.1 Paraffin-embedment of cells 
In order to perform IHC analysis on cells, which were cultured in vitro, the cells 
were first fixed in formalin and embedded in paraffin. Cells were harvested and 
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washed with PBS before being re-suspended in 2% (w/v) low melting 
temperature soft agar, which was dissolved in PBS and kept at 40 ºC in a water 
bath prior to use). The cell/soft agar suspension was transferred to a 5 mL 
syringe, which was cut at the bottom, and then kept at 4 C for 1 hr. After the 
agar had solidified, it was fixed in 10% formalin for 24 h and then transferred to 
70% ethanol. Paraffin embedment was performed by the pathology services of 
the Institute of Cancer (QMUL, London) .  
2.7.2.2 IHC analysis  
IHC analysis of CNR1 was performed by the Institute of Cancer (QMUL, 
London) pathology service using the Ventana Discovery
TM
 System (Illkirch, 
France) following the manufacturer‘s protocol 088. Simply, all slides were 
deparaffinised and processed for antigen retrieval with standard SSC. After 
blocking, the slides were incubated with the CNR1 primary antibody from 
Abcam (ab23703, synthetic peptide: MSVSTDTSAEAL, corresponding to C-
terminal amino acid 461-472) or CNR1 antiserum (2824.3) for 60 mins and anti-
rabbit secondary antibody for 16 mins. Staining for CNR1, was performed using 
the 3-3‘ diaminobenzidine (DAB) detection kit (Ventana). Slides were 
counterstained with H&E.  
 
Rabbit polyclonal antibody (F69-2) of BACH2 was a kind gift from Prof. 
Igarashi (Division of Biochemistry, Tohoku University Graduate School of 
Medicine). IHC of BACH2 was performed manually by a pathologist, Y.W. Yu. 
All slides were deparaffinised and antigen retrieval was performed by heating the 
sections immersed in Target Retrieval Solution, high pH (DAKO), in a pressure 
cooker for 15 mins. The primary antibody (at a dilution of 1:500) was incubated 
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for 40 mins at RT followed by secondary biotinylated universal antibody 
(Vectastain universal ABC kit, Vector Laboratory) for 30 mins at RT. Tissue 
slides were incubated in DAB at RT until the brown colour appeared.  Slides 
were then counterstained with H&E. 
2.7.2.3 Evaluation of staining 
The stained tissue sections were scored by a pathologist (L.Y. Xue, Cancer 
Hospital, Peking Union Medical College, Beijing, China) with the criteria of 
combined intensity with the rate of positive cells. The staining intensity was 
graded on a 0-3 scale: 0, negative; 1, weak; 2, moderate; 3, strong. The rate of 
positive cells was scored according to the percentage of stained cells in relation 
to the entire section as 0 point for <5%; 1 point, 5~25%; 2 points, 26~50%; 3 
points, 51%~75%; 4 points, >75%. A final score was achieved by multiplication 
of the two scores above. Scores of 0~4 were defined as negative expression (-); 
scores of 5~8 as weakly positive expression (+), and scores of 9~12 as strongly 
positive expression (++).  
2.8 Plasmid construction 
2.8.1 Commercial plasmids 
Two plasmids containing the Kozak sequence and coding sequence of the gene 
CNR1 were purchased from Missouri S&T cDNA Resource Center (USA).  The 
vector backbone of these plasmids is pcDNA3.1(+) (Invitrogen). pcDNA-CNR1, 
contains the CNR1 open reading frame sequence (1419 bp). pcDNA-
3HA_CNR1, contains CNR1 open reading frame sequence with three HA-tags at 
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the N-terminal of CNR1 (1503 bp). The vector, pmaxCloning, was purchased 
from Lonza, Germany.  
2.8.2 Plasmid construction 
2.8.2.1 pcDNA-CNR1_Flag plasmid construction 
In order to over-express CNR1 in prostate cancer cell lines, first of all, the open 
reading frame sequence of CNR1 (1419 bp) was PCR amplified from the cDNA 
of a BPH sample (P129), which was shown with high CNR1 expression at the 
RNA level. In the forward primer, Hind III restriction enzyme cutting site 
(AAGCTT) was incorporated; in the reverse primer, XbaI restriction enzyeme 
cutting site (TCTAGA) was included and a Flag-tag sequence 
(GATTACAAGGATGACGACGATAAG) was also added before the stop codon 
(TGA). The forward sequence was 5‘-AGTAAGCTTGAGGTTATGAAGTCGATC 
CTAGATGGC, and the reverse sequence was 5‘-ACTTCTAGATCACTTATCGTC 
GTCATCCTTGTAATCCAGAGCCTCGGCAGACGTG. The PCR was performed 
using the high fidelity Phusion DNA polymerase (Finnzymes). The PCR was 
preceded by initial denaturation at 98 C for 2 mins followed by 35 cycles of 
denaturing at 98 C for 10 s, annealing at 65 C for 30 s, extension at 72 C for 
90 s. The reaction followed by extension at 72 C for 10 mins. The PCR product 
was purified using a PCR purification kit (Qiagen) before being digested with 
both Hind III and XbaI at 37 C for 1 h. The plasmid pcDNA3.1 (+) (Invitrogen) 
was also digested with the same restriction enzymes under the same conditions. 
Digested PCR and pcDNA3.1 fragments were separated by agarose gel 
electrophoresis and purified using a Gel extraction kit (Qiagen). The PCR 
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product was ligated with pcDNA3.1 (+) using T4 DNA ligase (NEB) at 16 C 
overnight.  
2.8.2.2 pmaxCNR1 plasmid construction 
The open reading frame sequence of CNR1 (1419bp) with Kozak sequence 
(gccaccatgc) was inserted between the KpnI (ggtacc) and the SacI (gagctc) sites 
of the pmaxCloning multiclonal site (MCS). For gene cloning, the forward 
primer sequence is 5'-AGTGGTACCGCCACCATGAAGTCGATCCTAGATGGC 
and reverse primer sequence is 5‘-ACTGAGCTCTCACAGAGCCTCGGCAGACGT 
G. The PCR was performed by initial denaturation at 98 °C for 2 mins and 35 
cycles with denaturing at 98 °C for 10 s, annealing at 65 °C for 30 s, extension at 
72 °C for 90 s. The reaction was ended with an extension step at 72 °C for 10 
mins. The following procedures, including PCR product purification, restriction 
enzyme digestion and ligation with pmaxCloning plasmid, were completed as 
described in 2.8.2.1. 
2.8.2.3 Plasmid transformation 
The ligated plasmid was transformed into TOP10 chemically competent bacteria 
(Invitrogen) through co-incubation for 5 mins on ice, heat shock at 42 C for 40 s 
and incubation for 10 mins on ice. Then the transformed bacteria were spread on 
an LB agar plate containing 100 ng/mL ampicillin overnight. Single colonies 
were picked and cultured in LB media on an oscillating incubator shaking at 225-
300 rpm at 37 C overnight. The plasmids were extracted using a miniprep kit 
(Qiagen) and then sent to the Genome Centre (QMUL, London) for sequencing. 
The plasmid, which was confirmed to contain the correct cDNA sequence of the 
gene CNR1, was applied for further study. 
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2.9 Cell transfection 
2.9.1 Over-expression 
In order to study the cellular function of the gene CNR1, a potential tumour 
suppressor gene in prostate cancer, over-expression of CNR1 in prostate cancer 
cells in vitro is essential. In this study, CNR1 was over-expressed transiently in 
22RV1 and 293 cells; In addition, stably transfected 22RV1 cells were 
established. 
2.9.1.1 Transient transfection 
Cell transfection can be accomplished through several different methods. In this 
study, chemical reagents and electroporation (nucleofection) were attempted to 
deliver the plasmids into cells. For transfection with chemical reagents, the 
plasmid, pcDNA-GFP, was used to optimise the transfection protocol for each of 
the reagents used. pcDNA-GFP was a gift kindly provided by Dr Gunnel 
Hallden‘s group (Institute of Cancer, QMUL, London). This is a plasmid with 
the GFP open reading frame sequence inserted into the pcDNA3.1 (+) vector. 
For nucleofection transfection, pmaxGFP, a commercial control plasmid, with a 
GFP open reading frame sequence inserted to the pmaxCloning vector, was used 
to optimise the electrical transfection conditions. For different transfection 
reagents, cell density and the ratio of plasmid/reagent were used according to the 
manufacturer‘s recommendation.  
2.9.1.1.1 Transfection with JetPEITM-RGD reagent 
jetPEI™-RGD (Poly-Plus, Illkirch, France) is a Arg-Gly-Asp (RGD) peptide-
conjugated linear polyethylenimine (PEI). It allows selective and efficient 
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transfection of integrin-expressing epithelial (i.e. prostate cancer cells) and 
endothelial cells as many integrins bind multiple RGD peptide sequences present 
in serum and extracellular matrix proteins. Three different conditions were used 
for transfection with JetPEI-RGD. 2.5 x 10
5 
of
 
22RV1 cells were seeded per well 
in a 6-well plate with 1.8 mL culture media one day before transfection. 3 g of 
DNA and 6 μL of jetPEI™-RGD solution were diluted separately into 100 μL of 
150 mM NaCl. 100 μL of diluted jetPEI™-RGD solution was added to the 100 
μL DNA solution, followed by incubation for 30 mins at RT. Then 200 μL 
jetPEI™-RGD/DNA mixture was added to each well. Cells were incubated at 37 
°C in a CO2 incubator for 24-48 h prior to testing for transgene expression. 
2.9.1.1.2 Transfection with Effectene reagent 
Effectene transfection kit (Qiagen) is routinely used in our lab for transfection of 
HEK293 cells with, in our experience, approximately 50% transfection 
efficiency. 1.5 x 10
5 
HEK293 cells
 
were seeded per well in a 6-well plate and 
cultured overnight. 0.4 g of plasmid was diluted in 100 μL of buffer EC and 
then 3.2 μL of enhancer solution was added followed by incubation for 5 mins at 
RT. 10 μL of Effectene transfection reagent was then added to the mixture and 
incubation was carried out for another 10 mins at RT to allow transfection-
complex formation. In the meanwhile, cells were washed with PBS and refed 
with 1.6 mL growth media. Then 0.6 mL growth media was added to the 
transfection complexes before the whole mixture was applied to the cells. Cells 
were incubated for 24-48 h prior to testing for transgene expression. 
2.9.1.1.3 Transfection with Lipofectamine reagent 
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One day before transfection, 5 x 10
5
 of 22RV1 cells in 2 mL of growth media 
without antibiotics were plated in 6-well plates so that cells reached 90-95% 
confluency at the time of transfection. For each transfection, complexes were 
prepared as follows: 4 g DNA was diluted in 250 μL of serum-free/antibiotic 
free growth media; 10 μL of Lipofectamine™ 2000 (Invitrogen) was diluted in 
250 μL of serum-free/antibiotic free growth media. After incubation for 5 mins at 
RT, the diluted DNA was combined with diluted Lipofectamine™ 2000 followed 
by incubation for 20 mins at RT. 250 μL of complexes were added to each well. 
Cells were incubated at 37 °C in a CO2 incubator for 24-48 h prior to testing for 
transgene expression.  
2.9.1.1.4 Transfection with Nucleofector 
Cells were transfected using Nucleofector technology with the Amaxa cell line 
nucleofector kit V (Amaxa Biosystems, Gaithersburg, MD) according to the 
manufacturer's instructions. 1x10
6
 22RV1 cells and 4 μg of Amaxa's pmaxGFP 
vector, as well as the built-in programme, A-020, was found to result in 
approximately 100% transfection efficiency, thus it was selected for consecutive 
studies. Cells were split 48 h before transfection to obtain 70-80% confluency. 
Cells were then trypsinised and counted. 1x10
6
 cells were centrifuged at 100 g 
for 10 mins. Cell pellets were resuspended in 100 μL Nucleofector solution L 
provided in the kit (Amaxa). Upon the addition of 4 μg DNA, the cell-plasmid 
mix was electroporated on the nucleofector apparatus using programme A-020. 
Immediately after electroporation, 500 μL of pre-warmed cell culture media 
supplemented with 10% FBS was added and the cell-plasmid solution was 
transferred to a 6-well plate, which contained 1 mL of pre-warmed medium. 
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Cells were incubated at 37 °C in a CO2 incubator for 24-48 h prior to testing for 
transgene expression. 
2.9.1.2 Stable transfection 
In order to obtain cells expressing CNR1 stably, transient transfected cells were 
cultured under geneticin G418 (1 mg/mL) (Sigma-Aldrich) selection. G418 is a 
toxin but can be neutralised by the product of the neomycin resistance gene, 
which is constructed in the pcDNA3.1 (+) vector. Therefore, only cells that have 
the plasmid integrated into the nuclear genome would survive. Simply, cells were 
passaged into fresh growth media 24 h after transfection and G418 was add the 
following day to a final concentration of 1 mg/mL. Cells were maintained under 
this selection. Media was changed every 3 to 5 days until successful selection 
was achieved. Stably transfected 22RV1 cells were maintained in RPMI-1640 
supplemented with 10% FCS and G418 at 1 mg/mL.  
2.9.2 siRNA transfection 
CNR1 siGENOME SMARTpool (5 nmol) that targets the 3‘UTR/ORF of CNR1 
transcript was purchased from Dharmacon. CNR1 siRNA (5 nmol) and non-
targeting siRNA (NT siRNA) was dissolved in 500 μL of 1x siRNA buffer, 
which was diluted from 5x siRNA buffer (Dharmacon) in DEPC water, to reach 
20 M concentration. The dissolved siRNA was incubated for 30 mins at RT 
with rotation. The siRNA solution was stored as 50 μL aliquots at -20 °C prior to 
use. 
 
1.2 x 10
5 
of 22RV1 cells were seeded per well in a 6-well plate at 40-50% 
confluence. Cells were cultured overnight in RPIM-1640 media supplemented 
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with 10% FBS without antibiotics. 5 μL of each CNR1 siRNA and non-targeting 
(NT) siRNA was diluted in 180 μL unsupplemented media respectively; 10 μL 
oligofectamine (Invitrogen) was diluted in 40 μL unsupplemented media 
followed by incubation for 10 mins at RT. 25 μL of oligofectamine mix was 
added to CNR1 and NT siRNA mix respectively and incubated for 25 mins at 
RT. Cells in each well were washed with PBS and covered with 790 μL 
unsupplemented media. After the incubation, 210 μL transfection mixture was 
then added to each well and an additional 500 μL RPIM-1640 media, 
supplemented with 30% FBS, was added after 4 h.  
2.10 Cellular functional analysis 
2.10.1 MTS assay 
5x 10
3
 of 22RV1 cells in 100 μL growth media were seeded in each well of 96-
well plates. Media alone was used as control. MTS assay kit CellTitre 96 AQueous 
Non-Radioactive Cell Proliferation Assay (Promega, WI, USA) was used to 
determine cell proliferation/viability every 24 h for 5 days. The MTS assay is a 
colourimetric method for determining cell proliferation/viability, by using the 
tetrazolium compound (3-(4,5-dymethylthiazol-2-yl)-5 (3carboxymethoxyphenyl 
)-2-(4-sulphophenyl)2H-tetrazolium; MTS) combined with phenazine 
methosulphate (PMS), an electron coupling reagent. Mitochondrial enzymatic 
activity of viable cells reduces MTS to formazan that is water-soluble. The 
number of living cells is directly proportional to the concentration of formazan in 
the sample, determined by the absorbance at 490 nm. 2 mL of MTS and 100 μL 
PMS were mixed and 20 μL of the mixture was added to each well of the 96-well 
plate. Absorbance at 490 nm was measured after 3 h of incubation at 37 °C and 
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5% CO2, using an OpsysMR plate reader (Dynex Technologies Inc, Chantilly, 
US).  
2.10.2 Colony formation assay 
3000, 2000, 1000, 100, 10 of 22RV1 cells were plated per well in a 6-well plate 
in growth media. Cells were cultured for 14 days with media changed every three 
days. Media was removed and the colonies from each well were stained with 3 
mL of 1% crystal violet (0.5g dissolved in 500 mL of methanol) for 1 h at RT. 
The excess stain was removed with running water and the plate was left to dry. 
Experiments were carried out in triplicate. The stained colonies were captured 
using a camera. Analysis took place by measuring the area covered by colonies 
using ImageJ software. For each well, the same size of measuring area (230x236 
pixels) was set and the area covered by colonies was measured under the same 
defined thresholds. 
2.10.3 Invasion assay 
Invasion assays were performed using BD Biocoat Matrigel Invasion Chambers 
with 8-micron pores (BD Biosciences, Oxford, UK) in which the upper and 
bottom chambers were separated by a membrane coated with Matrigel. Invasion 
chambers were equilibrated for 2 h at RT and hydrated for 2 h with 500 μL 
serum-free media at 37 C. After rehydration of the Matrigel, 750 μL RPMI-
1640 media, supplemented with 10% FBS, was added to the lower chamber as a 
chemoattractant. 2.5 x 10
4 
cells in 500 L serum-free media were added to the 
upper chamber. The chamber was incubated for 48 or 72 h at 37 C. Cells that 
had invaded through the pores onto the lower surface of the filters were fixed 
with 100% methanol for 30 s. After washing the membrane with double distilled 
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H2O, non-invaded cells at the top of the Matrigel membrane were removed. Cells 
present on the bottom of the membrane represented the invading cells. The 
membranes were stained with 1% Giemsa Blue (Sigma-Aldrich) and the total 
number of invading cells was counted under an Olympus CX41 microscope at 
40x magnification. Each experiment was repeated in triplicate. 
2.11 Statistical analysis  
The statistical analyses regarding t(4;6)(q22;q15) were carried out by a 
statistician (L Ambroisine, CRUK). Associations between t(4;6)(q22;q15) status 
and categorical data were examined using the 2 test. Associations between 
t(4;6)(q22;q15) status and numerical variables were assessed using analysis of 
variance. Univariate and multivariate analyses using proportional hazard 
regression (Cox and Oakes, 1984) were applied to determine the impact of 
t(4;6)(q22;q15) on prostate cancer specific death and death for any cause. For the 
multivariate analyses the variables used were age at diagnosis, Gleason score, 
baseline PSA and tumour volume in the biopsy. For IHC analysis of CNR1 and 
BACH2, the statistical analyses were done by a pathologist (L.Y. Xue, Cancer 
Hospital, Peking Union Medical College, Beijing, China). The 2 test performed 
with SPSS 10.0 for Windows (SPSS, Chicago, IL, USA) was used to compare 
the immunoreactivity of CNR1 and BACH2 protein among prostate cancer and 
BPH samples. Regarding the DNA methylation analysis of CNR1, the statistical 
analyses were performed by Dr N Vasiljevic (Cancer Research UK Centre for 
Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive 
Medicine). The analyses were based on mean values of the four CG analysed. 
Methylation differences between normal and cancer were examined by Wilcoxon 
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signed-rank and Mann-Whitney test for matched or unmatched specimens 
respectively. The statistical calculations were conducted using software R 
version 2.9.2 (Team, 2009).  
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3 THE IDENTIFICATION OF 
CHROMOSOMAL TRANSLOCATION, 
T(4;6)(q22;q15), IN PROSTATE 
CANCER 
3.1 Introduction 
In 2005, identification of recurrent fusion genes, TMPRSS2:ERG and 
TMPRSS2:ETV1, in prostate cancer addressed the importance of chromosomal 
translocation and fusion genes in prostate cancer development. Our group has a 
long-standing interest in attempting to identify chromosomal translocation and 
fusion genes in prostate cancer. In 2007, we reported a recurrent chromosomal 
translocation, t(4;6), which was detected in three out of six prostate cancer cell 
lines and four of 25 primary tumours using M-FISH analysis (Lane et al., 2007). 
The breakpoints of the translocation were mapped in the LNCaP cell line using 
FISH analysis (Lane et al., 2007). It showed that the breakpoints locate at 4q22 
and 6q15. In addition, micro-deletions were identified adjacent to both of the 
breakpoints. Therefore there were two breakpoints at each of the 4q22 and 6q15 
locations. At distal breakpoint of 4q22, the gene unc-5 homolog C (UNC5C) lost 
its promoter and the first exon. UNC5C is one of the netrin-1 receptors and it 
belongs to the functional dependence receptor family, members of which share 
the ability to induce apoptosis in the absence of their ligands. UNC5C has been 
reported as a putative tumour suppressor gene (Thiebault et al., 2003). At 
proximal breakpoint of 4q22 and two breakpoints of 6q15, no known gene has 
been identified. Interestingly, copy number loss has been detected frequently on 
4q and 6q in prostate cancer as described in 1.6.3. 6q15, particularly, is one of 
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the most frequently deleted regions in prostate cancer, indicating that tumour 
suppressor gene(s) might locate in this region. 
Chromosomal translocation has a causal effect in haematological malignancy. A 
classic example is the Philadelphia chromosome, which is caused by 
t(9;22)(q34;q11), which presents in 95% of CML patients. The Philadelphia 
chromosome serves as a diagnostic marker, therapeutic target as well as a 
prognosis marker to predict the therapeutic outcome (Sessions, 2007). If t(4;6) is 
correlated with any clinical feature or patient outcome, it could, potentially, be 
used as a biomarker. The clinical prevalence of t(4;6) and its correlations with 
clinical outcome in prostate cancer were investigated in this study.  
 
3.2 Aims 
In this study, I aimed to examine the frequency of t(4;6)(q22;q15) using FISH 
analysis on prostate cancer tissue microarrays (TMAs) with probes located on 
4q22 and 6q15 and then correlate the translocation status with clinical features.  
 
3.3 Results 
3.3.1 Probe selection  
The t(4;6) can be examined by FISH signal co-localisation or splitting analysis. 
For signal co-localisation analysis, two probes binding to 4q22 or 6q15 were 
labelled as green or red respectively. In t(4;6) negative cases, red and green 
signals appeared to be apart from each other as they bind to different 
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chromosomes; whereas in t(4;6) positive cases, red and green signals appeared to 
be adjacent to each other (co-localised). For signal splitting analysis, two probes 
were utilised, which bind to each side of the breakpoint on 4q22 or 6q15. In 
t(4;6) negative cases, red and green signals were expected to be located adjacent 
to each other, whereas in t(4;6) positive cases, splitted red and green signals were 
expected to be observed. FISH signal co-localisation analysis was preferred 
initially as, in general, co-localised signals were easier to distinguish visually 
than splitting signals. Therefore we decided to apply FISH signal co-localisation 
analysis to investigate the t(4;6) fusion in large prostate cancer samples first and 
then perform signal splitting analysis to confirm the co-localised signals, which 
is caused by t(4;6) rather than random adjacent localisation of two chromosomes, 
in certain samples. 
 
Dual-colour probes that separately bind to the regions flanking the breakpoints 
on chromosome 4 and 6 were selected for FISH signal co-localisation analysis. 
Probes that separately bind to the regions flanking the distal breakpoint on 
chromosome 6 were selected for FISH signal splitting analysis. There were two 
different probe combinations: one was to use the probes binding to distal 4q22 
and proximal 6q15; the other was to use the probes binding proximal 4q22 and 
distal 6q15. Both combinations were tested in our group‘s previous study. The 
first probe combination showed co-localised signals in LNCaP cells and one 
primary prostate cancer sample, whereas the other pair did not. Further study 
demonstrated that, besides the translocation, the 6q15-25.3 fragment was 
inverted, which leads to the fusion of 4q22 to 6q25.3 in LNCaP cells; therefore 
there was a gap between the proximal 4q22 and the proximal 6q15 signals. 
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Although the inversion might only be specific to LNCaP cells, we preferred to 
investigate the t(4;6) using the first combination in primary prostate cancer 
samples. 
 
In order to generate good signals on FFPE TMAs, probe sets with a combination 
of more than one probe were considered. It has been reported that three 
overlapping BAC clones showed 400 times magnified signal intensity, with little 
increase of background noise, on FFPE tissue sections (Lambros et al., 2006). 
Therefore three probes were selected to hybridise simultaneously to distal 4q22 
or proximal 6q15. The probe information and their corresponding regions are 
shown in Table 3.1. For the co-localisation analysis of the t(4;6)(q22;q15), probe 
set I on distal 4q22 location (Figure 3.1a) was labelled with biotin; probe set II 
on 6q14.3 (Figure 3.1b) was labelled with DIG. For the 6q15 break-apart assay, 
probe set III (Figure 3.1c), corresponding to the 6q15 deleted region in LNCaP, 
was labelled with biotin and was used in combination with the DIG-labelled 
probe set II on proximal 6q15. For each location, one probe set was generated 
from three BACs. In addition to the probe sets I and II, a third probe set (set III) 
was generated in order to confirm the translocation. All the BACs listed in the 
Table 3.1 have been validated on metaphases of normal lymphocytes with 
chromosomal location specificities. 
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Table 3.1 Probe sets for t(4;6) detection and confirmation. 
Probe
set 
Chr. Location BAC clone Region Length 
(bps) 
Labelled Signal 
colour 
 
 
    I 
 
 
4 
 
 
 
Distal 4q  
RP11-18N21 98,354,298-
98,515,689 
63,210   
 
Biotinylate 
 
 
Red RP11-681L8 98,513,689-
98,622,889 
161,392  
RP11-240J11 98,832,380-
98,895,589 
109,201  
 
 
II 
 
 
6 
 
 
 
Proximal 6q 
RP11-111J1 87,249,921-
87,344,749  
97,534  
 
DIG 
 
 
Green RP11-595C20 87,344,650-
87,442,183  
59,031 
RP1-214H13 87,576,952-
87,635,982 
94,829  
 
 
III 
 
 
6 
 
 
 
Deleted 
RP1-44N23 90,814,536-
90,843,275 
28,740  
 
Biotinylate 
 
 
Red RP1-154G14 91,251,386-
91,352,280 
100,895 
RP11-104N3 91,549,094-
91,609,835 
60,742 
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Figure 3.1 Maps showing the position of the BACs used as probes in FISH 
assays.  
(a) Probe set I includes three BACs, RP11-18N21, RP11-681L8 and RP11-
240J11, corresponding to a 0.54Mb region of distal 4q22 breakpoint. (b) Probe 
set II includes three BAC clones, RP11-111J1, RP11-595C20 and RP1-214H13, 
corresponding to a 0.39Mb region of 6q14.3 (proximal to 6q15 breakpoint). (c) 
Probe set III includes three BACs, RP1-44N23, RP1-154G14 and RP11-104N3, 
corresponding to a 0.80Mb region of 6q15 deleted in LNCaP cells. 
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3.3.2 Co-localisation analysis  
3.3.2.1 Defining the cut-off for t(4;6) on control TMAs 
As co-localisation of the 4q22 and 6q14.3 probes can also be caused by co-
localisation of these two chromosomes by chance rather than translocation, we 
expected to see a low frequency of co-localised signals in normal tissue cells. 
Therefore, we determined the frequency of signal co-localisation on 16 
morphologically normal tissues (Table 3.2). The co-localised signals in all the 
normal samples occurred at a low frequency, ranging from 1% to 6% with the 
mean of 2.7094 and standard deviation (SD) of 1.2151. A sample area without 
co-localised signal is shown in Figure 3.3a. Although it is widely accepted that 
the diagnostic cut-off is calculated as the mean plus three times SD of false-
positive findings in at least five normal controls, we used a higher cut-off of 15% 
which is considered a reasonable cut-off for single co-localisation analysis 
(Ventura et al., 2006). We subsequently scored prostate tumour samples as 
positive for t(4;6)(q22;q15) if 15% or more co-localised signals were detected 
within a cancer lesion containing more than 50 cells with both green and red 
signals.  
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Table 3.2 Scoring of non-malignant control samples on the TMAs for co-
localisation of probes on 4q22 and 6q14.3 
Sample Total cells Co-localisation 
positive 
Percentage 
Appendix 98 5 5.10 
Breast 60 2 3.30 
Cervix 1 104 4 3.80 
Cervix 2 67 1 1.49 
Colon 59 1 1.69 
Foreskin 57 2 3.51 
Inflamed gall bladder 54 1 1.90 
Kidney 53 1 1.89 
Lung 50 1 2.00 
Placenta 60 2 3.30 
Prostate 65 1 1.50 
Small Intestine 59 3 5.10 
Stomach 55 1 1.80 
Testis 50 1 2.00 
Tonsil 63 2 3.17 
Uterus 55 1 1.80 
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3.3.2.2 Recurrence of t(4;6)(q22;q15) in primary tumour samples 
Applying the above criteria, we firstly screened for t(4;6)(q22;q15) on the BPH 
and prostate cancer samples on the Barts TMAs using FISH probe co-localisation 
analysis. Out of the 68 prostate cancer samples on the two Barts tissue arrays, 56 
were scorable and 4 out of these samples (7.2%) were considered positive for 
t(4;6)(q22;q15). A representative FISH image is shown in Figure 3.3b. A similar 
screening of the 34 BPH cases did not detect any positive samples. Cells with co-
localisation signals in these samples range from 0% to 9.7% with median of 
3.1%. 
 
After confirming the re-occurrence of the t(4;6)(q22;q15) chromosomal 
translocation in prostate cancer, we further investigated a large cohort of 
localised prostate cancers, initially managed conservatively, on 24 TMAs using 
the FISH probe co-localisation assay. Out of the 808 cancers, 667 cases could be 
analysed and 78 (11.7%) samples were t(4;6)(q22;q15) positive. The 
chromosomal translocations were confirmed using the signal break-apart 
approach on two randomly selected TMAs, which were re-hybridised for FISH 
analysis using probes either side of the 6q15 centromeric breakpoint of LNCaP 
cells (Figure 3.2c-e). Of the five t(4;6)(q22;q15) positive cases, all of them were 
confirmed with the break-apart assay: three cases with splitting signals and two 
cases showing loss of 6q15 probe red signals, indicating deletion of this 
chromosome region as shown in Figure 3.2e. Figure 3.4a and c show examples 
of cells with co-localised signals in the probe co-localisation analysis; Figure 
3.4b and d show the same cells but detected with the signal break-apart assay. 
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The cell with split red and green signals is indicated in Figure 3.2d and the cell 
with missing red signal was indicated in Figure 3.2e. 
 
During our FISH analysis, we also revealed that the t(4;6)(q22;q15) status was 
heterogeneous within each case of cancer. The t(4;6)(q22;q15) fusion was only 
found in some patched areas of each section. The high frequency of signal co-
localisations in one cancer area but lack of co-localisations in the other cancer 
areas indicates the heterogeneity of t(4;6)(q22;q15) in prostate cancer cells 
within individual samples.  
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Figure 3.2 Schematic representation of FISH detection of t(4;6)(q22;q15).  
In the signal co-localisation study (a-b), probe set I and II were used and in the signal 
split apart analysis (c-e), probe set II and III were used. (a) In a normal cell, there are 
two pairs of normal chromosome 4 and 6 carrying hybridised red (probe set I) and green 
(probe set II) signals respectively. In an interphase nucleus, it shows two pairs of 
separated green and red signals. (b) In a cancer cell with t(4;6)(q22;q15), there are one 
of each normal chromosome 4 and 6 carrying hybridised red and green signals. The 
translocation brings probe set I on chromosome 4 and probe set II on chromosome 6 
together. In an interphase nucleus, it shows one pair of separated red and green signals 
and one pair of co-localised red and green signals. (d) In a normal cell, one pair of 
chromosome 6 carry hybridised green (probe set II) and red (probe set III) signals. In an 
interphase nucleus, it shows two pairs of co-localised green and red signals. Bp1: 
centromeric breakpoint; bp2: telemetric breakpoint. (d) In a cancer cell with 
t(4;6)(q22;q15), one chromosome 6 carries hybridised green and red signals, but on the 
chromosome 6 with translocation, the signals are split apart. In an interphase nucleus, it 
shows one pair of co-localised green and red signals and another pair of separated red 
and green signals. (e) In the case of the telemeric part of 6q being lost or two 
breakpoints (bp1 and bp2) occurs due to the t(4;6) rearrangement, besides the normal 
chromosome 6 carrying hybridised red and green signals, only one green signal is left on 
the abnormal chromosome 6 fragment(s). In an interphase nucleus, it shows one pair of 
co-localised green and red signals and a single green signal. 
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Figure 3.3 Examples of FISH signals using the probe co-localisation analysis 
as illustrated in Figure 3.2a and b.  
(a) A co-localisation negative area in a normal control prostate sample where red 
signals were seen separated from the green signals. (b) In a prostate cancer 
sample, co-localisation of red (4q22 probes) and green (6q14.3 probes) signals 
(arrow) was found in many cells.  
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Figure 3.4 Confirmation of the t(4;6) positive cells using the split signal 
approach.  
(a) and (c) The co-localised signals generated by probes on 4q22 (probe set I, 
red) and 6q14.3 (probe set II, green) are indicated by yellow arrows. (b) and (d) 
The nuclei from (a) and (b), respectively, were re-hybridised with probes on 
6q14.3 (green) and 6q15 (probe set III, red). (b) The signals generated by probes 
on 6q14.3 and 6q15 showed split green and red signal (green and red arrows 
respectively), indicating translocation break point at 6q15 region as illustrated in 
Figure 3.2d. (d) A single green signal generated by the probe on 6q14.3 was 
detected (green arrow), whilst the red signal (probe on 6q15) was lost, indicating 
deletion at this region as illustrated in Figure 3.2e.  
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3.3.3 Clinical Significance of t(4;6)(q22;q15) 
As the clinical and patient outcome data are available for the large cohort of 
surveillance-managed cancers, we studied the correlation between the 
t(4;6)(q22;q15) status and these clinical data. The univariate Cox model analysis 
showed that t(4;6)(q22;q15) was not a significant prognostic factor of either 
cause-specific survival (2=1.01, p=0.30) or overall survival (2=0.16, p=0.69) 
(Figure 3.5a and b). The translocation was not significantly associated with 
patient age using 2 test for trend (Table 3.3). However, it presented at a higher 
frequency in tumours with higher Gleason score, clinical stage, baseline PSA and 
larger tumour volume in the biopsy (p=0.04, 0.001, 0.01 and 0.001 respectively).  
 
 
 
 
 
 
 
 
Figure 3.5 Kaplan-Meier analysis comparing prostate cancer patient 
outcomes with the t(4;6)(q22;q15) status.  
(a) and (b) Cause-specific survival and overall survival respectively. 
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Table 3.3 Relationship of t(4;6)(q22;q15) (as a binary variable) with 
demographics and tumour characteristics using a 15% cut-off to define 
negative and positive cases 
Variable 
t(4;6) % of positive cells 
p-value 
a
 
<15% (n=589) ≥15% (n=78) 
    
Mean age  ± SD (years) 69 ± 5 70 ± 5 0.93 
    
Classes of age (years)   0.93 
≤ 65 113 (90%) 13 (10%)  
> 65 - 70 159 (86%) 25 (14%)  
> 70 - 73 152 (89%) 19 (11%)  
> 73 - 76 165 (89%) 21 (11%)  
    
Gleason score 
b
   0.04 
<7 311 (91%)      29 (9%)  
=7 140 (83%)      28 (17%)  
>7 136 (87%)      21 (13%)  
    
Clinical stage 
c
   0.001 
T1 163 (93%)      12 (7%)  
T2 132 (90%)      15 (10%)  
T3  56 (78%)      16 (22%)  
    
Baseline PSA   0.01 
≤ 10 221 (92%)      18 (8%)  
> 4 - 10 123 (88%)      17 (12%)  
> 10 - 25 112 (86%)      18 (14%)  
> 25 - 50  85 (84%)      16 (16%)  
> 50 - 100  48 (84%) 9 (16%)  
    
Cancer in biopsy (%) 
d
   0.001 
≤ 6 180 (93%)      14 (7%)  
> 6 - 20 143 (89%)      18 (11%)  
> 20 - 40  86 (91%) 8 (9%)  
> 40 - 75  70 (82%)      15 (18%)  
> 75 - 100  99 (81%)      23 (19%)  
    
a
 Test for trend in ―≥15%‖ group (except for mean age). 
b
 Restricted to patients for which Gleason score was available.  
c
 Restricted to patients for which clinical T stage was available.  
d
 Restricted to patients for which extent of disease was available.  
Abbreviations: SD, standard deviation; PSA, prostate specific antigen.  
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3.3.4 Association of t(4;6)(q22;q15) with ERG gene 
rearrangements 
Since the translocation status of ERG was already defined in this large cohort of 
prostate cancers (Attard et al., 2008), we assessed whether there was an 
association between t(4;6)(q22;q15) and ERG gene rearrangements. In 510 cases 
of the cancer samples, both t(4;6)(q22;q15) and ERG gene rearrangement status 
were available. Although no correlation between t(4;6)(q22;q15) and ERG gene 
rearrangements was identified in these samples, t(4;6)(q22;q15) occurred more 
frequently in 2+Edel (two or more ERG deletion signals) positive, than negative, 
samples (26.5% vs. 14.5%) (Table 3.4).  
 
Table 3.4 Relationship of t(4;6) with ERG status (n=510 patients) 
ERG status 
t(4;6) status 
Negative 
(n=442) 
Positive 
(n=68) 
Normal 295 (67%)    40 (59%) 
1Esplit 36 (8%) 7 (10%) 
2+Esplit 17 (4%)      2 (3%) 
1Edel  60 (14%)    10 (15%) 
2+Edel     34 (8%) 9 (13%) 
1Esplit: one ERG split signal; 2+Esplit: two or more ERG split signals; 1Edel: 
one ERG deletion signal; 2+Edel: two or more ERG deletion signals. 
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3.4 Discussion 
Recent discovery of recurrent fusion genes in a range of carcinomas, (Choi et al., 
2008; Liu and Adams, 2007; Mitelman et al., 2007; Soda et al., 2007; Tognon et 
al., 2002) including prostate cancer, (Maher et al., 2009; Tomlins et al., 2007; 
Tomlins et al., 2005) suggests an important role for chromosomal 
rearrangements in solid tumours (Mitelman et al., 2007). Here we have 
confirmed the frequent occurrence of a novel chromosomal translocation in 
human prostate cancer. Previously, we reported the t(4;6) translocation in 
prostate cancer cell lines and a small set of primary prostate tumours, without 
definition of the chromosome breakpoints in these samples, except in LNCaP 
cells (Lane et al., 2007). Using BAC clones flanking the 4q22 and 6q15 
translocation breakpoints defined in LNCaP cells, we have now confirmed a 
similar translocation occurs in a considerable proportion of primary prostate 
cancers.  
 
In the current study, t(4;6)(q22;q15) translocation was not independently 
associated with prognostic potential, specifically not with poor patient outcome. 
However, it was significantly associated with tumours of high tumour volume 
and relatively late clinical T stage (p=0.001). The TMPRSS2:ERG fusion, 
previously linked to high clinical stage and more aggressive cancers (Mehra et 
al., 2007b; Perner et al., 2006; Wang et al., 2006), is not generally associated 
with prostate cancer patient outcome, except the amplified fusion genes with 
deletion between TMPRSS2 and ERG (Attard et al., 2008; Gopalan et al., 2009). 
In our previous analysis of factors affecting patient outcome in this cohort, 
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Gleason score was shown as the strongest predictor while the clinical T stage had 
little impact (Cuzick et al., 2006). Therefore, t(4;6)(q22;q15) itself may affect 
cancer cell proliferation locally in the prostate, but not contribute much to 
tumour metastasis or other features associated with poor patient outcome. In this 
study, the correlation between ERG gene rearrangements and t(4;6)(q22;q15) 
was determined. It showed that t(4;6)(q22;q15) occurred more frequently in 
2+Edel positive than negative prostate cancer samples. It has been shown that 
prostate cancers with 2+Edel are associated with a bad prognosis (Attard et al., 
2008). There might be a subtype of t(4;6) which is associated with 2+Edel 
positive and bad prognosis cancers. 
 
The recurrent chromosomal rearrangements previously identified mainly lead to 
gains of function of genes located at the breakpoints (Mitelman et al., 2007). 
However, the mechanism of action of the t(4;6)(q22;q15) translocation is less 
clear. In LNCaP cells, a small deletion adjacent to the translocation breakpoints 
occurred at both chromosomes 4 and 6 leading to four breakpoints instead of two 
(Lane et al., 2007). UNC5C located at the distal breakpoint on 4q22 was the only 
known gene interrupted by these four breakpoints. No currently known genes 
were located at the other three breakpoints. In our group‘s previous study, we 
failed to identify UNC5C fusion transcripts by RT-PCR in LNCaP cells and no 
fusion transcripts involved in UNC5C or corresponding to this chromosomal 
rearrangement have been identified in this cell line by deep sequencing using the 
next generation sequencing technology (Maher et al., 2009). Therefore, 
t(4;6)(q22;q15) might cause the inactivation of UNC5C. Down regulation of 
UNC5C occurs in various human tumours, including colorectal, breast, ovary, 
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uterus, stomach, lung, or kidney cancers. (Arakawa, 2004; Furuta et al., 2006; 
Latil et al., 2003; Thiebault et al., 2003). Aberrant methylation of UNC5C has 
been detected frequently in advanced colorectal cancer and inactivation of 
UNC5C has been demonstrated to be associated with colorectal cancer 
progression (Hibi et al., 2009) (Bernet et al., 2007). 4q and 6q are among the 
most frequently deleted chromosome regions in human tumours and 6q15 
deletion has been associated with a subtype of prostate cancer (Konishi et al., 
2003; Lapointe et al., 2007; Liu et al., 2007). The 6q15 chromosome region has 
been proposed to harbour candidate tumour suppressor genes in prostate cancer, 
such as the MAP3K7 (Liu et al., 2007). The subsequent effect of t(4;6)(q22;q15) 
may be a consequence of the inactivation of candidate tumour suppressor genes 
located either at the breakpoints or within the adjacent deleted regions. 
Inactivation of genes through chromosomal translocations has been reported 
previously (Belloni et al., 2004; Berger et al., 2006; Fernandez et al., 2008; 
Karenko et al., 2005; Mitelman et al., 2007; Panagopoulos et al., 2006; Popovici 
et al., 2002). The high resolution provided by recently developed microarray 
technology allows detection of sub-microscopic deletions associated with 
cytogenetically balanced translocations (Mao et al., 2007; Watson et al., 2007). 
In a wide range of leukaemias, including CML, AML and ALL, these 
microdeletions coupled with chromosomal translocations are associated with 
poor prognosis (Kolomietz et al., 2001). Therefore we hypothesise that the 
t(4;6)(q22;q15) may contribute to prostate cancer development through 
inactivation of tumour suppressor genes rather than gain of function by forming 
fusion genes.  
 
   
 147 
A second possibility is that the translocation is a reflection of genomic 
instability. Genomic instability is an important mechanism in carcinogenesis 
(Cahill et al., 1999; Mao et al., 2008) and there is evidence that genomic 
instability, particularly chromosomal instability which occurs as early as at the 
precursor stage, is involved in prostate cancer development and progression (De 
Marzo et al., 2003; Joshua et al., 2008; Karan et al., 2003). Prostate cancer 
frequently presents as multiple foci lesions and different genomic alterations, 
including multiple forms of TMPRSS2:ETS fusions, frequently occur in different 
foci within the same case of prostate cancer. This indicates that these multiple 
foci arise independently (Attard et al., 2009a; Clark et al., 2008; Joshua et al., 
2008; Mehra et al., 2007a). This independent generation of multiple foci within 
the same prostate, together with the identification of genetic alterations in the 
normal prostate epithelial cells adjacent to cancer lesions, suggests that there is 
an underlying mechanism leading to genomic instability in the prostate cells 
(Joshua et al., 2008). This genomic instability may induce multiple genomic 
alterations and chromosomal rearrangements, among them the t(4;6) 
translocation. This genomic instability induced t(4;6) translocation may explain 
why the t(4;6)(q22;q15) was identified in only a proportion of cancer cells in 
each specimen. The occurrence of genetic alterations in a proportion of cancer 
cells has been observed previously in prostate cancer, including the commonly 
deleted PTEN genes (Attard et al., 2009b; Klein et al., 2002). Heterogeneity of 
PTEN deletions has also been observed in our FISH analysis of prostate cancer 
samples from prostatectomy (unpublished data). While the t(4;6) translocation 
may represent genomic instability in the translocation positive samples, the 
frequent  detection of t(4;6)(q22;q15) may also indicate that 6q15 and 4q22 are 
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unstable genomic regions in prostate cancer cells, which correlates with the 
frequent genomic copy number changes of these regions as discussed above. 
Further investigations are now required to understand the biological mechanism 
of the t(4;6)(q22;15) translocation. 
 
In summary, t(4;6)(q22;q15) is a frequent chromosomal translocation in prostate 
cancer, which has now been confirmed in a large series of prostate cancer 
clinical samples. While it does not affect patient outcome independently, it does 
not occur in non-malignant prostatic epithelium and hence it may define the 
development of a specific cohort of prostate cancers. The consequence of this 
genomic alteration and affected genes should be studied further. In Chapter 4, 
the potential tumour suppressor genes in 6q15 deletion region associated with the 
t(4;6)(q22;q15) are investigated. 
4 6q15 DELETION AND GENE 
EXPRESSION ALTERATIONS IN 
PROSTATE CANCER 
4.1 Introduction  
As illustrated in the previous chapter, we identified a recurrent translocation, 
t(4;6)(q22;q15), in prostate cancer. We hypothesised that this translocation may 
contribute to prostate cancer development through inactivation of tumour 
suppressor gene(s). The first supporting evidence for this hypothesis is that the 
putative tumour suppressor gene UNC5C was identified to be disrupted by the 
distal breakpoint of the translocation on 4q22 in LNCaP cells. At the genomic 
level, UNC5C lost its promoter and the first exon caused by the t(4;6)(q22;q15) 
fusion as well as the micro-deletion on 4q22; at the transcriptional level, the 
expression of UNC5C could not be detected using RT-PCR analysis, indicating 
that UNC5C might have lost its expression due to the disruption of the genomic 
DNA. 
 
The second line of evidence is as described earlier: the micro-deletion on 4q22 
and 6q15 is another characteristic of t(4;6) in LNCaP cells. 6q15 is one of the 
most frequently deleted regions reported in prostate cancer (Cooney et al., 1996; 
Konishi et al., 2003; Liu et al., 2007). Our SNP array data are consistent with 
this identification showing that 6q15 was deleted in 53% (35 in 66) of prostate 
cancer patients (unpublished data). It is believed that there are one or more 
tumour suppressor gene(s) in 6q15. Liu et al. reported that loss of MAP3K7 gene 
in 6q15 was associated with high-grade prostate cancer (Liu et al., 2007). 
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MAP3K7 encodes Tak1, a mitogen activated protein kinase kinase kinase family 
member. MAP3K7 is the first gene distal to the telomeric breakpoint of 
t(4;6)(q22;q15) in the LNCaP cell line. Whilst there is evidence to suggest that 
the MAP3K7 
(TGF-β)-induced apoptosis in prostate cancer cells (Edlund et al., 2003), it has 
yet to be determined if MAP3K7 plays a role in prostate cancer pathogenesis. 
Other putative genes have been identified within the 6q15 deletion region, 
including CX62, MDN1, caspase 8 associated protein A2 (CASP8A2) and BTB 
and CNC homology 1, basic leucine zipper transcription factor 2 (BACH2)  (Liu 
et al., 2007). CASP8A2 is involved in CD95-induced apoptosis via caspase 8 
activation.  Therefore, deletion of this gene would be detrimental in terms of the 
cells‘ ability to undergo apoptosis. One study has shown that CASP8A2 is 
frequently mutated in mismatch repair-deficient colorectal cancer cell lines (Park 
et al., 2002). BACH2 is a B-cell specific transcription factor, which has been 
implicated as a putative tumour suppressor gene. There have been several reports 
demonstrating high frequency of LOH in human B-cell lymphomas (Sasaki et 
al., 2000; Vieira et al., 2001). Over-expression of BACH2 in the Raji cell line 
(which does not express endogenous BACH2) results in enhanced apoptosis upon 
exposure to cytotoxic drugs, which are oxidative stressors, such as etoposide, 
doxorubicin and cytarabine (Kamio et al., 2003). Although these genes are 
considered as putative target genes in the 6q15 deletion region, no detailed 
analysis of these genes has been made relating to prostate cancer.  
 
Minimisation of the commonly deleted region on 6q may facilitate the 
identification of the putative tumour suppressor genes. According to our group‘s 
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previous SNP array data (unpublished), the minimum overlapping deleted region 
was on 6q15, detected in 33 out of 71 clinical prostate cancer samples within 
87.21-90.35 Mbp. 34 out of 71 cancer samples were detected covering 90.88- 
91.35 Mbp, which was overlapped with the deleted region in LNCaP cells 
(88.55-91.7 Mbp). 
 
In this study, I examined the frequency of 6q15 deletion in primary prostate 
cancer samples using FISH analysis and investigated the potential tumour 
suppressor genes, for which the RNA expression was down-regulated. 
Expression microarray is one of the ideal approaches to examine the expression 
alterations of all the genes located at 6q15 systematically in prostate cancer. The 
application of the high resolution, high throughput Exon Array has facilitated the 
systematic interrogation of genome-wide differentially expressed genes as well 
as alternative splicing variants in various types of cancer (Gardina et al., 2006; 
Moller-Levet et al., 2009; Thorsen et al., 2008). In this study, Exon Array was 
applied to investigate the commonly down-regulated genes located at 6q15 in six 
prostate cancer cell lines and one clinical prostate cancer sample.  
 
4.2 Aim 
The aim of this study was to determine the frequency of 6q15 deletion in primary 
prostate cancer samples and identify commonly down-regulated genes caused by 
6q15 deletion in prostate cancer. At the same time, I aimed to reveal 
differentially expressed genes and cancer specific alternative splicing in prostate 
cancer using this Exon Array data.  
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4.3 Results 
4.3.1 Frequency of 6q15 deletion in primary prostate 
cancer samples 
In order to examine the frequency of 6q15 deletion in primary prostate cancer 
samples, FISH analysis was applied with a probe set (Table 4.1) spanning the 
region between 90.82-91.25 Mbp. 
 
Table 4.1 Probe set for 6q15 deletion detection 
Location BAC clone Region Length (bps) Labelled Signal colour 
6q15 
RP1-44N23 
90,814,536-
90,843,275 
28,740 
DIG Green 
RP1-154G14 
91,251,386-
91,352,280 
100,895 
 
A commercially available centromere probe for chromosome 6 (labelled as red) 
was used as a control. FISH analysis was performed on two TMAs containing 68 
prostate cancer samples and six morphologically non-malignant prostate 
samples. According to the criteria described in 2.3.2.4, 28 prostate cancer 
samples and four non-malignant control samples were considered informative. 
Among the four control samples, one sample showed 6.25% more red signal than 
green, while the other three showed 4.5%, 0% and 0% respectively (Table 4.2). 
Based on this ratio and consideration of the hybridisation efficiency and 
possibility of artificial truncation of the cells during the slide-cutting process, a 
higher cut-off of 20% was set for detection of the 6q15 deletion. That is, TMA 
cores with more than 20% more red than green signals in all counted cells ( 50 
cells) were considered deletion-positive. Thirteen of 28 (out of 68) prostate 
cancer samples (46%) were assessed as 6q15-deletion positive. The Gleason 
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score of the 28 informative samples was distributed as follows:  16 of them were 
between 2-6 and 37.5% (6 of 16 cases) were deletion positive; seven had a 
Gleason score of 7 with 57.1% (4 of 7 tumours) were deletion-positive; three of 
them were between 8-10 with 75% (3 of 4 tumours) deletion-positive. This 
suggests that 6q15 deletion may associate with high-grade disease but, since 
there was only a small number of patient samples, chi-square test showed no 
statistical significance (P > 0.05).  
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Table 4.2 Frequency of 6q15 deletion using prostate cancer TMAs   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PC- prostate cancer; N- normal prostate;   
 Case  6q15 
Negative/
Core
No. Positive No.
PC1 N A 208 184 3+2
PC2 N A 67 63 5+4
PC3 N A 97 99 4+3
PC4 P A 120 75 3+4
PC6 P A 50 29 3+4
PC7 N A 62 65 3+3
PC8 P A 76 29 4+5
PC9 N A 80 75 3+3
PC10 P A 75 39 4+4
PC11 N A 154 124 2+2
PC12 N A 86 88 1+2
PC13 N A 69 70 1+2
PC14 N A 87 76 3+4
A 36 34
B 82 81
A 65 64
B 54 50
A 137 125
B 38 27
A 104 69
B 148 91
A 24 13
B 102 51
A 177 110
B 58 47
A 41 34
B 71 44
B 15 11
B 8 2
A 52 49
B 13 9
B 21 9
A 199 205
B 142 138
C 105 107
A 110 63
B 254 140
C 115 97
A 140 68
B 37 34
C 59 56
A 9 7
B 60 55
C 4 4
A 122 89
B 26 15
C 51 29
A 6 3
B 92 47
C 95 39
A 305 188
B 155 147
C 138 125
D 24 17
N1 A 47 50
N2 A 75 78
A 140 134
B 141 144
N4 A 85 80
Red Signal Green Signal Gleason Score
PC16 N 3+3
PC17 N 3+3
PC18 N 3+3
PC19 P 3+3
PC20 P 3+3
PC21 P 2+2
PC22 P 3+4
PC25 N -
PC27 N 3+4
PC28 P 3+4
PC29 P 4+4
PC30 N 2+3
PC31 P 3+2
2+2
PC33 P 3+3
N3
PC32 P
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4.3.2 Expression of UNC5C and 6q15 deletion associated 
genes in prostate cancer  
As micro-deletion in 6q15 was confirmed in 46% of prostate cancer samples 
using FISH analysis, the genes down-regulated in the deletion region were 
investigated using Exon Array analysis. Affymetrix Exon 1.0 ST Array analysis 
was applied to six prostate cancer cell lines (LNCaP, PC3, 22RV1, DU145, 
VCaP and MDA PCa 2b), one clinical prostate cancer sample (p127) and two 
BPH samples (p143 and p2) as a control. 
4.3.2.1 Down-regulated genes in the 6q15 region 
Within the 4.14 Mbps region (87.21-91.35 Mbps), there are 29 protein-coding 
genes, 12 pseudo-genes and one non-protein coding RNA according to the NCBI 
database (Human genome, build 36.3) (Table 4.3). No known ESTs or 
microRNAs have been identified in this region. IGB software was used to 
visualise the expression variations of individual genes in all the tested samples. 
Three genes, cannabinoid receptor 1 (CNR1), proline-rich nuclear receptor 
coactivator 1 (PNRC1) and gap junction protein, alpha 10 (CX62), were found to 
be down-regulated in prostate cancer cell lines and the clinical prostate cancer 
sample compared to the two BPH controls (Figure 4.1, Figure 4.2 and Figure 
4.3). Partek software was also used to examine all genes within 88.8-92.9 Mbp. 
Apart from the three genes CNR1, PNRC1 and CX62, the gene BACH2 was also 
commonly down-regulated in prostate cancer cells and the cancer sample 
compared to the BPH controls. 
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Table 4.3 Genes located within 87.21- 91.35 Mbps in 6q15 
Gene Symbol Gene type Region (bps) Description 
LOC643971 Pseudo 87680152- 
87680976 
Similar to 60S ribosomal protein L7 
HTR1E Protein 
coding 
87647024- 
87726397 
5-hydroxytryptamine (serotonin) receptor 1E 
CGA Protein 
coding 
87795333- 
87804824 
Glycoprotein hormones, alpha polypeptide 
LOC442234 Pseudo 87831411- 
87832406 
Similar to Reticulocalbin-1 precursor 
ZNF292 Protein 
coding 
87865269- 
87973406 
Zinc finger protein 292 
LOC644016 Pseudo 88008490- 
88010180 
Similar to heat shock protein 1 (chaperonin) 
GJB7  Protein 
coding 
87992697- 
88038996 
Gap junction protein, beta 7, 25kDa 
C6orf162 Protein 
coding 
88032306- 
88052043 
Chromosome 6 open reading frame 162 
C6orf163 Protein 
coding 
87992697- 
88174183 
Chromosome 6 open reading frame 163 
TAF13P Pseudo 88057220- 
88299735 
TAF13 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, pseudogene 
C6orf165 Protein 
coding 
88117721- 
88174183 
Chromosome 6 open reading frame 165 
SLC35A1 Protein 
coding 
88182643- 
88222057 
Solute carrier family 35 (CMP-sialic acid 
transporter), member A1 
RARS2 Protein 
coding 
88224096- 
88299735 
Arginyl-tRNA synthetase 2, mitochondrial 
ORC3L Protein 
coding 
88299843- 
88377169 
Origin recognition complex, subunit 3-like (yeast) 
AKIRIN2 Protein 
coding 
88384578- 
88411985 
Akirin 2 
NCRNA00120 MiscRNA 88410020- 
88410933 
Non-protein coding RNA 120 
SPACA1 Protein 
coding 
88,814,226-
88,833,269 
Sperm acrosome associated 1 
CNR1 Protein 
coding 
88,906,302-
88,932,385 
Cannabinoid receptor 1 (brain) 
ACTBP8 Pseudo 89,043,958- 
89,769,338 
Actin, beta pseudogene 8 
LOC100130179  Pseudo 89,435,019- 
89,437,344 
Similar to env protein 
RNGTT RNA  Protein 
coding 
89,730,067- 
89,376,708 
Guanylyltransferase and 5'-phosphatase 
CYCSP16  Pseudo 89,769,338- 
89,769,168 
Cytochrome c, somatic pseudogene 16 
LOC100131124  Pseudo 89,826,066- 
89,826,773 
Similar to adaptor-related protein complex 4, sigma 
1 subunit 
PNRC1  Protein 
coding 
89,487,216- 
89,851,598 
Proline-rich nuclear receptor coactivator 1 
SRrp35  Protein 
coding 
89,884,519- 
89,862397 
Serine-arginine repressor protein 
PM20D2  Protein 
coding 
89,912,488- 
89,932,003 
Peptidase M20 domain containing 2 
GABRR1  Protein 
coding 
89,983,779- 
89,944,691 
Gamma-aminobutyric acid (GABA) receptor, rho 1 
GABRR2  Protein 
coding 
90,081,686- 
90,023,958 
Gamma-aminobutyric acid (GABA) receptor, rho 2 
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UBE2J1  Protein 
coding 
90,119,338- 
90,093,063 
Ubiquitin-conjugating enzyme E2, J1 
RRAGD  Protein 
coding 
90,178,497- 
90,134,313 
Ras-related GTP binding D 
LOC100128021  Pseudo 90,239,358- 
90,188,537 
Similar to mCG17022  
ANKRD6  Protein 
coding 
90,199,616- 
90,400,124 
Ankyrin repeat domain 6 
LYRM2  Protein 
coding 
90,405,195- 
90,398,664 
LYR motif containing 2 
MDN1  Protein 
coding 
90,586,163- 
90,409,952 
Midasin homolog (yeast) 
LOC100132736  Pseudo 90,581,116- 
90,581,903 
Similar to family with sequence similarity 64, 
member A 
CASP8AP2  Protein 
coding 
90,596,379- 
90,640,876 
Caspase 8 associated protein 2 
LOC644269  Pseudo 90,652,055- 
90,654,295 
Hypothetical LOC644269 
CX62  Protein 
coding 
90,660,909- 
90,662,540 
Gap junction protein, alpha 10 
LOC100129711  Protein 
coding 
90,716,538- 
90,718,429 
Similar to mCG1050952 
BACH2  Protein 
coding 
91,063,182- 
90,692,969 
BTB and CNC homology 1, basic leucine zipper 
transcription factor 2 
MAP3K7  Protein 
coding 
91,353,628- 
91,282,074 
Mitogen-activated protein kinase kinase kinase 7 
LOC100129847  Pseudo 92,582,852- 
92,582,279 
Hypothetical LOC100129847 
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Figure 4.1 Graphical representation of comparison of the CNR1 expression 
levels in different samples viewed with IGB 
Green bars represent two transcript isoforms of CNR1. The narrow part of the green 
bars indicates untranslated region (UTR) with the wider part indicating exon(s). The red 
bars represent the probe sets that detect the expression of the corresponding region of 
the gene CNR1. Seven samples including four prostate cancer cell lines (DU145, 
LNCaP, PC3, VCaP) and one primary prostate cancer sample (P127), plus two control 
BPH samples (P143 and P2) are shown in this figure. The height of the black bars 
indicates the expression level detected by the corresponding probes. The average 
expression level of each sample detected by four probe sets is compared visually with 
the average level of two controls. The average expression levels of all the prostate 
cancer cell lines and the cancer sample are lower compared to the controls. The lowest 
expression was found in PC3 and LNCaP cells.  
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Figure 4.2 Graphical representation of comparison of the PNRC1 expression 
levels in different samples viewed with IGB 
PNRC1 has only one transcript isoform. The detailed illustration of the common 
features of the figures is described in the legend of Figure 4.1. The average 
expression levels of all the prostate cancer cell lines and the cancer sample 
detected by five probe sets are lower compared to the average level of the two 
controls. The lowest expression is shown in LNCaP cells. 
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Figure 4.3 Graphical representation of comparison of the CX62 (GJA10) 
expression levels in different samples viewed with IGB  
CX62 has one transcript isoform with one exon. The detailed illustration of the 
common feature of the figures is described in the legend of Figure 4.1. The 
average expression levels of all the prostate cancer cell lines and the cancer 
sample detected by two probes are lower compared to the average level of the 
two controls. The lowest expression is in VCaP cells.  
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4.3.2.2 Down-regulation of UNC5C  
As the Exon Array data were available, the expression of the gene UNC5C was 
examined using IGB. It showed that UNC5C was down-regulated in the clinical 
prostate cancer sample and all the cell lines.  
4.3.2.3 qRT-PCR validation of down-regulated genes 
qRT-PCR analysis was applied to validate the down-regulation of the four genes, 
located in the 6q15 region (CNR1, PNRC1, CX62 and BACH2),  and the gene 
UNC5C, using the pre-designed TaqMan gene expression probes detailed in 
2.6.6.2. 
 
The housekeeping gene GAPDH was used as control for gene validation by qRT-
PCR. RNA extracted from the BPH samples, p129, was used as an internal 
calibrator to obtain comparative results (Custom TaqMan gene expression 
assay protocol at http://www.appliedbiosystems.com). 
 
Relative expression of four genes (CNR1, PNRC1, BACH2 and UNC5C) was 
measured by qRT-PCR from one BPH sample (p143) and the six prostate cancer 
cell lines plus one clinical prostate cancer sample (p127) used for the Exon Array 
study. Relative expression of these four genes measured by qRT-PCR was 
consistent with the Exon Array data, showing down-regulation in all prostate 
cancer cell lines and the clinical sample (p127) compared to the BPH sample 
(p143) (Figure 4.4, Figure 4.5, Figure 4.6 and Figure 4.7) 
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As the amount of cDNA from the BPH sample p143 was insufficient, the relative 
expression of CX62 was measured in another BPH sample, p125, instead. The 
qRT-PCR result showed that the expression level of CX62 was too low to be 
detected in all the examined samples including the six prostate cancer cell lines, 
the clinical prostate cancer sample (p127) and the BPH sample p125 (Figure 
4.8). Because the different BPH sample was applied to correlate the Exon Array 
data and relative expression of the gene CX62, it is difficult to draw a conclusion 
as to on whether the qRT-PCR result correlated with the Exon Array data or not.   
 
Additional control samples, including five BPH samples (p125, p6, p112, p37, 
p61) and two primary prostate cancer samples (p105 and p98), were applied to 
further examine the expression alterations of the five genes in clinical samples. 
With the additional samples, CNR1 and BACH2 still showed common down-
regulation in prostate cancer samples. The average expression level of UNC5C in 
the three prostate cancer samples was lower than the average level in seven BPH 
samples (Figure 4.7), but there was only a small number of patient samples, one-
tailed Student‘s t-test showed no statistically significant difference (p=0.0509). 
In contrast, PNRC1 and CX62 did not show common down-regulation in prostate 
cancer samples. The expression of PNRC1 in prostate cancer sample p127 was 
higher than the additional five BPH samples (Figure 4.5). The expression level 
of CX62 was still too low to be detected in all the additional BPH samples 
(Figure 4.8).  
 
The expression levels of CNR1 and BACH2 were further examined in more 
clinical samples. Thirteen prostate cancer and 24 BPH samples were macro-
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dissected to obtain relatively pure cancer and benign prostate tissue respectively 
as described in 2.6.1.2. qRT-PCR analysis was then applied to examine the 
relative expression of CNR1 and BACH2 in these samples. In total, 28 BPH 
samples and 16 clinical prostate cancer samples were applied to examine CNR1 
expression. It showed that the expression of CNR1 was significantly down 
regulated in 16 prostate cancer samples compared to the 28 BPH samples 
(p=0.0201) (Figure 4.4).  As for studies with the gene BACH2, its expression 
was measured in 19 BPH samples and 14 clinical prostate cancer samples. It 
showed that the expression of BACH2 was significantly down regulated in the 14 
prostate cancer samples compared to the 19 BPH samples (p=0.0156) (Figure 
4.6).
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Figure 4.4 Relative expression of CNR1 in fresh frozen clinical tissue samples and prostate cancer cell lines as measured by qRT-PCR.  
The expression of the gene CNR1 was measured by qRT-PCR relative to the expression of the housekeeping gene GAPDH and normalised to the 
p129 as a positive control. N stands for normal BPH sample and T stands for tumour sample. 
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Figure 4.5 Relative expression of PNRC1 in fresh frozen tissue samples and 
prostate cancer cell lines as measured by qRT-PCR. 
The expression of PNRC1 was measured by qRT-PCR relative to the expression 
of the housekeeping gene GAPDH and normalised to the BPH sample p129 as a 
positive control. N stands for normal BPH sample and T stands for tumour 
sample. 
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Figure 4.6 Relative expression of BACH2 in fresh frozen clinical tissue samples and prostate cancer cell lines as measured by qRT-PCR.  
The expression of the gene BACH2 was measured by qRT-PCR relative to the expression of the housekeeping gene GAPDH and normalised to 
the p129 as a positive control. N stands for normal BPH sample and T for tumour sample.  
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Figure 4.7 Relative expression of UNC5C in fresh frozen tissue samples and 
prostate cancer cell lines as measured by qRT-PCR. 
The expression of UNC5C was measured by qRT-PCR relative to the expression 
of the housekeeping gene GAPDH and normalised to the BPH sample p129 as a 
positive control. N stands for normal BPH sample and T stands for tumour 
sample.  
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Figure 4.8 Relative expression of CX62 in fresh frozen tissue samples and 
prostate cancer cell lines as measured by qRT-PCR. 
The expression of CX62 was measured by qRT-PCR relative to the expression of 
the housekeeping gene GAPDH and normalised to the BPH sample p129 as a 
positive control. N stands for normal BPH sample and T stands for tumour 
sample. 
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4.3.3 qRT-PCR validation of other genes in prostate cancer 
As the Exon Array data were available, it was possible to investigate the genes 
with abnormally spliced/truncated mRNA forms or showing consistent over-
/under-expression. 
 
As mentioned earlier, our group has been dedicated to identifing chromosomal 
translocations and fusion genes ever since it was established. Exon Array data 
can be applied to identify potential fusion genes. Using bioinformatic analysis as 
described in 2.6.3.1, two genes: 5 alpha-reductase type 2 gene (SRD5A2, 2p23) 
and keratin 23 (KRT23, 17q21.2), were shown to have a truncated expression 
pattern in all the prostate cancer cell lines and the clinical cancer samples as 
compared to BPH controls. As shown in Figure 4.9, the expression intensity of 
the first exon of the gene SRD5A2, which was detected by four probe sets 
(2547250, 2547249, 2547248 and 2547247), is similar in all prostate cancer cell 
lines and two BPH samples. Conversely the expression intensity of the remaining 
four exons, which were detected by probe set 2547241 for exon 2, 2547240 for 
exon 3, 2547238 and 2547237 for exon 4, 2547236 and 2547235 for exon 5, 
were shown to be lower in all prostate cancer cell lines as compared to the BPH 
controls. The expression pattern of KRT23 (Figure 4.10) was similar to SRD5A2. 
The expression intensity of exon 1 of KRT23, which was detected by three probe 
sets (3756612, 3756611 and 3756610), was similar in all prostate cancer samples 
and two BPH control samples. However the expression intensity of the other 
eight exons, which were detected by probe sets 3756610 and 3756609 for exon 2, 
3756605 for exon 3, 3756604 for exon 4, 3756603 for exon 5, 3756602 for exon 
6, 3756597 for exon 7, 3756596 for exon 8, 3756594, 3756593 and 3756592 for 
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exon 9, was lower in cancer samples as compared to the BPH controls. This 
expression pattern could be caused by genomic alterations, such as translocation, 
deletion, inversion, in which the breakpoint could disrupt SRD5A2 and KRT23 
and lead to the truncated expression pattern of these two genes.  
 
qRT-PCR analysis was performed to validate the expression of different exons in 
these two genes. For each gene, three different TaqMan gene expression probes 
(described in 2.6.6) were used to investigate the expression of different exons. 
For SRD5A2 the expression levels of exon 1, exons 2-3 and exons 4-5 were 
compared. For KRT23 the expression levels of exon 1-2, exons 3-4 and exons 8-9 
were evaluated. Results showed that the overall expression of the gene SRD5A2 
was down-regulated dramatically in all prostate cancer cell lines, although there 
was an indication of differential expression between different exons (Figure 
4.11). Similar to SRD5A2, the expression of KRT23, as examined by three 
different probes, was not detected with 40 cycles of qRT-PCR reaction in all 
prostate cancer cell lines (Figure 4.12). This demonstrated that down-regulation 
of SRD5A2 and KRT23 were the dominant events in gene expression alterations 
in prostate cancer cell lines. In order to examine the expression of these two 
genes in clinical samples, five BPH samples (p125, p6, p112, p37, p61) and three 
primary prostate cancer samples (p105, p98 and p127) were used to examine the 
expression of SRD5A2 using qRT-PCR analysis. Using a TaqMan probe 
binding to the exon 2-3 boundary, the expression of SRD5A2 was shown to be 
down-regulated in prostate cancer samples as compared to BPH controls (Figure 
4.13). Using a TaqMan probe binding to the exon 3-4 boundary, the expression 
of KRT23 was examined in five BPH samples (p125, p6, p112, p37, p61) and 
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two primary prostate cancer samples (p105 and p127). It showed that the 
expression of KRT23 was down-regulated in prostate cancer samples as 
compared to BPH controls (Figure 4.14).  
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Expression plot of the gene SRD5A2 as detected by a series of 
probe sets. 
The expression intensities of five exons detected by ten probe sets, showed 
differential expression between prostate cancer cell lines and BPH controls in 
exon 2-5 but not exon 1. Red dots represent two BPH control samples and blue 
dots represent six prostate cancer cell lines and the clinical prostate cancer 
sample. The red and blue lines indicate the average expression intensity of the 
BPH samples and cancer samples respectively. 
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Figure 4.10 Expression plot of the gene KRT23 as detected by a series of 
probe sets. 
The expression intensities of nine exons, detected by 13 probe sets, showed 
differential expression between prostate cancer cell lines and BPH controls in 
exons 3-9 but not exons 1-2. Red dots represent two BPH control samples and 
blue dots represent six prostate cancer cell lines and the clinical prostate cancer 
sample. The red and blue lines indicate the average expression intensity of the 
BPH samples and cancer samples respectively. 
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Figure 4.11 Relative expression of SRD5A2 exons in BPH and prostate 
cancer cell lines as measured by qRT-PCR 
Using a BPH (p143) and six prostate cancer cell lines (LNCaP, PC3, DU145, 
VCaP, 22RV1 and MDA PCa 2b), the expression levels of exon 1, exon 2-3 and 
exon 4-5 were measured by qRT-PCR relative to the expression of the 
housekeeping gene GAPDH and normalised to the exon 1 of p143 as a positive 
control. 
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Figure 4.12 Relative expression of KRT23 exons in BPH and prostate cancer 
cell lines as measured by qRT-PCR 
Using a BPH (p143) and six prostate cancer cell lines (LNCaP, PC3, DU145, 
VCaP, 22RV1 and MDA PCa 2b), the expression levels of exons 1-2, exons 3-4 
and exons 8-9 were measured by qRT-PCR relative to the expression of the 
housekeeping gene GAPDH and normalised to exons 1-2 of p143 as a positive 
control. 
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Figure 4.13 Relative expression of SRD5A2 in prostate cancer cell lines and 
fresh frozen clinical tissue samples  
The expression levels of SRD5A2 were measured by qRT-PCR relative to the 
expression of the housekeeping gene GAPDH and normalised to the BPH sample 
p129 as a positive control. N stands for normal BPH sample and T stands for 
tumour sample. 
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Figure 4.14 Relative expression of KRT23 in prostate cancer cell lines and 
fresh frozen clinical tissue samples 
The expression levels of KRT23 were measured by qRT-PCR relative to the 
expression of the housekeeping gene GAPDH and normalised to the BPH sample 
p129 as a positive control. N stands for normal BPH sample and T stands for 
tumour sample. 
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Bioinformatic analysis (as described in 2.6.3.1) was also applied to identify 
consistently over-/under-expressed genes in prostate cancer. 1715 and 963 
significantly up- or down-regulated genes, respectively, were identified in six 
prostate cancer cell lines as compared to BPH controls. Nine and 34 significantly 
up-regulated and down-regulated genes were identified in the clinical prostate 
cancer samples. Four over-expressed and 34 under-expressed genes were found 
in both the prostate cancer cell lines and the clinical samples (Table 4.4). 
Analysis of these 38 genes using Ingenuity Pathways Analysis (IPA) software 
(details in 2.6.3.2) showed that 15 of the 38 genes were involved in cancer. 
Further analysis of the 15 genes using IPA revealed that the most significant 
molecular and cellular function, with 10 of the 15 genes involved, was cell death 
(Table 4.5).  
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Table 4.4 Up- and down-regulated genes in prostate cancer cell lines and 
clinical cancer samples  
Affy ID Symbol Location Gene name 
 
Down-regulated genes 
 
3942021 NEFH 22q12.2 Neurofilament, heavy polypeptide 
2672140 LTF 3p21.31 Lactotransferrin 
3301263 SORBS1 10q23.33 Sorbin and SH3 domain containing 1 
3434012 HSPB8 12q24.23 Heat shock 22kDa protein 8 
3549757 SERPINA3 14q32.1 Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 
3756591 KRT23 17q21.2 Keratin 23 (histone deacetylase inducible) 
3367673 MPPED2 11p13 Metallophosphoesterase domain containing 2 
2840393 GABRP 5q33-q34 Gamma-aminobutyric acid (GABA) A receptor, pi 
3455186 KRT6A 12q12-q13 Keratin 6A 
3421511 LYZ 12q15 Lysozyme (renal amyloidosis) 
3407453 PDE3A 12p12 Phosphodiesterase 3A, cGMP-inhibited 
3279313 ITGA8 10p13 Integrin, alpha 8 
4018080 CHRDL1 Xq23 Chordin-like 1 
3518766 EDNRB 13q22 Endothelin receptor type B 
2794704 ASB5 4q34.2 Ankyrin repeat and SOCS box-containing 5 
3908934 PTGIS 20q13.13 Prostaglandin I2 (prostacyclin) synthase 
2902958 C4A 6p21.3 Complement component 4A (Rodgers blood group) 
3102372 SULF1 8q13.1 Sulfatase 1 
2777113 SPARCL1 4q22.1 SPARC-like 1 (hevin) 
2599153 TNS1 2q35-q36 Tensin 1 
2591367 CALCRL 2q32.1 Calcitonin receptor-like 
4018755 LRCH2 Xq23 Leucine-rich repeats and calponin homology (CH) 
domain containing 2 
3446919 ABCC9 12p12.1 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 9 
3278057 CCDC3 10p13 Coiled-coil domain containing 3 
4006210 MAOB Xp11.23 Monoamine oxidase B 
3411810 PDZRN4 12q12 PDZ domain containing ring finger 4 
2453006 PIGR 1q31-q41 Polymeric immunoglobulin receptor 
3310953 CPXM2 10q26.13 Carboxypeptidase X (M14 family), member 2 
3324447 LOC387758 11p14.2 Fin bud initiation factor homolog (zebrafish) 
3401704 CCND2 12p13 Cyclin D2 
3389353 CASP1 11q23 Caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 
2521574 LOC653632 2q33.1 Similar to 130kDa-Ins(1,4,5)P3 binding protein 
3626312 ALDH1A2 15q21.3 Aldehyde dehydrogenase 1 family, member A2 
3671695 WFDC1 16q24.3 WAP four-disulfide core domain 1 
 
Up-regulated genes 
 
2840664 ---   
3749684 ---   
2844293 ---   
3375307 CYBASC3 11q12.2 Cytochrome b, ascorbate dependent 3 
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Table 4.5 Ten commonly down-regulated genes involved in cell death, 
determined using IPA 
Gene 
symbol 
Location Name 
LTF 3p21.31 Lactotransferrin 
SERPINA3 14q32.1 Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 
LYZ 12q15 Lysozyme (renal amyloidosis) 
PDE3A 12p12 Phosphodiesterase 3A, cGMP-inhibited 
EDNRB 13q22 Endothelin receptor type B 
PTGIS 20q13.13 Prostaglandin I2 (prostacyclin) synthase 
SULF1 8q13.1 Sulfatase 1 
CALCRL 2q32.1 Calcitonin receptor-like 
CCND2 12p13 Cyclin D2 
ALDH1A2 15q21.3 Aldehyde dehydrogenase 1 family, member A2 
 
   
 181 
qRT-PCR analysis was performed to validate the expression of two genes SULF1 
and PTGIS. As insufficient cDNA was obtained from BPH sample p143, the 
cancer sample p127 and prostate cancer cell line MDA PCa 2b, the relative 
expression of SULF1 and PTGIS was measured from two BPH samples (p125 
and WX83I) and five prostate cancer cell lines (LNCaP, PC3, DU145, VCaP and 
22RV1). As shown in Figure 4.15A and B, the expression levels of SULF1 and 
PTGIS were down-regulated in prostate cancer cell lines as compared to BPH 
controls. As different BPH samples were applied, and no clinical cancer sample 
was available, it cannot be said that the qRT-PCR result correlates with the Exon 
Array data. 
 
qRT-PCR analysis was also performed to validate the expression of ARMCX1 
(armadillo repeat containing, X-linked 1). According to the Exon Array data, 
ARMCX1 was down-regulated in both prostate cancer cell lines and the clinical 
prostate cancer sample (p127) as compared to BPH controls. Using the same 
samples that were applied to the Exon Array, qRT-PCR analysis validated the 
Exon Array result (Figure 4.16). With an additional five BPH samples (p125, 
p6, p112, p37, p61) and two primary prostate cancer samples (p105 and p98), 
ARMCX1 was still shown to be commonly down-regulated in prostate cancer 
(Figure 4.16). 
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A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 4.15 Relative expression levels of SULF1 and PTGIS in BPH and 
prostate cancer cell lines as measured by qRT-PCR. 
The expression levels of SULF1 (A) and PTGIS (B) were measured by qRT-PCR 
relative to the expression of the housekeeping gene GAPDH and normalised to 
the BPH sample p129 as a positive control.  
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Figure 4.16 Relative expression levels of ARMCX1 in fresh frozen tissue 
samples and prostate cancer cell lines as measured by qRT-PCR. 
The expression levels of ARMCX1 were measured by qRT-PCR relative to the 
expression of the housekeeping gene GAPDH and normalised to the BPH sample 
p129 as a positive control. N stands for normal BPH sample and T stands for 
tumour sample. 
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4.4 Discussion  
Because of our hypothesis that t(4;6)(q22;q15) may contribute to prostate cancer 
development through inactivation of tumour suppressor gene(s), I have focused 
on identifying the potential target gene(s). The micro-deletion on 4q22 and 6q15 
is a characteristic of t(4;6) in LNCaP cells and it might contribute to the 
aggressiveness of prostate cancer. It has been demonstrated that chromosome 
translocation t(9;22)(q34, q11), coupled with small deletions, is associated with 
poor prognosis in leukaemia  (Lee et al., 2006). Loss of chromosomal regions of 
6q has been reported widely as a common occurrence not only in prostate cancer, 
but also in other cancers such as breast, colon and melanoma (Sun et al., 2006; 
Sheng et al., 1996; Walker et al., 1994; Tibiletti et al., 2001). A number of 
studies have subsequently evaluated the frequency of multiple 6q deletions in 
prostate tumours, with reports of up to 48% in some cases (Verhagen et al., 
2002; Sun et al., 2006; Cooney et al., 1996; Srikantan et al., 1999; Alers et al., 
2000; Hyytinen et al., 2002; Konishi et al., 2003). In the present study, using 
tissue microarrays, I found that a similar rate (46%) of prostate cancer samples 
had specific loss of the 6q15 region. Previous studies indicated that loss of 6q 
regions might occur at an intermediate stage of disease development with either 
more locally invasive or metastatic progression (van Dekken et al., 2004; Ribeiro 
et al., 2006a). In my study, 6q15 deletion seems likely to occur with a high 
Gleason score (75% with Gleason score between 8-10 vs 43.5% with Gleason 
score less than 8), however, the number of cases is too small to draw a solid 
conclusion.  Although 6q15 deletion has been widely recognised as a frequent 
event in prostate cancer (Cooney et al., 1996; Konishi et al., 2003; Liu et al., 
   
 185 
2007), the target tumour suppressor gene(s) located in this region are still yet to 
be identified. Liu et al. applied SNP array analysis on 55 matched prostate cancer 
and non-malignant tissue samples and identified a minimum overlapped deletion 
region between 90,3493 and 91,310 Kb (817 Kb), which was shared by 20 
tumours. Five genes (MAP3K, CASP8A2, CX62, MDN1 and BACH2) were 
located in this small region. Further analysis of MAP3K7 revealed the correlation 
of its down regulation with high-grade prostate cancer (Liu et al., 2007). It has 
yet to be determined if MAP3K7 plays a role in prostate cancer pathogenesis. 
According to our Exon Array data, MAP3K7 was not shown to exhibit common 
down-regulation in prostate cancer cell lines and the clinical cancer sample. In 
fact, higher expression of MAP3K7 was shown in PC3 and DU145 cells as 
compared to BPH controls. Regardless of all the identifications indicating the 
existence of tumour suppressor genes in 6q15, to date, no strong candidate genes 
have been discovered relating to prostate cancer. 
 
In this study, I performed Exon Array analysis to interrogate systematically the 
expression alterations of the genes located in 6q15. Four genes (CNR1, PNRC1, 
CX62 and BACH2) were identified with common down-regulation in six prostate 
cancer cell lines and one clinical prostate cancer sample. Followed by qRT-PCR 
validation of these four genes in enlarged clinical prostate cancer samples, CNR1 
and BACH2 were still found to be down-regulated but PNRC1 and CX62 were 
not. 
 
CNR1 is one of the two cannabinoid receptors, responsible for the well-known 
psychotropic effects of cannabinoids. CNR1 is highly expressed in the central 
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nervous system, but lower levels are also present in immune cells and peripheral 
tissues, including prostate. In contrast, cannabinoid receptor 2 (CNR2) is 
expressed predominantly in immune cells. Over past decades, anti-tumourigenic 
effects of cannabinoids have drawn great attention. Apart from their pro-
apoptotic and anti-proliferative action, recent research has shown that 
cannabinoids may also affect angiogenesis, migration, invasion, adhesion, and 
metastasis in various cancers (Freimuth et al., 2010). Extensive molecular and 
pharmacological studies have demonstrated that cannabinoids perform their anti-
tumourigenic effect through CNR1 and CNR2. However, whether CNR1 or 
CNR2 specifically exert tumour suppressor effects has not been well-studied. A 
recent report demonstrated that CNR1 expression was silenced in human 
colorectal cancer due to methylation of the CNR1 promoter and that loss of 
CNR1 accelerated intestinal tumour growth in vivo (Wang et al., 2008). 
According to our identification of down-regulation of CNR1 in clinical prostate 
cancer samples, it seems promising to investigate further the role of CNR1 in 
prostate tumourigenesis. 
 
BACH2 is a B-cell-specific transcription repressor and has been implicated as a 
B-cell specific tumour suppressor. In non Hodgkin's Lymphoma, a relatively 
high frequency of loss of heterozygosity was detected for BACH2 (Sasaki et al., 
2000). Moreover, the BACH2 expression level has proven to be a useful marker 
to predict disease-free and overall survival of patients with diffuse large B-cell 
lymphoma, where a favourable prognosis is correlated with a high expression 
level of BACH2 (Sakane-Ishikawa et al., 2005). It has also been suggested that 
loss or down-regulation of BACH2 expression may contribute to B-cell 
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lymphomagenesis (Liu et al., 2009). In addition, a recent genome-wide 
association study identified a risk locus inside of the gene BACH2 in type 1 
diabetes (Cooper et al., 2008). In this study, the down-regulation of BACH2 was 
consistent with the genomic deletion in 6q15. Whether it also plays a tumour 
suppressor role need to be further explored.  
 
As the Exon Array data were available, the expression of UNC5C was also 
investigated in six prostate cancer cell lines, clinical prostate cancer and BPH 
samples. As illustrated previously, UNC5C was the only gene disrupted by 
breakpoints of t(4;6)(q22;q15). The inactivation of UNC5C has been identified in 
various human tumours, including colorectal, breast, ovary, uterus, stomach, 
lung, kidney and others (Arakawa, 2004; Furuta et al., 2006; Latil et al., 2003; 
Thiebault et al., 2003). Inactivation of UNC5C has been demonstrated to be 
associated with colorectal cancer progression (Bernet et al., 2007). Therefore 
UNC5C has been recognised as a putative tumour suppressor gene (Thiebault et 
al., 2003). In our Exon Array data, the expression of UNC5C was down-
regulated in all prostate cancer cell lines and one clinical prostate cancer sample. 
qRT-PCR analysis confirmed the Exon Array data and, with more clinical 
samples, a trend toward decreased UNC5C expression in tumours compared to 
normal tissue was found.  
 
SRD5A2 and KRT23 were initially selected from the Exon Array data as potential 
truncated genes. However, qRT-PCR validation using probes binding to different 
exons showed that the down-regulation of these two genes was a dominant 
effect. SRD5A2 is an isoenzyme of 5-alpha-reductases, which convert 
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testosterone irreversibly into dihydrotestosterone (DHT). Both normal and 
pathological growth of the prostate depends on DHT synthesis. It has been 
demonstrated that SRD5A2 expression decreases in prostatic intraepithelial 
neoplasia (PIN) and prostate cancer, compared with non-malignant prostate 
tissue. However, the expression of another isoenzyme, SRD5A1, increases as a 
complement to these declines in SRD5A2 levels(Thomas et al., 2008b) (Thomas 
et al., 2008c). Moreover both isoenzymes appear increased in high-grade, as 
compared to low-grade localised, cancer (Thomas et al., 2008c). Until now, no 
study has demonstrated a tumour suppressor role for this gene.  
 
KRT23 is a member of the acidic keratin family. It has been reported that KRT23 
is induced by sodium butyrate in different pancreatic cancer cells through p21 
(WAF1/CIP1), which serves as an important mediator. NaBu was shown to 
induce cell differentiation and apoptosis in the human pancreatic cancer cell line 
AsPC-1 (Zhang et al., 2001). It also has been shown that KRT23 impaired the 
proliferation of human colon cancer cells significantly, leading to cell death in 
microsatellite-unstable, but not microsatellite-stable, cell lines (Birkenkamp-
Demtroder et al., 2007). There currently is no evidence showing that KRT23 is 
associated with prostate cancer. 
 
The Exon Array data were also applied to investigate consistent expression 
changes of genes located on other chromosome regions. The down-regulation of 
the gene ARMCX1 had been reported to be correlated with DNA copy number 
loss at Xq21.33-q22.2 in primary prostate cancer samples (Jiang et al., 2008). 
Our SNP array data (unpublished) also showed copy number loss at Xq21.33-
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q22.2 in 8 out of 71 (11.3%) clinical prostate cancer samples and also in 22RV1 
and VCaP cells. The common down regulation of ARMCX1 was identified from 
our Exon Array data. With further clinical samples, the expression of ARMCX1 
was still shown to be down-regulated in prostate cancer cell lines and the clinical 
prostate cancer samples using qRT-PCR analysis. ARMCX1 is a member of the 
armadillo repeat family, which has been implicated in tumourigenesis, 
embryonic development and maintenance of tissue integrity (Kurochkin et al., 
2001). The mRNA expression of ARMCX1 is lost, or significantly reduced, in 
various human cancer types including lung, prostate, colon, pancreas, and 
ovarian carcinomas and also in cell lines established from human carcinomas. It 
has been speculated that ARMCX1 may play a role in tumour suppression 
(Kurochkin et al., 2001); however, no further studies have yet confirmed this 
possibility.  
 
Fifteen commonly down-regulated genes among prostate cancer cell lines and 
the clinical prostate cancer sample were shown to be involved in cancer. Ten out 
of the fifteen genes were shown to be associated with cell death and six of them, 
(including LTF (3p21.31), EDNRB (13q22), CCND2 (12p13) and ALDH1A2 
(15q21.3)), have been reported to be down-regulated in various cancers (Chen et 
al., 2009; Evron et al., 2001; Frigola et al., 2005; Henrique et al., 2006; Kim et 
al., 2005; Lai et al., 2008; Phe et al.; Shaheduzzaman et al., 2007; Yu et al., 
2003). In prostate cancer, LTF, EDNRB, CCND2 and ALDH1A2 have been 
shown to play a tumour suppressor role (Henrique et al., 2006; Kim et al., 2005; 
Phe et al.; Shaheduzzaman et al., 2007). Down-regulation of LTF has been 
revealed to be associated with reduced PSA recurrence-free survival 
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(Shaheduzzaman et al., 2007); Hypermethylation of EDNRB is correlated with 
the grade and stage of the primary prostate cancer, and inversely correlated with 
PSA-free-survival (Bastian et al., 2007; Yegnasubramanian et al., 2004). 
Inactivation of CCND2 in prostate cancers correlates with poor prognosis (Padar 
et al., 2003). Reduction of ALDH1A2 protein was indicated as an early event in 
prostate cancer using the transgenic prostate adenocarcinoma mouse model 
(Touma et al., 2009). As to the gene SULF1 (8q13.2-q13.3), its down-regulation 
was observed in the majority of cancer cell lines and its tumour suppressor 
function was well-documented showing inhibition of cell proliferation, migration 
and invasion in various cancers, including breast, pancreatic, ovarian, myeloma 
and hepatocellular carcinoma (Abiatari et al., 2006; Chen et al., 2009; Lai et al., 
2003; Lai et al., 2008; Lai et al., 2006; Narita et al., 2006). However, there 
currently is no study showing its expression and function in prostate cancer. 
Similarly to SULF1, although there is evidence showing frequent 
hypermethylation of PTGIS (20q13.13) observed in colorectal cancer, no study 
has examined PTGIS expression in prostate cancer (Frigola et al., 2005). The 
qRT-PCR analysis confirmed the down-regulation of SULF1 and PTGIS in 
prostate cancer cell lines. It would be encouraging to further confirm the 
expression alterations of these two genes in clinical prostate cancer samples. 
 
In summary, the common down regulation of CNR1 and BACH2 in clinical 
prostate cancer samples was consistent with frequent genomic deletion in 6q15. 
Therefore CNR1 and BACH2 might be target tumour suppressor genes located in 
6q15 in prostate cancer. Other genes, including SRD5A2, KRT23, ARMCX1, 
SULF1 and PTGIS have been shown to exibit common down regulation in 
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prostate cancer. Whether these genes have a tumour suppressor role in prostate 
cancer needs to be studied further. 
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5 FURTHER INVESTIGATION OF CNR1 
AND BACH2 AT THE PROTEIN LEVEL 
AND OTHER GENOMIC CHANGES OF 
CNR1 
5.1 Introduction 
In the previous chapter, I described the identification of putative tumour 
suppressor genes involved in the recurrent chromosomal translocation, 
t(4;6)(q22;q15), which are associated with prostate cancer. Using Exon array 
analysis to examine the expression alterations of the genes located in 6q15 
systematically and then using qRT-PCR for confirmation, two genes, CNR1 and 
BACH2 were shown to be commonly down regulated in clinical prostate cancer 
samples at the RNA level. Using the same approach, there was a trend toward 
decreased expression of UNC5C in clinical prostate cancer samples. However, 
the function of genes is fulfilled by their encoded proteins and IHC in 
combination with TMAs is the most efficient method to investigate gene 
expression in a large cohort of clinical samples.  
 
CNR1 encodes a transmembrane protein belonging to the G-protein coupled 
receptor family, which possesses seven -helical transmembrane domains with 
extracellular amino and intracellullar carboxyl termini (Figure 5.1A). Several 
CNR1 polyclonal antibodies binding to different protein domains were available 
through commercial sources. However, concern about the specificity of these 
CNR1 antibodies has been generated, since a recent study tested a range of 
commercial CNR1 antibodies, none of which were shown to have high 
specificity (Grimsey et al., 2008). Some of the tested antibodies had been applied 
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in previously reported studies, thus calling into question the reliability of those 
studies. It suggested that the selection of CNR1 antibody to be used needs to be 
approached cautiously and the specificity should be examined carefully prior to 
application for such studies. 
 
BACH2 is a transcription factor containing a basic leucine zipper (bZip), a BTB 
(broad complex Tramtrack bric-a-brac) domain (Vieira et al., 2001). It possesses 
one nuclear localisation signal (NLS) and one cytoplasmic localisation signal 
(CLS) (Figure 5.1B). BACH2 mainly is localised in the cytoplasm through its C-
terminal evolutionarily conserved CLS. Regarding the protein expression of 
BACH2, so far, only one study on ovarian cancer applied the antibody generated 
by Santa Cruz on tissue samples (Motamed-Khorasani et al., 2007), others all 
applied the rabbit polyclonal antibody, F69-2, generated by Prof. Igarashi‘s 
group, who discovered the gene BACH2 in 1996 (Oyake et al., 1996). 
 
In this study, I continued to examine the protein expression alterations of CNR1 
and BACH2 in primary prostate cancer samples in order to identify whether the 
protein expression patterns of these three genes are consistent with the RNA 
expression alterations. 
  
   
 194 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic representation of protein regions of CNR1 and 
BACH2 
(A) CNR1 encodes a transmembrane protein (472 amino acid) possessing seven 
transmembran domains (TM) with extracellular (EC) domain at N-terminal and 
intracellular (IC) domain at C-terminal. The CNR1 polyclonal antibody from 
Abcam is generated by immunizing rabbits with a synthetic peptide against the 
C-terminal amino acid 461-472. (B) BACH2 encodes a transcription factor (841 
amino acid) containing a BTB domain at N-terminal, a bZip/nuclear localisation 
signal (NLS) domain and a cytoplasmic localisation signal (CLS) domain at C-
terminal. The BACH2 polyclonal antibody F69-2 is produced by immunizing 
rabbits with a fusion protein containing C-terminal 329 amino acids of BACH2. 
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5.2 Aims 
I aimed to investigate the protein expression alterations of the CNR1, BACH2 
and UNC5C genes in clinical prostate cancer samples using IHC analysis. 
 
5.3 Results  
5.3.1 Antibody selection 
The specificity of the antibody is crucial for examining protein expression 
alterations. Therefore the antibodies against CNR1, BACH2 and UNC5C 
products were carefully selected and antibody working conditions were 
optimised prior to their application to primary prostate cancer samples. A recent 
study reported a series of CNR1 antibodies, which were unspecific, therefore the 
selection of the CNR1 antibody was even more careful and stringent. One CNR1 
antibody, generated by Abcam Inc. and one antiserum (2814.3), developed by 
Prof. Maurice‘s research group (Queen Mary, University of London), were 
applied, since the specificity of these antibodies has been verified by lack of 
staining in FFPE CNR1
-/- 
mice brain tissue in contrast to the extensive staining in 
wild-type mice (Chung et al., 2009; Egertova and Elphick, 2000). Moreover, the 
specificity of the CNR1 antibody from Abcam has also been demonstrated in 
FFPE prostate tissue from CNR1
+/+
, CNR1
+/- 
and CNR1
-/- 
mice and shown to 
provide an appropriate staining pattern in FFPE sections of human cerebellum 
(Chung et al., 2009). Although human brain tissue, where CNR1 is highly 
expressed, would be the best positive control for CNR1 antibody optimisation, 
they were not available in our research centre. According to my previous qRT-
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PCR analysis result, CNR1 was shown to be expressed at the RNA level in BPH 
samples but down-regulated in prostate cancer cell lines (section 4.3.2.3). In 
general, the protein expression correlated with the RNA expression level. 
Therefore CNR1 antibody specificity examination and working conditions 
optimisation was done on FFPE BPH samples as a positive control and four 
FFPE prostate cancer cell lines, including LNCaP, PC3, 22RV1 and DU145, as 
negative controls. A range of dilutions of the CNR1 antibody from Abcam 
(ab23703, Abcam) were used, including 1:50, 1:100, 1:200, 1:300, 1:500. The 
antibody at 1:100 dilution showed strong staining and weak background on FFPE 
BPH (Figure 5.2A) and very weak or no staining in prostate cancer cell lines 
(Figure 5.2C-E), which was consistent with the RNA expression level 
determined by qRT-PCR analysis. In contrast, the CNR1 antiserum (2824.3) 
showed very weak staining in various dilutions (1:100; 1:300; 1:500; 1:1000; 
1:2000). Therefore the CNR1 antibody from Abcam was applied for further IHC 
analysis in this study.  
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Figure 5.2 CNR1 antibody specificity for IHC analysis 
(A) Representative image of CNR1 staining in a core of a BPH sample. CNR1 
was localised to the cell membrane of epithelial cells. (B) to (E) Representative 
images of CNR1 expression in 22RV1, DU145, PC3 and LNCaP cells, 
respectively. CNR1 staining was negative in these four cell lines. The 
magnification used was 40x. 
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Regarding the selection of a BACH2 antibody F69-2, generated by Prof. 
Igarashi‘s group, was applied. The antibody working condition was optimised on 
tonsil tissue, where BACH2 is highly expressed, and the 1:500 dilution was 
shown to give strong staining with a low background.  
 
At the time of selection of the UNC5C antibody, there was no study reporting the 
application of a UNC5C antibody for IHC and also there were only two 
commercial antibodies available for IHC: one was from Santa Cruz Int. and the 
other is from Sigma-Aldrich. The antibody from Santa Cruz was tested on FFPE 
ovary, uterus and kidney tissue samples, which have been reported to express 
UNC5C (Thiebault et al., 2003), with different concentrations and dilutions, but 
none of the conditions generated good signals. According to the IHC images 
using the antibody from Sigma-Aldrich (http://www.proteinatlas.org/), no 
staining was shown in normal prostate tissue. Therefore the IHC analysis of 
UNC5C could not be performed due to the lack of a good quality commercial 
antibody.  
5.3.2 Protein expression of CNR1 in primary prostate 
cancer samples 
5.3.2.1 CNR1 immunoreactivity in non-malignant prostate tissue 
CNR1 expression was assessed in a TMA made from 34 BPH cases. Five of them 
had only stromal tissue without prostate glands and three cases were missing so 
they were excluded from the analysis. The staining intensity varied between 
samples, but CNR1 was localised to the plasma membrane of both basal and 
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luminal epithelial cells, and with little or no staining of the stroma. An example 
from a core with a strong CNR1 staining is shown in Figure 5.2A. 
5.3.2.2 Comparison of CNR1 expression in clinical prostate cancer 
and non-malignant tissue  
A total of 68 prostate cancer cases and six BPH cases in two TMAs (details in 
2.1.2) were assessed using IHC analysis. Among the 68 cancer cases, 10 of them 
were excluded from the interpretation as the tissue cores were missing or 
contained very few cancer cells. Among the six BPH cases, one case was 
missing. Therefore 58 cancer cases and five BPH cases were informative for 
CNR1 expression evaluation in these two TMAs. Combined with 26 BPH cases 
from the BPH TMA, 31 BPH cases in total were available to compare the CNR1 
protein expression with the 58 prostate cancer cases. Using the detailed 
evaluation of IHC staining described in 2.6.2.3, 3 (10.3%), 16 (55.2%), 10 
(34.5%) of 29 BPH samples were shown to have negative (-), weakly positive 
(+), or strongly positive (++) CNR1 expression in the cell membrane, 
respectively. In addition, there were two BPH cases shown with CNR1 
expression at a nuclear localisation. In contrast, 43 (75.4%), 14 (24.6%) and 0 of 
57 cancer cases were shown to have negative (-), weakly positive (+) and 
strongly positive (++) CNR1 expression in the cell membrane, respectively. 
There was one cancer case with nuclear staining of CNR1 (Table 5.1). Examples 
of cancer cores scored as negative (-) and weakly positive (+) are shown in 
Figure 5.3A-D. Based on the membrane staining, cancer cases have a 
statistically weaker CNR1 expression than BPH cases (p<0.001). Among 58 
prostate cancer cases, 45 cases have matched normal glands. 40 out of the 45 
cases (88.9%) showed lower expression of CNR1 in the cancer tissue as 
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compared with adjacent normal glands. A representative image is shown in 
Figure 5.3E. 
 
 
 
Table 5.1 CNR1 expression in clinical prostate cancer and BPH samples  
Immunoreactivity CNR1 expression in PCa 
(% with membrane 
staining) 
CNR1 expression in 
BPH (% with 
membrane staining) 
p-value 
Membrane staining    <0.001 
- (negative) 43 (75.4)    3 (10.3)  
+ (weakly positive) 14 (24.6) 16 (55.2)  
++ (strong positive)                0 (0) 10 (34.5)  
    
Nuclear staining 1 2  
    
Missing/not 
scoreable 
10 3  
    
Total cases 68 34  
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Figure 5.3 CNR1 immunoreactivity in prostate cancer TMAs. 
(A) and (C) Representative images of prostate cancer cores with negative CNR1 
expression at magnification 20x and 40x, respectively. (B) and (D) 
Representative images of prostate cancer cores with weakly positive CNR1 
expression at magnification 20x and 40x, respectively. (E) Representative image 
of a tissue core with lower CNR1 expression in cancer cells compared with 
adjacent normal glands. 
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5.3.3 Protein expression of BACH2 in primary prostate 
cancer samples 
BACH2 expression was assessed in three TMAs containing 124 prostate cancer 
samples (details in 2.1.2) and one TMA made from 34 BPH cases. Among 124 
prostate cancer samples, 38 of them were excluded from interpretation either 
because the tissue cores were missing or there were too few cancer cells to be 
informative. Among 34 BPH samples, three of them had only stromal tissue 
without prostate glands and two cases were missing so that they were excluded 
from the analysis. Following detailed evaluation of IHC staining as described in 
2.6.2.3, 22 of 26 BPH samples (84.6%) were shown to have weakly positive (+) 
staining in the cytoplasm and 3 cases had nuclear staining. In contrast, 39 of 86 
informative prostate cancer cases were shown to have nuclear staining (Figure 
5.4D-E) and 25.5% (12/47), 38.3% (18/47) and 36.2% (17/47) of the cancer 
samples were shown to have negative (-), weakly positive (+) and strong positive 
(++) staining of the cytoplasm respectively (Table 5.2 and Figure 5.4A-C).  
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Table 5.2 BACH2 expression in clinical prostate cancer and BPH samples 
Immunoreactivity BACH2 expression  
in PCa (% with 
cytoplasmic staining) 
BACH2 expression  
in BPH (% with 
cytoplasmic staining) 
P value 
Cytoplasm staining    0.001 
- (negative) 12 (25.5) 2 (7.7)  
+ (weakly positive) 18 (38.3) 22 (84.6)  
++ (strong positive) 17 (36.2) 2 (7.7)  
    
Nuclear staining   0.001 
Positive 39 3  
Negative 47 26  
    
Missing/not 
scoreable 
38 5  
    
Total cases 124 34  
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Figure 5.4 BACH2 immunoreactivity in prostate cancer TMAs. 
(A) to (C) Representative images of prostate cancer cores with negative (-), 
weakly positive (+) and strong positive (++) CNR1 expression, respectively, at 
magnification 20x. (D) and (E) Representative images of prostate cancer cores 
with BACH2 expression in nuclei at magnification 20x and 40x, respectively. 
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5.3.4 CNR1 mutation in prostate cancer 
As illustrated above, 43 prostate cancer cases were shown to have negative 
staining for CNR1 protein, indicating that the CNR1 expression might be down-
regulated in these samples. The inactivation of a gene can be caused by DNA 
mutation, genomic deletion or methylation. As CNR1 is located at 6q15, one of 
the most frequently deleted regions in prostate cancer, it seems highly likely that 
the genomic deletion is accounting for the CNR1 inactivation in some of the 43 
cancer samples. Whether mutations also occur in the CNR1 genomic DNA was 
further explored. Five prostate cancer cases, which had high purity of cancer 
cells on the cores of TMAs, were selected from the 43 cancer cases with low or 
no CNR1 expression for sequencing. In addition, CNR1 genomic DNA in 22RV1 
cells was also sequenced, as the 22RV1 cell line will be utilised for CNR1 
functional studies due to its better transfection rate compared to other prostate 
cancer cell lines.  
5.3.4.1 PCR amplification and sequencing of CNR1 genomic coding 
region  
Tumour tissue from the five FFPE prostate cancer cases was micro-dissected and 
genomic DNA from these five samples and 22RV1 cells was extracted as 
described in 2.4.1. As CNR1 has only one exon, using a pair of primers flanking 
the genomic coding region (~ 1.4 Kb) of the CNR1 gene (Figure 5.5), PCR 
analysis was performed on the genomic DNA of the five cancer cases. The 
coding region of CNR1 was amplified successfully from 22RV1 cells and four of 
the five cancer cases except one sample, from which no PCR product was 
generated using the same primers and PCR working conditions. PCR products 
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from 22RV1 cells and the four cancer cases were purified and sequenced. A 
nucleotide change (G-->A) at position 1359 was identified in 22RV1 cells. It is a 
silent intragenic SNP of the gene CNR1 in codon 435 (Thr). No mutation was 
identified from any of the four clinical samples.  
 
The reason for no generated PCR product from the one sample might be that a 
mutation existed in the primer-binding region or genomic alterations, such as 
deletion, translocation, occurred in the genomic coding region of CNR1. In order 
to identify any DNA alterations, a series of PCR analyses were performed using 
the primers, which were designed across the genomic region of CNR1 with the 
expected PCR product size ranging from ~120 - 400 bp (details in 2.4.2). As 
shown in Figure 5.6, no PCR products were generated within a ~5 Kb region, 
including ~ 4.8 Kb of intron region and ~ 200 bp of coding region. It indicated a 
homozygous deletion was present in the genomic DNA of CNR1. However, 
using a few different pairs of primers, which flanked the deleted region, no 
specific PCR product was generated. This was taken to indicate that, apart from 
the deletion, there might be other genomic alterations that have occurred, such as 
translocation, inversion or insertion, in this sample. In order to confirm that there 
was such a genomic alteration, the breakpoints of the deletion need to be mapped 
and sequenced.  
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Figure 5.5 Schematic representation of genomic DNA of the gene CNR1 
CNR1 has one exon with a coding region of 1419 bp. A pair of PCR primers 
flanking the coding region was designed to amplify CNR1 for sequencing. Red 
and yellow bars represent the transciption and intron region, respectively, in the 
genomic DNA of CNR1.  
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Figure 5.6 Deletion breakpoint mapping in genomic DNA of CNR1 using 
PCR analysis 
A series of PCR analyses were performed using the primers, which were 
designed across the genomic region of CNR1. No PCR products were generated 
within a ~5 Kb region including ~ 4.9 Kb of intron region (16.1 Kb- 20 Kb) and 
~ 200 bp of coding region. Upstream and downstream deletion breakpoints were 
indicated with green bars. N stands for normal control sample. T stands for 
tumour sample (p6363). 
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5.3.4.2 CNR1 breakpoint mapping 
Genome-walking assay (detailed in 2.4.3) was performed to map the actual 
breakpoint of CNR1 in the clinical cancer case, which had been demonstrated to 
have an homozygous deletion within CNR1 genomic DNA. The basic principle 
of genome-walking analysis is that the genomic DNA is fragmented by different 
blunt end restriction enzymes and then ligated with adaptors to generate different 
libraries; from each library, nested PCR was performed with the gene and 
adaptor specific primers; then the amplified PCR product was purified and 
sequenced. Two forward primers distal to the CNR1 intron breakpoint (IFP1, 
IFP2) and two reverse primers proximal to the CNR1 coding region breakpoint 
(CRP1, CRP1) were designed as gene specific primers.  
 
Initially, four genomic libraries were generated with blunt-end restriction 
enzymes, including PvuII, EcoRV, DraI and StuI. From each library, two nested 
PCR were performed: one was using primer pair IFP1/AP1 and IFP2/AP2 to map 
the intron breakpoint; the other was using primer pair CRP1/AP1 and CRP2/AP2 
to map the coding region breakpoint (Figure 5.7). For the intron breakpoint 
mapping, the PCR product was obtained only from the StuI library; however, it 
was too small (<100 bp) to be informative. For the coding region breakpoint 
mapping, specific PCR products were generated from DraI and EcoRV libraries 
with a size around 300 bp (Figure 5.8). The PCR product was purified and 
cloned into the commercial T-vector for sequencing. The sequencing result from 
the DraI library showed that there was 11 bp of unknown sequence 
(AAACTTAAGCT) fused with genomic CNR1 and this sequence was 7 bp 
upstream from the start codon (ATG) of the CNR1 (Figure 5.9A). This fusion 
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was then confirmed by PCR analysis using primers binding to the boundary of 
the unknown sequence and the CNR1 genomic region (Figure 5.9B).  
 
Although it was known that the recognition site of DraI restriction enzyme is 
TTT｜AAA, 11 bp plus 3 bp of TTT (TTTAAACTTAAGCT) was still too short 
to align to any specific genomic sequence. Therefore it was not clear at this point 
which gene or genomic fragment had been fused with CNR1 in this prostate 
cancer case. More genomic libraries were generated with blunt end restriction 
enzymes, including HincII and RsaI, to map the intron breakpoint. However, so 
far, no specific PCR product has been characterised. 
 
 
 
 
 
 
 
 
Figure 5.7 Schematic representation of CNR1 deletion breakpoint mapping 
using genome walking assay 
AP1 and AP2 are adaptor-binding primers for primary and nested PCR 
respectively. IFP1, IFP2, CRP1 and CRP2 are CNR1 gene-specific primers. IFP1 
and CRP1 are used for primary PCR. IFP2 and CRP2 are applied for nested 
PCR. 
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Figure 5.8 Primary and nested PCR for CNR1 deletion breakpoint mapping  
Lanes 1 to 4 represent libraries of PvuII, DraI, StuI and EcoRV, respectively, 
generated using genomic DNA of the prostate cancer patient p6363. Lane 5 
represents the PvuII library generated from normal control genomic DNA. From 
each library, primary and nested PCR were performed. Primer pairs IFP1/AP1 
and IFP2/AP2 were used for mapping the intron breakpoint; Primer pairs 
CRP1/AP1 and CRP2/AP2 were applied for mapping the coding region 
breakpoint. For the coding region breakpoint mapping, a specific PCR product 
was generated from DraI and EcoRV libraries with a size between 300 – 400 bp. 
1 Kb plus DNA ladder (Invitrogen) was used. 
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Table 5.3 Primer sequence for confirmation of the CNR1 fusion 
Chimeric fwd 5'-AACTTAAGCTTGAGGTTATG 
Chimeric rvsS 5‘-AAGGACGAGAGAGACTTG 
Chimeric rvsL 5‘- TCTATGTCCATGAAGTTCTC 
 
 
 
 
 
 
 
 
 
                                          A                                                                      B      
Figure 5.9 CNR1 fusion from sequencing data and PCR confirmation 
(A) Sequencing data of CNR1 from DraI library of the prostate cancer patient 
p6363; (B) Using forward primer binding to the fusion boundary and two reverse 
primers binding to downstream of CNR1 coding region (Table 5.3), the CNR1 
fusion was confirmed using PCR analysis. Lane 1 is the PCR product generated 
using primer pair chimeric fwd and rvsL. Lane 2 is the PCR product generated 
using primer pair chimeric fwd and rvsS. 
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5.3.4.3 Exclusion of translocation and large scale chromosome 
rearrangement affecting CNR1 
As illustrated above, a homozygous deletion and fusion in genomic DNA of 
CNR1 was identified in one prostate cancer sample, which had down-regulated 
CNR1 expression. According to the evidence in this case, it seems to fit in with 
our hypothesis regarding the identification of t(4;6)(q22;q15) and that 
translocation may contribute to cancer development though inactivation of 
tumour suppressor gene(s), which locate at breakpoint or adjacent deletion 
regions.  
 
Whether the fusion is caused by inversion was examined using PCR analysis. As 
mentioned earlier, 14 bp of unknown sequence (TTTAAACTTAAGCT) was 
fused with CNR1 genomic DNA. A minimum of 15 bp is required to blast with 
the whole human genome from Ensembl database 
(http://www.ensembl.org/Multi/blastview). Therefore, A, T, G, C was added to 
the 14 bp respectively and each sequence was blasted with the human genome. 
Eight regions on chromosome 6 were shown with the matched sequence. Semi-
nested PCR analysis was performed with the forward primers binding to the 
potential fusion region and the two reverse primers, chimeric rvsS and rvsL, 
which were used to confirm the fusion in CNR1 (described in the previous 
section). No specific product was generated after two rounds of PCR reaction 
indicating that the fusion was not caused by inversion.  
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Table 5.4 Eight regions on chromosome 6 matching with the 15 bp unknown 
sequence 
Fusion sequence Region Strand Position 
ATTTAAACTTAAGCT 6q16 Plus 103846431 - 103846445 
TTTTAAACTTAAGCT 
6q25 Plus 155118846 - 155118860 
6q22 Plus 129899803 - 29899817 
6p22 Plus 21901382 - 21901396 
6q22.31 Minus 122742768 -122742782 
6q21 Minus 114977922 -114977936 
6p21 Minus 42659850 - 42659864 
CTTTAAACTTAAGCT 6q25.3 Minus 155717426 -155717440 
GTTTAAACTTAAGCT No match   
 
 
Table 5.5 Forward primers used for investigation of the potential inversion 
involved in the gene CNR1 
Primer Sequence 
6q16fwd 5'-CAACTCCTGTCCTAGGATG 
6q25fwd 5'-AAAGTGCTGGGATTACAG 
6q22fwd 5'-TCCTTCATGTAAGTGTCATC 
6p22fwd 5'-CAAGAGTACTGTGCTCCTG 
6q22.31fwd 5'-TCAGCTCAAGATGCTCTG 
6q21fwd 5'-GAACATTAGTGTAAAACTCACTG 
6p21fwd 5'-ACAAGAGAATATCACTGTCTG 
6q25.3fwd 5'-CTTCTTGGCTTGAAGTCTC 
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In order to examine whether the fusion in CNR1 genomic DNA in the prostate 
cancer case was caused by chromosomal translocation or large scale 
chromosome level deletion and insertions, FISH analysis was performed on the 
TMA containing the cancer case using dual-colour probes binding both sides of 
the identified CNR1 breakpoint (Table 5.6). The FISH result showed that red and 
green signals were co-localised rather than split (Figure 5.10), suggesting that 
chromosome translocation or large scale chromosome level deletions or 
insertions were not responsible for the fusion.  
 
Table 5.6 FISH probes for detection of potential translocation 
Probeset Region BAC clone Region Length 
(bps) 
Labelled Signal 
colour 
 
I 
 
Distal CNR1 
RP1-102H19 
88,009,641-
88,111,280 
101,640 
Biotinylated Red 
RP1-249N8 
88,688,904-
88,750,812 
61,908 
 
II 
 
Proximal CNR1 
RP1-72A23 
89,632,912-
89,781,452 
148,540 
DIG Green 
RP3-322A2 
90,145,402-
90,277,901 
132,499 
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Figure 5.10 Representative FISH image for detection of potential 
translocation 
Using probe sets binding to distal (red) and proximal (green) genomic DNA of 
CNR1, FISH analysis was applied to detect the potential translocation involved 
in the gene CNR1 in the patient sample p6363. The representative image above 
shows all red and green signals to be co-localised in nuclei (blue) demonstrating 
there was no translocation involved in CNR1 in this sample.  
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5.3.5 CNR1 methylation in prostate cancer 
In addition to genomic alterations, I also investigated whether DNA methylation 
contributed to CNR1 down-regulation in prostate cancer. Ten BPH samples, 29 
prostate cancer samples and 19 pairs of the normal and cancer samples were 
examined in this study. 24 bp (CGCCAGCGCCTTCCCTTGGCCCGG) of the 
promoter region (1027 bp) was analysed. There was no significant difference 
between the matched normal and cancer samples (p=0.922); in order to exclude 
the possibility that methylation of CNR1 is a preneoplastic change, so that the 
methylation can occur in both cancerous and matched noncancerous tissues, we 
also compared the CNR1 methylation in all the 48 cancer samples with ten BPH 
samples. However, there was still no significant difference (p=0.319) (Table 
5.7). 
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Table 5.7 CNR1 methylation status in 10 BPH and 48 clinical prostate 
cancer samples 
No. Diagnosis 
PAI
RED 
Age 
Gleason 
score 
PSA 
(ng/ml) 
Procedure 
CNR1 (% 
methylation) 
1 BPH No 74 N.A 2.6 (TURP)         0.0 
2 BPH No 73 N.A 6.2 (TURP) 3.1 
3 BPH No 80 N.A 4.2 (TURP) 2.5 
4 BPH No 67 N.A N.A (TURP) 1.7 
5 BPH No 85 N.A N.A (TURP) 4.1 
6 BPH No 60 N.A N.A (TURP) 2.7 
7 BPH No 69 N.A N.A (TURP) 3.0 
8 BPH No 65 N.A N.A (TURP) 3.8 
9 BPH No 83 N.A 1.57 (TURP) 3.2 
10 BPH No 74 N.A 4.66 (TURP) 2.5 
11 Tumour No 62 3+3=6 N.A N.A 8.8 
12 Tumour No 62 4+4=8 N.A N.A 2.9 
13 Tumour No 72 5+4=9 N.A N.A   12.6 
14 Tumour No 73 4+4=8 N.A N.A 1.6 
15 Tumour No 52 3+3=6 N.A Prostatectomy 4.1 
16 Tumour No 77 3+4= 7 N.A channel TURP 8.5 
17 Tumour No 75 5+5 = 10 14 channel TURP 2.7 
18 Tumour No 77 5+4=9 13 channel TURP 3.2 
19 Tumour No 72 5+4=9 N.A channel TURP 3.8 
20 Tumour No 58 4+5=9 29 channel TURP 3.4 
21 Tumour No 66 4+5=9 95 channel TURP 8.8 
22 Tumour No 71 4+5=9 N.A N.A   12.7 
23 Tumour No 64 4+3 = 7 N.A Prostatectomy 8.3 
24 Tumour No  4+3 = 7 N.A Prostatectomy 8.9 
25 Tumour No 74 3+3=6 5.2 Prostatectomy   12.5 
26 Tumour No 67 3+4=7 5.6 Prostatectomy 0.0 
27 Tumour No 39 3+3=6 16 Prostatectomy 1.8 
28 Tumour No 65 4+4=8 22.7 Prostatectomy   11.0 
29 Tumour No 65 3+4=7 9.9 Prostatectomy   10.7 
30 Tumour No 57 4+3=7 26.3 Prostatectomy 1.1 
31 Tumour No 70 3+4=7 10.6 Prostatectomy 7.1 
32 Tumour No 60 4+3=7 9.27 Prostatectomy 0.0 
33 Tumour No 74 5+4=9 37.01 Prostatectomy 8.6 
34 Tumour No 58 4+3=7 72.6 Prostatectomy 1.5 
35 Tumour No 53 3+4=7 15.47 Prostatectomy 4.3 
36 Tumour No 67 3+4=7 11.08 Prostatectomy 2.4 
37 Tumour No 78 5+4=9 88.68 Prostatectomy 4.0 
38 Tumour No 53 3+3=6 6.7 Prostatectomy 0.7 
39 Tumour No 50 4+3=7 8.5 Prostatectomy 2.6 
40 Normal Yes N.A N.A N.A N.A 5.4 
41 Normal YES N.A N.A N.A Prostatectomy   11.5 
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42 Normal YES N.A N.A N.A Prostatectomy 3.0 
43 Normal YES N.A N.A N.A Prostatectomy 9.1 
44 Normal YES N.A N.A N.A Prostatectomy   11.8 
45 Normal YES N.A N.A N.A Prostatectomy 3.4 
46 Normal YES N.A N.A N.A Prostatectomy 7.6 
47 Normal YES N.A N.A N.A Prostatectomy 2.3 
48 Normal YES N.A N.A N.A Prostatectomy 0.0 
49 Normal YES N.A N.A N.A Prostatectomy 0.0 
50 Normal YES N.A N.A N.A Prostatectomy 1.5 
51 Normal YES N.A N.A N.A Prostatectomy 2.7 
52 Normal YES N.A N.A N.A Prostatectomy 1.7 
53 Normal YES N.A N.A N.A Prostatectomy 1.6 
54 Normal YES N.A N.A N.A Prostatectomy 1.3 
55 Normal YES N.A N.A N.A Prostatectomy 0.0 
56 Normal YES N.A N.A N.A Prostatectomy 6.1 
57 Normal YES N.A N.A N.A Prostatectomy 2.2 
58 Normal YES N.A N.A N.A Prostatectomy 7.2 
59 Tumour Yes 54 4+3 = 7 N.A Prostatectomy 3.1 
60 Tumour YES 70 3+4=7 10.3 Prostatectomy 2.3 
61 Tumour YES 50 3+3=6 8.4 Prostatectomy   11.1 
62 Tumour YES N.A 3+3=6 N.A Prostatectomy 7.4 
63 Tumour YES 55 3+3=6 6.5 Prostatectomy 4.7 
64 Tumour YES N.A 3+4=7 N.A Prostatectomy 7.3 
65 Tumour YES 62 3+4=7 9.3 Prostatectomy 1.6 
66 Tumour YES 69 4+4=8 31.16 Prostatectomy 2.1 
67 Tumour YES 75 3+4=7 11.24 Prostatectomy 3.8 
68 Tumour YES 57 4+3=7 10.74 Prostatectomy 5.7 
69 Tumour YES 77 4+3=7 6.28 Prostatectomy   11.4 
70 Tumour YES 59 4+3=7 26.86 Prostatectomy 0.0 
71 Tumour YES 75 4+4=8 100 Prostatectomy 2.1 
72 Tumour YES 51 3+3=6 13.8 Prostatectomy 3.6 
73 Tumour YES 65 3+4=7 7.38 Prostatectomy 8.5 
74 Tumour YES 75 3+4=7 27.17 Prostatectomy 1.2 
75 Tumour YES 66 3+5=8 8.29 Prostatectomy 0.0 
76 Tumour YES 74 4+3=7 97 Prostatectomy 3.4 
77 Tumour YES 75 5+3=8 22.59 Prostatectomy 1.8 
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5.4 Discussion 
Previously we applied Exon array analysis to examine systematically the 
expression alterations of all the genes located at the 6q15 deletion region. After 
qRT-PCR confirmation on enlarged clinical samples, CNR1, BACH2 and CNR1 
showed common down-regulation in the prostate cancer samples. In this study, I 
further examined CNR1 and BACH2 protein expression and other genomic 
changes of CNR1. 
 
Antibody specificity is critical for accurately examining protein localisation and 
expression while being applied to IHC analysis. In this study, the selection of 
CNR1 was very careful as a recent study demonstrated a series of commercial 
antibodies that were not specific for either Western blot or IHC analysis. The 
CNR1 antibody applied here for IHC analysis was purchased from Abcam, and 
has been demonstrated to have high specificity in prostate tissue (Chung et al., 
2009). This specificity was confirmed by my own study. CNR1 is a cannabinoid 
receptor localised at the plasma membrane. FFPE prostate cancer cells, including 
LNCaP, PC3, DU145 and 22RV1, were used as negative controls, as they were 
demonstrated previously to have very low CNR1 expression using qRT-PCR 
analysis. The initial IHC analysis showed no or very weak staining of the 
prostate cancer cell lines, which was consistent with the low RNA expression. In 
BPH samples, the staining intensity varied between samples, but this also 
correlated with previous qRT-PCR results showing different RNA expression 
levels among BPH samples. In addition, CNR1 was shown to be localised to the 
plasma membrane of both basal and luminal epithelial cells, and there was little 
or no staining of the stroma. Therefore the specificity of the CNR1 antibody from 
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Abcam was well demonstrated in this study. None of the 58 cancer cases showed 
strong CNR1 expression. In contrast, among 31 informative BPH samples, 32.3% 
of them showed strong positive expression and 51.6% of them showed weakly 
positive expression. Only a very small proportion of the 31 BPH samples had 
negative CNR1 expression. Moreover, among 58 prostate cancer cases, 45 cases 
have matched normal glands. The majority of them showed lower expression of 
CNR1 in cancer cells compared with adjacent normal glands and none of the 45 
cases had higher CNR1 expression in cancer cells than in the matched normal 
cells. This study, therefore, demonstrated that the protein expression of CNR1 
frequently was down-regulated in prostate cancer samples. Results in accord with 
the low levels of RNA expression determined previously by qRT-PCR analysis.    
 
So far, only one reported study has examined CNR1 expression using IHC 
analysis in 372 prostate cancer cases and 349 BPH samples  (Chung et al., 2009) 
and this study used the same CNR1 antibody (Abcam). Using a slightly different 
scoring for evaluation of CNR1 staining, the immunoreactive intensity of CNR1 
was scored ranging from 0 – 3 (0 is absent and 3 is high). 61.6% of the BPH 
samples and 75.3% of the cancer samples were scored  2. Analysis of 269 
prostate cancer patients, who were conservatively managed, for CNR1 expression 
showed that a score  2 was associated with poorer disease specific survival 
(Chung et al., 2009). Therefore, using the same antibody, an exactly opposite 
correlation between CNR1 level and prostate carcinogenesis was observed in my 
study. I did not find any prostate cancer samples showing strong CNR1 
expression. As CNR1 activation generally is considered to prevent tumour 
development (Alexander et al., 2009) and mutation of CNR1 has been reported 
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(Gadzicki et al., 1999), the previously observed overexpression of CNR1 seems 
counter intuitive but I am unable to explain the reason for the difference between 
these two investigations. 
 
The inactivation of gene expression can be caused by somatic mutation and 
epigenetic methylation. PCR and sequencing analysis revealed a nucleotide 
change in 22RV1 cells and a small deletion (~ 5Kb) in the upstream and 5‘ UTR 
region of the CNR1 gene in one of five clinical prostate cancer samples. After the 
breakpoint of the deletion was mapped, an 11 bp unknown sequence, 7bp 
upstream of the CNR1 start codon (ATG), was identified. Gene fusion (or 
genomic fragment fusion) can be caused by chromosomal translocations, internal 
deletions, inversions or insertions. As the possibility of large scale chromosome 
rearrangements and inversion in causing this gene fusion has been excluded, 
small deletion and/or insertion might be the possible mechanism to cause this 
genomic fusion. However, due to the upstream breakpoint of the deletion failing 
to be mapped, it is difficult to draw this conclusion with any confidence yet.  
 
A silent mutation (1359G-->A) in codon 453 (Thr) of the CNR1 gene was 
identified in the genome of 22RV1 cells. This nucleotide change 1359 (G/A) has 
been reported as a common polymorphism in Caucasian populations (Gadzicki et 
al., 1999). Recently, a study in colorectal cancer has shown that patients, who 
had genotype G/A plus A/A, had a shorter overall survival time than G/G wild-
type patients (Bedoya et al., 2009b). A similar study in oesophageal cancer has 
shown that the patients with the A/A type had a reduced survival time in 
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comparison to the G/G type (Bedoya et al., 2009a). So far, no study has been 
performed to examine CNR1 sequence detail in prostate cancer.  
 
The inactivation of the gene CNR1 due to methylation of the CNR1 promoter has 
been reported in colorectal cancer (Wang et al., 2008). In this study, the CNR1 
methylation was examined in 48 prostate cancer samples and ten BPH control 
samples. Some prostate cancer samples were shown to have a higher percentage 
of cells (> 10%) with CNR1 promoter methylation than the average of ten BPH 
samples (2.66%). However, there was no significant difference between BPH 
and all of the cancer samples (p=0.319). These results were taken to indicate that 
DNA methylation might account for the CNR1 inactivation in some of the 
prostate cancer samples but it is not the prevalent mechanism.  
 
The expression of the gene BACH2 was also examined in prostate cancer 
samples in this study. Cytoplasmic expression of BACH2 was slightly less in the 
examined cancer cases as compared with BPH samples. However, nuclear 
expression of BACH2 was significantly higher in prostate cancer cases than in 
BPH samples (p=0.001). Therefore, at the protein level, the major difference in 
BACH2 expression between prostate cancer and BPH samples seems to be an 
altered localisation rather than a changed expression level.  
 
The transcription factor BACH2 is a member of the protein family, which 
harbours a basic region leucine zipper (bZip) DNA binding domain. In addition, 
BACH2 possesses a BTB domain. Both of these domains are involved in forming 
heterologous protein-protein interactions (Albagli et al., 1995; Vinson et al., 
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2006). The cytoplasmic localisation of the BACH2 protein is controlled by the 
cytoplasmic localisation signal present in the bZip domain and a C-terminal 
nuclear-export signal (Hoshino et al., 2000). In B-cells, BACH2 is predominantly 
cytoplasmic, whereas oxidative stress induces its nuclear accumulation. Once in 
this subcellular location, it induces expression of genes involved in apoptosis 
(Kamio et al., 2003; Yoshida et al., 2007). In a study of ovarian cancer, it was 
shown that cytoplasmic BACH2 expression was increased significantly in 
ovarian cancer relative to benign cases. In addition, increased nuclear BACH2 
levels in ovarian cancer samples were associated with decreased time to disease 
recurrence (Motamed-Khorasani et al., 2007). The full significance of altered 
BACH2 expression in ovarian cancer still is unknown. However, it was 
postulated that the different BACH2 isoforms localise to different cellular 
compartments where they may participate in cell processes distinct from 
transcriptional regulation (Motamed-Khorasani et al., 2007). The results from 
our study and the ovarian cancer study indicated further analysis of BACH2 
isoform expression and potential cytoplasmic/nuclear function in prostate or 
ovarian epithelial cells is warranted. 
 
In conclusion, the protein expression of CNR1 is down-regulated in clinical 
prostate cancer samples compared with BPH controls, which is consistent with 
my previous study showing lowered RNA expression in prostate cancer samples. 
In contrast, the protein expression of BACH2 was not correlated with previously 
examined RNA expression patterns in clinical prostate cancer samples. Further 
study of CNR1 and BACH2 cellular function is needed to demonstrate whether, 
and how, they play a tumour suppressor role in prostate cancer. 
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6 TUMOUR SUPPRESSOR ROLE OF 
CNR1 IN PROSTATE CANCER 
6.1 Introduction 
In the previous three chapters, I have explained the reasons and processes used 
for the identification of candidate tumour suppressor genes located at 6q15, 
which is one of the most frequently deleted regions in prostate cancer. CNR1 was 
the only gene identified so far that showed down-regulated expression at both the 
RNA and protein level in clinical prostate cancer samples.  
 
To date, the majority of studies in the literature reported have supplied only 
indirect evidence for the relationship between CNR1 and cancer. The ligands of 
CNR1, such as endocannabinoids and CNR1 agonists, have been demonstrated 
by many studies to have an anti-tumourigenic effect, affecting cell growth, 
apoptosis, angiogenesis, migration, invasion, adhesion, and an ability to 
metastasise in various cancers (Freimuth et al., 2010). Although it has been 
demonstrated that cannabinoids exerted their anti-tumourigenic effects through 
CNR1 and CNR2 (Alexander et al., 2009), whether CNR1 or CNR2 itself have a 
tumour suppressor role has not been well studied. The only direct evidence 
favouring a possible tumour suppressor role for CNR1 was a recent study in 
colorectal cancer, which demonstrated that the expression of CNR1 was silenced 
due to methylation of its promoter (Wang et al., 2008). Moreover, loss of 
expression of CNR1 has been shown to accelerate intestinal tumour growth in 
vivo (Wang et al., 2008). In another study, in hepatocellular carcinoma, over-
expression of CNR1 was shown to correlate with improved prognosis of the 
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patients (Xu et al., 2006). No previous studies on the role of CNR1 in prostate 
cancer have been reported. Because of my identification of the common down-
regulation of CNR1 in clinical prostate cancer samples, I was encouraged to 
investigate further the cellular function of CNR1 in prostate cancer.  
 
6.2 Aim 
I aimed to examine the cellular function of CNR1 in vitro in prostate cancer cells 
to determine if it has a role as a tumour suppressor. 
 
6.3 Results 
6.3.1 CNR1 transient over-expression 
6.3.1.1 Plasmid construction  
As described earlier, CNR1 expression levels were very low in six prostate 
cancer cell lines. In four immortalised prostate epithelial cell lines available in 
our group, including PNT1A, PNT2, PNT2-C2 and RWPE, low expression 
levels of CNR1 were also revealed by qRT-PCR analysis. The expression of 
CNR1 was not detected with 40 cycles of qRT-PCR reaction in these four cell 
lines. Therefore, it was considered that over-expressing CNR1 in prostate cancer 
cell lines would be more feasible than knocking down its expression. In order to 
over-express CNR1 in prostate cancer cells, a plasmid incorporating the coding 
sequence of CNR1 was constructed. Using cDNA from a BPH sample (p129), 
which was demonstrated to have a high expression of CNR1 (section 4.3.2.3), as 
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a template, the coding sequence of CNR1 with a flag tag sequence incorporated 
before the stop codon of CNR1 was amplified using PCR analysis (details in 
2.7.2.1). A specific band was obtained (Figure 6.1), which was at the expected 
size of ~1.5 Kb. Then the PCR product was purified, digested with restriction 
enzymes and ligated to the vector pcDNA3.1 (+) as described in 2.8.2.1. The 
ligated plasmids were transformed into competent bacteria cells, which were then 
cultured until single clones of bacteria were obtained. Five single colonies were 
inoculated and cultured. Then the plasmids were extracted and sequenced (details 
in 2.8.2.1). The plasmid with the correct CNR1 and flag tag sequence, named 
pcDNA-CNR1flag, was used for my further study. 
 
 
Figure 6.1 CNR1 coding sequence amplification using PCR analysis. 
PCR analysis was performed to amplify the coding sequence of CNR1 from 
cDNA of one BPH sample (p129). The expected size of the PCR product is 1467 
bp. 1 Kb Plus DNA ladder (Invitrogen) and the PCR product were run on a 1% 
agarose gel. 
 
Ladder CNR1
1.0 Kb
1.65 Kb
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6.3.1.2 Transfection efficiency optimisation in 22RV1 cells 
Prostate cancer cell lines are known to be difficult to transfect. Four cell lines, 
LNCaP, PC3, DU145 and 22RV1, commonly are used for studying prostate 
cancer. However, in terms of DNA transfection, only 22RV1 cells are easily 
transfected. Therefore 22RV1 cells were chosen to be used in this study as a 
model to study the function of CNR1 in vitro.  
 
Two chemical transfection reagents, JetPEI-RGD and Lipofectamine™ 2000, 
were used to optimise transfection conditions in 22RV1 cells. JetPEI-RGD was 
indicated for the transfection of cell lines of epithelial origin that were poorly 
transfectable. Lipofectamine™ 2000 was commonly used in our laboratory and 
has been shown to have a high transfection efficiency in various human cell 
lines. 
 
pcDNA-GFP (described in 2.8.1.1) was used to determine the transfection 
efficiency of each reagent in 22RV1 cells. The pcDNA-GFP transfected cells 
were observed using a fluorescence microscope 48 h after transfection. Less than 
5% of 22RV1 cells transfected using JetPEI-RGD reagent expressed visually 
detectable GFP.  In contrast, approximately 40-50% of 22RV1 cells transfected 
using Lipofectamine™ 2000 reagent expressed visually detectable GFP. 
Lipofectamine™ 2000 was therefore chosen for further transfection experiments.  
6.3.1.3 CNR1 transient over-expression in 22RV1  
The plasmids, pcDNA-CNR1flag and pcDNA3.1(+) (as a control), were 
transfected into 22RV1 cells using Lipofectamine™ 2000 reagent. The RNA 
expression of CNR1 was examined 24 h after transfection. The RNA extracted 
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from the transfected cells was treated with DNase to remove residual 
genomic/plasmid DNA contamination before cDNA was synthesised. Since 
commercial TaqMan gene expression assays are all designed to examine CNR1 
expression using probes binding to the 5‘-UTR region 
(https://www.appliedbiosystems.com/absite/us/en/home.html), they were not 
appropriate to examine CNR1 over-expression since the plasmid constructed 
contained only the coding sequence of CNR1. Therefore semi-quantitative RT-
PCR analysis was performed, as the primers, which previously were used to map 
deletion breakpoints of the gene CNR1 in a clinical prostate cancer sample 
(section 5.3.2.2), already were available. Using the housekeeping gene, -actin, 
as a control, the expression of CNR1 in pcDNA3.1 and pcDNA-CNR1flag 
transfected 22RV1 cells was examined. The same amount of cDNA (300 ng) was 
used in all the PCR reactions. After 35 cycles of amplification, equal volumes of 
PCR products were loaded on a 1.5% agarose gel. Results showed that CNR1 
was expressed at a markedly higher level in pcDNA-CNR1flag transfected 
22RV1 cells than in pcDNA3.1(+) transfected cells (Figure 6.2).  
 
The protein expression of CNR1 was examined at 48 h after transfection using 
Western blot analysis. The expected molecular weight of CNR1 is 54 kDa (non-
glycosylated) or 63 kDa (glycosylated). 50 g of total protein from each of the 
pcDNA3.1(+) and pcDNA-CNR1flag transfected 22RV1 cells was used to detect 
CNR1 expression. Using a CNR1 antibody from Abcam, multiple bands were 
obtained. Between the molecular weights 52 kDa and 72 kDa, there was one 
strong band.  There were also a few very weak bands between 52 kDa and 72 
kDa, but they most probably were artificial bands generated because of the 
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prolonged exposure. However, none of the bands was shown to have an 
increased intensity in pcDNA-CNR1flag transfected 22RV1 cells compared with 
the pcDNA3.1(+) transfected cells (Figure 6.3A). In order to examine CNR1 
expression using an anti-Flag antibody, a positive control sample was included to 
demonstrate that the antibody itself works properly. The positive control 
consisted of total protein extracted from 293 cells, which were transiently over-
expressing pcDNA-DARRP32flag, obtained from Dr Yaohe Wang‘s group in 
our Institute (www.cancer.qmul.ac.uk/staff/wang.html). The DARRP32/flag 
over-expression in these cells previously has been demonstrated, using Western 
blot analysis with the same anti-Flag antibody, by his group. The expected size 
of DARRP32flag was 32 kDa. Using the anti-Flag antibody, no band was 
detected in either pcDNA3.1 or pcDNA-CNR1flag transfected 22RV1 cells, 
although the positive control showed a strong and specific band (Figure 6.3B). It 
indicated that although CNR1 was over-expressed in 22RV1 cells at the RNA 
level, it was not overexpressed at the protein level. 
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Figure 6.2 CNR1 expression in transiently transfected 22RV1 cells, 
measured by semi-quantitative RT-PCR analysis 
Semi-quantitative RT-PCR analysis was performed to examine the CNR1 and β-
actin (as a loading control) expression in pcDNA-CNR1flag and pcDNA3.1(+) 
transfected 22RV1 cells. (1) Invitrogen 1 Kb Plus DNA ladder; (2) and (3) β-
actin expression (expected size at 250 bp) in pcDNA-CNR1flag transfected 
22RV1 cells as measured in duplicate; (4) and (5) CNR1 expression in pcDNA-
CNR1flag (expected size at 681 bp) transfected 22RV1 cells as measured in 
duplicate; (6) and (7) β-actin expression in pcDNA3.1(+) transfected 22RV1 
cells as measured in duplicate; (8) and (9) CNR1 expression in pcDNA3.1(+) 
transfected 22RV1 cells as measured in duplicate. All of the PCR products were 
run on a 1.5% agarose gel. 
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Figure 6.3 Protein expression of CNR1 in transiently transfected 22RV1 cells 
examined by Western blot analysis 
(A) Using a CNR1 antibody (Abcam, 1:200 dilution), CNR1 expression was 
examined in 22RV1 cells transfected with pcDNA3.1(+) and pcDNA-CNR1flag. 
(B) Using an anti-Flag antibody (Sigma, 1:1000 dilution), Flag-tag expression 
was examined in one positive control sample (expected size 32 kDa) and 22RV1 
cells transfected with pcDNA3.1(+) and pcDNA-CNR1flag. No protein was 
detected in pcDNA3.1(+) and pcDNA-CNR1flag transfected 22RV1 cells. β-
actin was used as a loading control with an expected size of 43 kDa.  
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6.3.1.4 CNR1 transient over-expression using Nucleofector 
technology 
I tried to increase the transfection efficiency, in case the lack of over-expression 
of CNR1 was due to a low transfection efficiency, by using the nucleofector 
transfection method, which has been demonstrated to increase the transfection 
rate in various types of cells. Using 4 μg of Amaxa's pmaxGFP control vector 
with the built-in programme, A-020, it was found to result in an approximate 
100% transfection efficiency in 22RV1 cells at 48 h after transfection, as 
observed using a fluorescence microscope. However, using pcDNA-GFP 
under the same conditions, transfection efficiency reached only approximately 
30-40%. This result suggested that the vector itself could affect gene expression 
efficiency dramatically. 
 
In order to achieve a better transfection efficiency in the 22RV1 cells, the open 
reading frame sequence of CNR1 with a Kozak sequence was inserted between 
KpnI and SacI of the pmaxCloning MCS, which was the same site as the GFP 
sequence in the pmaxCloning vector (pmaxGFP) (details described in 2.8.2.2). 
This plasmid was named pmaxCNR1. The pmaxCNR1 plasmid was transfected 
into 22RV1 cells using the optimised conditions illustrated above. The RNA and 
protein expression of CNR1 was examined at 24 h and 48 h respectively after 
transfection. Similarly to previous observations, CNR1 was over-expressed at the 
RNA level in pmaxCNR1 transfected 22RV1 cells compared with pmaxCloning 
transfected cells (Figure 6.4). However, at the protein level, no difference in the 
intensity of the band (between 52 kDa and 72 kDa) was shown between 
pmaxCNR1 and pmaxCloning transfected 22RV1 cells using Western blot 
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analysis (Figure 6.5). Whether it was caused by the possibility that 22RV1 cells 
lost the ability to translate the CNR1 mRNA to a protein, or it was due to the 
ineffectiveness of the CNR1 antibody for Western blot analysis, still needs to be 
clarified.  
 
 
 
 
 
 
 
 
 
 
Figure 6.4 CNR1 expression in transient transfected 22RV1 cells measured 
by semi-quantitative RT-PCR analysis 
Semi-quantitative RT-PCR analysis was performed to examine the CNR1 and β-
actin (as a loading control) expression in pmaxCNR1 and pmaxCloning 
transfected 22RV1 cells respectively. CNR1 and β-actin expression in each of the 
transfected 22RV1 cells were measured in duplicate. Invitrogen 1 Kb Plus DNA 
ladder was used. All of the PCR products were run on a 1.5% agarose gel. 
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Figure 6.5 Protein expression of CNR1 in transiently transfected 22RV1 
cells, examined by Western blot analysis 
Using the CNR1 antibody (Abcam, 1:200 dilution), CNR1 expression was 
examined in 22RV1 cells transfected with pmaxCloning and pmaxCNR1. β-actin 
was used as a loading control with an expected size of 43 kDa. 
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6.3.1.5 CNR1 transient over-expression in 293 cells 
In order to reveal whether the lack of detection of the CNR1 protein over-
expression was associated only with the 22RV1 cell line, HEK293 cells were 
used as a control to demonstrate if CNR1 can be over-expressed. HEK293 cells 
are well known for being easy to transfect and have been used widely to express 
various exogenous genes. Several studies have reported the stable over-
expression of CNR1 in HEK293 cells. Moreover, HEK293 cells were used 
routinely in our laboratory as a model to study the function of various genes, so 
the transfection conditions have been optimised. Using the Effectene transfection 
reagent, a transfection efficiency of approximately 50% can be achieved. 
 
In addition, two commercial plasmids were purchased in case the Flag tag at the 
C-terminal of CNR1 affected the translation or reduced the stability of the CNR1 
protein. One of the plasmids, named pcDNA-CNR1, only contains the CNR1 
open reading frame sequence. The other plasmid, named pcDNA-3HA_CNR1, 
had three HA-tags at the N-terminal of CNR1.  
 
The plasmids, pcDNA3.1(+), pcDNA-CNR1, pcDNA-3HA_CNR1 and 
pmaxCNR1 were transfected into HEK293 cells respectively using the Effectene 
reagent (details in 2.8.1.1.2). The RNA and protein expression of CNR1 was 
examined at 24 h and 48 h respectively after transfection. Again, the over 
expression of CNR1 was detected at the RNA level but not at the protein level. 
Using a CNR1 antibody from Abcam, no difference in the intensity of the bands 
(between 52 kDa and 72 kDa) was detected between CNR1 over-expressed and 
control 293 cells using Western blot analysis (Figure 6.6). Using an anti-HA 
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antibody, no band was detected in pcDNA-3HA_CNR1 transfected 293 cells. 
Accordingly, the non-detection of CNR1 expression at the protein level was not 
associated with cell type. It was considered that these inconclusive results most 
probably were caused by the ineffectiveness of the CNR1 antibody for Western 
blot analysis. As for the non-detection of HA-tag, it may have been caused by 
protein instability, which is due to the extra tag sequence at the N-terminal of 
CNR1.  
 
 
 
 
 
 
 
 
Figure 6.6 Protein expression of CNR1 in transiently transfected 293 cells 
examined by Western blot analysis 
Using a CNR1 antibody (Abcam, 1:200 dilution), CNR1 expression was 
examined in 293 cells transfected with pcDNA3.1(+) (lane 1), pcDNA-CNR1 
(lane 2), pcDNA-3HA_CNR1 (lane 3) and pmaxCNR1 (lane 4), respectively. β-
actin was used as a loading control with an expected size of 43 kDa. 
 
6.3.1.6 Functional study of CNR1 in transiently over-expressed 
22RV1 cells 
Although the detection of the CNR1 protein did not prove possible, I considered 
its expression might still be increased without being detected using the currently 
   
 238 
available approach. If CNR1 expression was increased, it should have played a 
role in 22RV1 cells. Therefore I took a further step to examine the function of 
CNR1 in transiently transfected 22RV1 cells. It was demonstrated previously that 
the transfection efficiency of the chemical reagent Lipofectamine™ 2000 
achieved 40-50% in 22RV1 cells whereas the Nucleofection method reached 
approximate 100% transfection efficiency in 22RV1 cells. Although chemical 
reagent transfection was less efficient than the Nucleofection method, 40-50% 
transfection efficiency should be sufficient to generate distinguishable cellular 
functional changes (if CNR1 indeed was over-expressed) compared with the 
vector alone in transfected cells. Therefore 22RV1 cells were transfected with 
pcDNA-CNR1 and pcDNA3.1 using the Lipofectamine™ 2000 reagent and also 
transfected with pmaxCNR1 and pmaxCloning using the Nucleofection method 
to examine the functional effects of transiently over-expressing CNR1 in 22RV1 
cells. 
 
I first examined the effects of exogenous CNR1 on 22RV1 cell viability using an 
MTS assay. Results from both transfection methods showed no difference in the 
cell viability of 22RV1 cells (Figure 6.7). Next I studied the effect of CNR1 on 
the cell proliferation of 22RV1 cells using a colony formation assay. The results 
from both transfection methods showed fewer colonies formed in CNR1 
putatively over-expressing 22RV1 cells (Figure 6.8). I further analysed whether 
CNR1 has any effect on the invasion of 22RV1 cells. The results from both 
transfection methods showed that exogenous CNR1 led to a decreased number of 
invading cells (Figure 6.9). 
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Figure 6.7 Over-expression of CNR1 in transiently transfected 22RV1 cells 
does not affect cell viability as assessed by a MTS assay. 
(A) Transiently transfected 22RV1 cells with pcDNA3.1 (control) and pcDNA-
CNR1 were seeded respectively onto a 96-well plate at 5000 cells/well. The 
MTS assay was applied every 24 h for 5 days. (B) Transiently transfected 22RV1 
cells with pmaxCloning (control) and pmaxCNR1 were seeded onto 96-well 
plate at 5000 cells/well. The MTS assay was applied every 24 h for 5 days No 
significant difference was noted between the CNR1 over-expressing 22RV1 cells 
and control cells. 
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Figure 6.8 The effect of CNR1 on cell proliferation examined by colony 
formation assay 
(A) and (B) Representative images showing colonies formed from transiently 
transfected 22RV1 cells with pcDNA3.1(+), pcDNA-CNR1, pmaxCloning, 
pmaxCNR1, respectively. (C) and (D) Bar charts show the area covered by 
colonies measured using ImageJ software (details in 2.10.2). The colony area is 
smaller in pcDNA-CNR1 transiently transfected 22RV1 cells compared with 
pcDNA3.1(+) transfected cells (C). The colony area is smaller in pmaxCNR1 
transiently transfected 22RV1 cells compared with pmaxCloning transfected 
22RV1 cells (D). The graph represents an average of three replicates  standard 
error.  
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Figure 6.9 The effect of CNR1 on cell invasion in transiently transfected 
22RV1 cells examined by Matrigel invasion assay. 
Bar charts show the percentage of invading cells through the Matrigel-coated 
transwell chambers measured after 48 h. Results are represented normalised to 
control. (A) Mean value of three replicates of invading cells from pcDNA3.1(+)  
and pcDNA-CNR1 transfected 22RV1 cells. (B) Mean value of three replicates 
of invading cells from pmaxCloning and pmaxCNR1 transfected 22RV1 cells. 
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6.3.2 CNR1 stable over-expression in 22RV1 cells 
6.3.2.1 CNR1 over-expression confirmation  
As CNR1 has been stably over-expressed in HEK293 cells, but its protein level 
expression cannot be detected in my transient transfected cells, a 22RV1 cell line 
with stably over-expressed CNR1 was deemed necessary to be established in 
order to demonstrate over-expression of CNR1 at the protein level and also to 
further perform cellular functional studies. Four plasmids, pcDNA3.1, pcDNA-
CNR1, pcDNA-CNR1flag and pcDNA-3HA_CNR1, were transfected into 
22RV1 cells respectively and clones with exogenous CNR1 expressed were 
selected using geneticin according to the details described in 2.8.1.3. The 
plasmid pmaxCNR1 could not be used for establishing stable transfected cells as 
the vector itself does not contain the neomycin resistance gene for the selection 
of stable cells. Three stable cell lines with over-expression of CNR1, CNR1flag 
and 3HA_CNR1 respectively and one control stable cell line with pcDNA3.1 
vector were generated after approximately six weeks selection. No obvious 
morphological or proliferative changes were observed in the resistant cells. The 
RNA expression was examined using SYBR-Green qRT-PCR analysis to 
measure the precise fold change of CNR1 expression (details in 2.5.6.2.2). It 
showed that CNR1 expression was 6904, 3381, 2380 fold higher in CNR1, 
3HA_CNR1 and CNR1flag over-expressed 22RV1 cells, respectively, as 
compared with the control cell line (Figure 6.10).  
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Figure 6.10 Over-expression CNR1 at the RNA level in stably transfected 
22RV1 cells using SYBR green qRT-PCR analysis.  
The expression of CNR1 RNA levels in stably transfected 22RV1 cells with 
pcDNA-CNR1, pcDNA-3HA-CNR1 and pcDNA-CNRflag, were measured by 
SYBR green qRT-PCR respectively relative to the expression of the 
housekeeping gene β-actin and normalised to the pcDNA3.1(+) transfected 
22RV1 cells as a control.  
 
 
 
 
 
 
The over-expression of CNR1 was then examined using Western blot analysis. 
As previously observed in the transiently transfected cells, using CNR1 antibody, 
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no difference in intensity of the band (between 52 kDa and 72 kDa) was shown 
between CNR1 over-expressing and control cells (Figure 6.11). 
 
 
 
 
 
 
 
 
Figure 6.11 Protein expression of CNR1 in stably transfected 22RV1 cells 
examined by Western blot analysis 
Using CNR1 antibody (Abcam, 1:200 dilution), CNR1 expression was examined 
in 22RV1 cells transfected with pcDNA3.1(+) (lane 1), pcDNA-CNR1 (lane 2), 
pcDNA-3HA_CNR1 (lane 3) and pcDNA-CNR1flag (lane 4), respectively. β-
actin was used as a loading control with expected size at 43 kDa. 
 
Because CNR1 over-expression could not be demonstrated by Western blot 
analysis, I performed IHC analysis to detect CNR1 protein expression. The CNR1 
expression was demonstrated previously in clinical BPH and prostate cancer 
samples (Chapter 5). Therefore, I speculated that the CNR1 antibody might not 
be good for Western blot analysis but that it would be fine for IHC or other 
analysis methods.  
 
Cells from four stable cell lines were paraffin embedded and IHC analysis with 
CNR1 antibody from Abcam was performed to examine CNR1 expression at the 
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protein level (details in 2.7.2). The CNR1 was shown to be over-expressed in 
pcDNA-CNR1 transfected 22RV1 cells, with the staining intensity and number 
of stained cells being substantially higher in pcDNA-CNR1 transfected 22RV1 
cells as compared with control cells (Figure 6.12). In contrast, CNR1 was not 
shown to be over-expressed in pcDNA-CNR1flag and pcDNA-3HA_CNR1 
transfected cells, although these two cell lines had 2380 and 3381 fold over-
expression of CNR1 at the RNA level respectively.  
 
In order to determine the specificity of the CNR1 antibody for IHC analysis, 
siRNA was used to knock down CNR1 expression in the stably transfected 
22RV1 cells. CNR1-targeting siRNA and non-targeting siRNA were transfected 
respectively into pcDNA-CNR1 transfected stable 22RV1 cells (details described 
in 2.8.2). Protein expression of CNR1 was examined using IHC analysis at 96 h 
of siRNA transfection. It showed that CNR1 protein expression was down-
regulated in CNR1-targeting siRNA transfected 22RV1 cells as compared with 
non-targeting siRNA transfected cells ( 
Figure 6.13). 
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(A) pcDNA3.1 
 
 
 
 
  
  
 
 
(B) pcDNA-CNR1 
 
Figure 6.12 CNR1 expression in stably transfected 22RV1 cells using IHC 
analysis 
(A) IHC analysis of CNR1 expression in stably transfected 22RV1 cells with 
pcDNA3.1; (B) IHC analysis of CNR1 expression in stably transfected 22RV1 
cells with pcDNA-CNR1. 
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(A) Non-targeting siRNA 
 
 
 
 
 
 
 
(B) CNR1-targeting siRNA 
 
Figure 6.13 CNR1 expression in siRNA knock down 22RV1 cells using IHC 
analysis 
The siRNA knock down analysis was applied to stably transfected 22RV1 cells 
with pcDNA-CNR1. (A) CNR1 expression in the 22RV1 cells transiently 
transfected with non-targeting siRNA; (B) CNR1 expression in the 22RV1 cells 
transiently transfected with CNR1-targeting siRNA. 
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6.4 Discussion 
In order to over-express CNR1 in 22RV1 cells efficiently, chemical transfection 
reagents, including JetPEI-RGD and Lipofectamine 2000, and Nucleofector 
Technology were applied in this study. Using the JetPEI-RGD reagent, less than 
5% of 22RV1 cells were observed to express GFP after 48h transfection with 
pcDNA-GFP, which was not as expected. As 40-50% of transfection efficiency 
was achieved using Lipofectamine 2000 in 22RV1 cells, I used the latter rather 
than spending time trouble shooting the JetPEI-RGD. 
 
Nucleofector Technology (Necleofection) was invented by the biotechnology 
company Amaxa. Compared with other commonly used non-viral transfection 
methods, which rely on cell division for the transfer of DNA into the nucleus, 
Nucleofection is a physical method of electroporation to transfer substrates 
directly into the cell nucleus and the cytoplasm. Therefore it has been applied to 
transfer substrates into mammalian cells so far considered difficult, or even 
impossible, to transfect. In this study, almost 100% of pmaxGFP transfected 
22RV1 cells were detected with GFP expression after 48 h of transfection, 
suggesting that Nucleofection potentially is the best technology so far for 
plasmid transfer in prostate cancer cell lines. It was also noticed that, under the 
same transfection conditions, pcDNA-GFP only achieved 30-40% transfection 
efficiency, indicating that the vector itself could dramatically affect gene 
expression efficiency. One major difference between pmaxCloning vector 
(backbone of pmaxGFP) and pcDNA3.1 is that there is a 137 bp chimeric intron 
sequence before the multiple cloning sites (MCS) in pmaxCloning vector to 
enhance gene expression. There were potentially other ‗tricks‘ in the vector to 
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make such a dramatic difference, but the precise information on plasmid 
structure as a ‗commercial secret‘ was not available.  
 
Detection of CNR1 protein using Western blot analysis failed using anti-CNR1, 
anti-flag and anti-HA antibodies in this study. The reason for the failed detection 
using the CNR1 antibody proved to be due to the inefficiency of the antibody for 
Western blot analysis, although it worked very well for IHC analysis. The 
specificity of this antibody for IHC analysis was also confirmed using siRNA 
knockdown analysis in this study. The possible explanation for the failed 
Western blot analysis is that the protein conformation might change during the 
sample denaturation, and this might affect the antibody recognition of the 
epitope. As to the failure of Western blot analysis for CNR1flag detection using 
anti-flag antibody, the tag sequence at the C-terminal of CNR1 might affect 
CNR1 protein stability. This possibility was supported by the fact that CNR1 was 
over-expressed 2380 fold higher at the RNA level in pcDNA-CNR1flag stably 
transfected 22RV1 cells compared with the control cells, whereas no increased 
protein level was detected. Similarly, using anti-HA antibody, no protein was 
detected using Western blot analysis and no increased protein expression was 
observed using IHC analysis, although CNR1 was over-expressed 3381 fold 
higher at the RNA level in pcDNA-3HA_CNR1 stably transfected 22RV1 cells 
compared with the control cells. It is possible that the HA tag at the N-terminal 
of CNR1 also caused the CNR1 protein instability.  
 
As mentioned previously a recent study examined a series of commercial CNR1 
antibodies and demonstrated that most of the antibodies were not specific for 
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either IHC or Western blot analysis. In accordance with my study, even though 
the CNR1 antibody was demonstrated to be specific for IHC analysis, it proved 
to be very difficult to be applied for Western blot analysis. Therefore, a concern 
regarding the reliability of previously reported studies of CNR1 in prostate 
cancer was generated. Several studies have shown that the CNR1 was highly 
expressed in prostate cancer cell lines, including LNCaP, PC3 and DU145, using 
IHC or Western blot analysis (Ruiz-Llorente et al., 2003; Sarfaraz et al., 2005; 
Czifra et al., 2009). According to our qRT-PCR and IHC analysis in prostate 
cancer cell lines, none of them showed high expression but, rather, they all 
exhibited very low or non-detectable levels of the CNR1 expression. Although it 
is possible that the differences generated between the studies were caused by 
different cell lineages or distinct cell culture conditions, such as different media 
or serum used, the misrecognition of a nonspecific band at the expected size of 
the CNR1 protein might well have been the main reason for these conflicting 
results. 
 
The majority of reported studies regarding CNR1 have supplied only indirect 
evidence of the relationship between CNR1 and cancer. The ligands of CNR1, 
such as endocannabinoids and CNR1 agonists, have been demonstrated to have 
anti-tumourigenic effects through activation of CNR1 in various cancers 
(Freimuth et al., 2010). In prostate cancer, the treatment with cannabinoid 
receptor agonists, including R(+)-Methanandamide (MET) and WIN-55,212-2, 
resulted in inhibition of cell growth in LNCaP and PC3 cells through inhibition 
of AKT and activation of ERK (Olea-Herrero et al., 2009; Sarfaraz et al., 2006; 
Sanchez et al., 2003; Sarfaraz et al., 2005). The treatment of cannabinoid 
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receptor agonists consistently was reported to inhibit cell growth in breast 
cancer, melanoma and colorectal cancer cells (Qamri et al., 2009; Blazquez et 
al., 2006; Laezza et al., 2010; Patsos et al., 2010). Different methods have been 
applied to examine the cell growth, including MTT, MTS, [
3
H]-thymidine 
incorporation assays for cell viability, cell counting, colony formation and cell 
cycle assays for cell proliferation (Takeda et al., 2008; Olea-Herrero et al., 2009; 
Santoro et al., 2009). In this study, the effect of over-expression of CNR1 on cell 
viability was examined in transiently transfected 22RV1 cells using the MTS 
assay. There was no significant difference between CNR1 over-expressing and 
control cells. However the colony formation assay did show that over-expression 
of CNR1 inhibited cell proliferation in transiently transfected 22RV1 cells. 
 
Apart from the inhibition of cell growth, the ligand of CNR1, endogenous 2-
arachidonoylglycerol (2-AG), has also been reported to inhibit invasion of 
prostate cancer cells. Similar effects, generated by cannabinoid through 
activating the CNR1, have also been identified in gastric, cervical and lung 
cancer cells (Ramer and Hinz, 2008; Ramer et al., 2010; Xian et al., 2010). In 
addition, up-regulation of tissue inhibitor of matrix metalloproteinase-1 (TIMP-
1) was suggested to mediate the anti-invasive effect of cannabinoids (Ramer and 
Hinz, 2008; Ramer et al., 2010). In this study, impaired invasion was observed in 
22RV1 cells with transient over-expression of the CNR1 gene. However, due to 
time limitations, inhibition of proliferation and invasive activity of CNR1 has not 
been confirmed in stably transfected 22RV1 cells. Had I had more time available 
I would have gone on to conduct the experiments. 
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In conclusion, the accurate examination of CNR1 expression at the protein level 
can be achieved by IHC analysis but not the Western blot analysis using the 
CNR1 antibody (Abcam). Transient over-expression of CNR1 in the prostate 
cancer cell line, 22RV1, was shown to have an anti-invasive effect. Further study 
is needed to confirm the anti-invasive effect of CNR1 and also to identify the 
underlying molecular mechanism.  
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7 FINAL DISCUSSION AND FUTURE 
PLANS 
7.1 Micro-deletions with unbalanced chromosomal 
translocation  
Since the identification of highly recurrent fusion genes in prostate and lung 
cancer, gene fusions have been recognised as a common event in almost all types 
of cancers, including haematological malignancies, sarcomas and carcinomas. In 
haematological malignancies, fusion genes mainly were caused by chromosomal 
translocations through juxtaposing promoter/enhancer elements from one gene 
with the intact coding region of another gene, or recombining the coding regions 
of two different genes. Due to the low resolution of banding technology, many 
translocations were originally recognised as balanced chromosomal 
rearrangements. Whereas with the development of molecular cytogentic 
technology and microarray technology, sub-microscopic deletions, which are 
associated with cytogenetically balanced translocations, were detected (Mao et 
al., 2008; Watson et al., 2007). In a wide range of leukaemias, including CML, 
AML and ALL, these microdeletions coupled with chromosomal translocations 
are associated with poor prognosis (Kolomietz et al., 2001).  
 
In prostate cancer, the most common gene fusion is TMPRSS2-ERG, present in 
50-80% of the cancer patients. This gene fusion falls into the category that an 
oncogene is fused with promoter elements of another gene: ERG belongs to the 
ETS oncogene family and the promoter of TMPRSS22 is androgen regulated. 
TMPRSS2-ERG fusion can be caused either by intrachromosomal deletion or 
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inversion, as the two genes are about 3 Mb apart on chromosome 21. It has been 
shown that TMPRSS2-ERG fusions generated by intrachromosomal deletions 
tend to correspond with worse prognosis than those created by inversions, 
suggesting tumour suppressor gene(s) might locate in the deletion region (Attard 
et al., 2008). 
 
Our group has a long-standing interest in identifying chromosomal translocation 
and fusion genes in prostate cancer. In 2007, we reported a recurrent 
chromosomal translocation, t(4;6), in prostate cancer cell lines and a small set of 
primary prostate tumours  (Lane et al., 2007). The breakpoints of the 
translocation were identified to locate at 4q22 and 6q15 in the LNCaP cell line. 
In addition, micro-deletions were identified adjacent to both of the breakpoints. 
The only gene disrupted by the breakpoints was UNC5C, a putative tumour 
suppressor gene, which lost its promoter and the first exon (Lane et al., 2007). In 
this study, using probes located on distal 4q22 and proximal 6q15, I performed 
FISH signal co-localisation analysis in a large series of clinical localised prostate 
cancer samples to examine the prevalence and clinical significance of 
t(4;6)(q22;q15). It was shown that the t(4;6)(q22;q15) presents in 78 of 667 cases 
(11.7%). The t(4;6)(q22;q15) was not independently associated with patient 
outcome, however it occurs more frequently in high clinical T stage, high tumour 
volume specimens and in those with high baseline PSA (P=0.001, 0.001 and 0.01 
respectively). Accordingly, we demonstrated that t(4;6)(q22;q15) is a frequent 
event in prostate cancer. However, as the recurrent chromosomal rearrangements 
previously identified mainly lead to gain of functions of genes located at the 
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breakpoints (Mitelman et al., 2007), the mechanism of action of the 
t(4;6)(q22;q15) translocation was not clear.  
 
The putative tumour suppressor gene UNC5C was shown to be disrupted by the 
distal breakpoint of the translocation on 4q22 in LNCaP cells. At the genomic 
level, UNC5C lost its promoter and the first exon; at the transcriptional level, the 
expression of UNC5C was not detected by RT-PCR analysis in our previous 
study; In addition, no fusion transcripts involving UNC5C or corresponding to 
this chromosomal rearrangement have been identified in this cell line by deep 
sequencing using the next generation sequencing technology (Maher et al., 
2009). Therefore, t(4;6)(q22;q15) might cause the inactivation of UNC5C. 
Moreover, micro-deletions on 4q22 and 6q15 were also identified to be 
associated with t(4;6)(q22;q15) in LNCaP cells. 4q and 6q are among the most 
frequently deleted chromosome regions in human tumours. 6q15, particularly, is 
one of the most frequently deleted regions in prostate cancer, indicating that 
tumour suppressor gene(s) might locate in this region. Therefore, we 
hypothesised that the t(4;6)(q22;q15) may contribute to prostate cancer 
development through inactivation of tumour suppressor genes at the breakpoint 
or/and micro-deletion region rather than gain of function by forming fusion 
genes. As illustrated above, microdeletions coupled with chromosomal 
translocations have been identified in leukaemias and prostate cancer associated 
with poor prognosis, indicating that any tumour suppressor gene(s) are located in 
the deletion region. Tumour suppressor genes inactivated through disruption of 
translocation/deletion breakpoints have been well demonstrated in breast cancer 
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(Howarth et al., 2008; Huang et al., 2004). For example, translocation/deletion 
breakpoints in neuregulin 1 (NRG1) are present in at least 6% of breast cancers 
(Huang et al., 2004). Cell lines with breakpoints in the NRG1 gene express less 
NRG1 transcript than normal breast epithelial cells, and most breast cancer cell 
lines express none at all, often as a result of promoter methylation (Chua et al., 
2009). Now it is believed that NRG1 is a tumour suppressor gene on 8p and that 
the breaks within the gene are one of several ways of reducing its activity (Chua 
et al., 2009; Pole et al., 2006). 
7.2 Identification of tumour suppressor genes in 
prostate cancer  
Deletion is one of the most frequent genetic alterations detected in cancer cells. 
Non-random deletions detected in certain regions have been widely interrogated 
to identify tumour suppressor genes. In prostate cancer, most commonly deleted 
regions were summarised in 1.6.3.1. Recently, an integrated oncogenomic 
analysis was applied on 218 primary and metastatic prostate cancer cases as well 
as 12 cell lines and xenografts. The assessment of DNA copy number changes in 
these samples confirmed the frequent deletion in 6q15 in prostate cancer (Taylor 
et al., 2010). However, the tumour suppressor gene(s) in this region has not been 
identified.  
 
In this study, we combined different approaches to identify candidate tumour 
suppressor genes in 6q15. Using high resolution SNP array analysis, two 
minimum overlapping deletion regions within 87.21-90.35 Mbp and 90.88-91.35 
Mbp in 6q15 were detected in 33 and 34 out of 71 clinical prostate cancer 
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samples, respectively. In order to examine systematically the expression 
alterations of all the genes located in these two regions, we applied Exon array 
analysis to six prostate cancer cell lines and one clinical prostate cancer sample. 
Use of cell lines has been questioned, because the process of immortalisation in 
vitro could generate artificial events when compared to native tissue (Dairkee et 
al., 2004). A solution is to use cell lines for their purity and convenience, and at 
the same time, include primary prostate cancer samples to exclude the artefacts. 
The difficulties in obtaining pure prostate cancer cells and also extracting good 
quality RNA from those cancer cells hampered the number of primary samples 
applied for Exon array analysis. First, the instability of RNA requires the cancer 
tissue to be fresh frozen immediately after being removed from the patients; 
second, micro-dissection is needed to obtain pure malignant epithelial cells. 
Micro-dissection is a time consuming process and the degradation of RNA 
during the dissection is inevitable. In addition, the quantity of RNA is not 
guaranteed from the limited amount of dissected cancer cells available. 
Therefore, only one primary prostate cancer sample with more than 70% purity 
of cancer cells was included in the Exon array analysis. We decided to identify 
commonly down-regulated genes at 6q15 in prostate cancer cell lines and one 
clinical cancer sample; and then confirm the features in enlarged clinical prostate 
cancer samples. Four genes, CNR1, PNRC1, GJA10 and BACH2, were identified 
with common down-regulation located at 6q15. Using qRT-PCR analysis, CNR1 
and BACH2 were still shown to exhibit down-regulated expression in the 
enlarged cancer samples, which were macro-dissected with relatively pure 
populations of cancer cells.  
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Whether protein expression of these two genes are correlated with RNA 
expression was examined further in FFPE prostate cancer samples using IHC 
analysis. CNR1 was still shown to exhibit down-regulated protein expression in 
prostate cancer cases as compared with BPH or adjacent normal tissue. In 
contrast, BACH2 protein was shown to have an altered cellular localisation in 
prostate cancer samples compared with BPH controls. Cytoplasmic localisation 
of BACH2 was detected in the majority of BPH samples (89.7%), whereas 
nuclear localisation of BACH2 was shown in 45.3% of prostate cancer cases. It 
has been shown that nuclear accumulation of BACH2 in B-cells was caused by 
oxidative stress and associated with induction of apoptosis (Kamio et al., 2003; 
Yoshida et al., 2007). However, increased nuclear expression of BACH2 in 
ovarian cancer has been associated with decreased time to disease recurrence 
(Motamed-Khorasani et al., 2007). The full significance of altered BACH2 
expression still is unknown. Further analysis of BACH2 isoform expression and 
potential cytoplasmic function in prostate cells is needed. 
 
As down-regulated expression of CNR1 at the RNA and protein level was 
consistent with the identification of frequent genomic deletions in 6q15, we 
wondered if other mechanisms, such as mutation or methylation, also play a role 
in the inactivation of CNR1. Random sequencing of five prostate cancer cases, 
which did not express CNR1, revealed a homozygous deletion inside the CNR1 
genome in one of the five samples. Therefore it is considered this is an 
encouraging finding for examining more cancer samples to identify if there are 
other mutations present and also to investigate the prevalence of these mutations 
in a wider series of cases. Methylation analysis showed that, in some prostate 
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cancer samples, CNR1 promoter methylation occurred in a higher percentage of 
cells (> 10%) compared with the methylation in the average percentage of cells 
(2.66%) in ten BPH samples. However, there was no significant difference 
between BPH and all of the cancer samples (p= 0.319). It is possible that DNA 
methylation might only account for the CNR1 inactivation in some of the 
prostate cancer samples; or, since only very short (24 bp) of the promoter region 
(1027 bp) was analysed, the methylation status of other promoter regions, which 
are unknown, might be important. It is plausible to investigate the other promoter 
regions to finally draw a conclusion regarding the frequency of CNR1 
mehtylation in prostate cancer. 
 
From genomic study to transcript and protein expression analysis, CNR1 was 
shown as a potential tumour suppressor gene in 6q15. In order to confirm and 
clarify its tumour suppressor role, CNR1 was further studied at the cellular level. 
As RNA expression of CNR1 was very low in prostate cancer cell lines and 
immortalised prostate epithelial cells, the siRNA knock down analysis was not 
considered suitable for studying CNR1 in prostate cancer cells. Therefore 
transient/stable over-expression of CNR1 was the only approach to investigate its 
cellular function.  
 
We are now in the stage that I have obtained stably transfected 22RV1 cells with 
over-expression of CNR1. The MTS analysis demonstrated that CNR1 over-
expression does not affect cell proliferation in transiently and stably transfected 
22RV1 cells. Using Matrigel invasion assay, over-expression of CNR1 was 
shown to decrease cell invasion in transiently transfected 22RV1. However, it 
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needs to be further confirmed in the stably transfected cells and this is the type of 
additional study I would conduct if I had more time available.  
7.3 Future plans 
7.3.1 CNR1 protein expression and clinical significance of 
CNR1 inactivation in prostate cancer  
In this study, different approaches were combined to identify candidate tumour 
suppressor genes in the 6q15 deletion region. So far, multiple lines of evidence 
indicate that CNR1 might be the target gene. The preliminary IHC analysis on 
two prostate cancer TMAs showed that protein expression of CNR1 was down 
regulated in cancer samples. In the next step, I will continue to perform IHC 
analysis on other batches of TMAs (details in 2.1.1) to further confirm the altered 
expression of CNR1 in the cancer samples.  
 
Using FISH analysis, I demonstrated a frequent 6q15 deletion (46%) in prostate 
cancer and also correlated the deletion status with the Gleason score. It was 
shown that 6q15 deletion might occur in cases with a high Gleason score, but 
more cases are required to draw a firm conclusion. If the gene CNR1 was the 
target tumour suppressor in 6q15, in theory, the expression of CNR1 should be 
associated with clinical and/or patient outcome. Therefore, the expression status 
of CNR1 obtained from IHC analysis on TMAs will be correlated with clinical 
significance in prostate cancer. 
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7.3.2 CNR1 mutation and methylation 
In this study, a small deletion inside of CNR1 genomic DNA was identified in 
one of the five clinical prostate cancer samples with inactivated protein 
expression of CNR1. Whether there are other mutations in CNR1 genomic DNA, 
and the frequency of the mutations, will be investigated through sequencing of 
the CNR1 coding region in more clinical cancer samples; specifically thoses 
which were shown with down regulated protein expression. In the meanwhile, 
the methylation of CNR1 in prostate cancer will continue to be investigated in 
more regions of the entire promoter sequence.  
7.3.3 Cellular functional study of the gene CNR1 in 22RV1 
cells 
7.3.3.1 Separation of CNR1 expressed and unexpressed cells from 
stably transfected 22RV1 cells 
According to the IHC analysis of stably transfected 22RV1 cells, CNR1 was not 
shown with uniform over-expression in every 22RV1 cell. There were some cells 
with very weak or no expression of CNR1. In order to clearly define the function 
of CNR1 in prostate cancer, first of all, cells with or without CNR1 expression 
will be sorted from stably transfected 22RV1 cells using FACS analysis.  
7.3.3.2 Cellular functional analysis and molecular mechanism 
identification 
A series of functional assays will be applied to investigate the tumour suppressor 
role of CNR1 in prostate cancer. It has been shown in this study that CNR1 over-
expression did not affect cell viability, using the MTS assay. After cells with or 
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without CNR1 expression are sorted, the MTS assay will be repeated to draw a 
final conclusion regarding the role of CNR1 in cell viability. In parallel, Matrigel 
invasion and Transwell migration assays will be applied to examine the role of 
CNR1 in cell invasion and migration; soft agar colony formation assay will be 
performed to investigate the role of CNR1 in cell adhesion, in terms of anchorage 
independent growth. According to the tumour suppressor role of CNR1, which I 
have identified, the corresponding molecular mechanisms regarding the cell 
signalling pathways affected will be investigated. 
7.3.3.3 CNR1 agonist treatment on stably transfected 22RV1 cells  
The majority of reported studies regarding the gene CNR1 have focused on the 
anti-tumour effect of CNR1 agonists and not much attention has been paid to the 
potential tumour suppressing effect of CNR1. Whether CNR1 expression is 
essential for the anti-tumour effects of CNR1 agonists will be examined. 
Different dosages of a CNR1 agonist, (i.e HU210), will be applied to treat 
22RV1 cells with or without CNR1 expression. Ideally, a certain dose of the 
agonist, which has no cell toxicity effect on 22RV1 cells without CNR1 
expression but which induces death of the cells with CNR1 expression, will be 
identified.  
7.3.4 Functional study of CNR1 in vivo  
If cellular function studies in vitro suggest that CNR1 plays a tumour suppressor 
role, further functional study of CNR1 will be performed in vivo. For more 
accurate measurement and stable expression of CNR1, a Tet-Off inducible gene 
expression system will be established, which permits the modulation of gene 
expression both in vitro and in vivo (http://www.clontech.com). First of all, 
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tetracycline transactivator-producing 22RV1 cell line will be established.  Next 
the complete open reading frame of CNR1 will be incorporated into pTet-Off 
vector (named pTet-CNR1) before being transfected in the presence of 
doxycycline into the 22RV1 cells constitutively producing the tetracycline 
transactivator. Finally, cell clones, which show the best tetracycline regulation 
(at least 100-fold difference of CNR1 expression between induced and repressed 
state), will be selected. Using the established inducible gene expression system, 
CNR1 will be expressed in the absence, but not in the presence, of tetracycline or 
its analog doxycycline. For in vivo study, a total of 10
7
 established 22RV1 cells 
would be injected in different sites in nude mice. The tumour formation and size 
will be investigated and compared among nude mice with or without CNR1 
expression.  
7.3.5 Investigation of BACH2 isoforms and the 
corresponding protein localisation  
In this study, BACH2 protein was shown with altered cellular localisation in 
prostate cancer samples compared with BPH controls. It was postulated that the 
different BACH2 isoforms localise to different cellular compartments where they 
may participate in cell processes distinct from transcriptional regulation. In the 
following step, we will apply IHC analysis on prostate cancer cell lines and 
immortalised prostate epithelial cell lines to detect the localisation of BACH2. If 
the different localisation of BACH2 is identified among the cell lines, the mRNA 
splicing isoforms of BACH2 will be investigated and the protein isoforms will be 
examined using Western blot analysis. If the different isoforms of BACH2 
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account for the altered cellular localisation, the function of the different isoforms 
will be further studied.  
7.4 The potential clinical implications of CNR1 in 
prostate cancer 
The initial goal of this project was to investigate the clinical significance of 
t(4;6)(q15;q22) in prostate cancer. Although the result showed that 
t(4;6)(q15;q22) did not correlate with clinical outcome, it might contribute to 
prostate cancer development through inactivation of TSG(s) which are associated 
with the common 6q15 deletion in prostate cancer. Based on the information 
from the literature and my study, CNR1 is likely to be the target gene associated 
with 6q abnormalities in prostate cancer. Although a few steps are required to 
confirm the tumour suppressor role of CNR1, here I would like to postulate the 
potential significance and clinical implications of CNR1 in prostate cancer. 
 
Clinically, there are three major problems in managing prostate cancer. First of 
all, although PSA has been widely used for screening of prostate cancer, more 
specific and sensitive early diagnostic markers are still needed to avoid over-
diagnosis of prostate cancer. Second, as illustrated previously, the clinically 
localised prostate cancers are biologically diverse, ranging from indolent 
tumours to a subset of aggressive tumours with a potential for recurrence and 
metastasis. Prognosis markers that can accurately identify and stratify these 
subsets of clinically localised cancer need to be identified in order to refrain from 
over-treatment of the cancer patients. Third, there is no effective treatment of 
androgen-resistant prostate cancer. Because CNR1 encodes a trans-membrane 
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protein, which is not secreted into human fluids (such as serum and urine) for 
easy collection from the patients, it will not be an ideal marker for early 
diagnosis. However, as 6q deletion is commonly but not universally presented in 
prostate cancer and the expression of CNR1 was frequently down-regulated in 
clinical prostate cancer samples in my study, CNR1 might have a prognostic 
value if it is differentially expressed in indolent and aggressive cancers (van 
Dekken et al., 2004; Ribeiro et al., 2006). The association of CNR1 expression 
with clinical outcome need to be investigated in order to identify whether 
expression status of CNR1 could supplement Gleason score to distinguish 
indolent from clinically aggressive prostate cancer. Moreover, there is a greater 
chance that CNR1 will serve as a therapeutic target. Currently, various CNR1 
agonists have been developed and are commercially available. The ligands of 
CNR1, such as endocannabinoids and CNR1 agonists, have been demonstrated 
by many studies to have an anti-tumourigenic effect, affecting cell growth, 
apoptosis, angiogenesis, migration, invasion, adhesion, and an ability to 
metastasise in various cancers (Freimuth et al., 2010). As my study strongly 
supports the tumour suppressor role of CNR1, clinically approved CNR1 agonists 
could be applied to the cancer patients with down-regulated CNR1 expression. 
For those who carry cancer cells without, or with very low level of, CNR1 
expression, gene therapy might be applied to deliver exogenous CNR1. Other 
approaches, such as targeting the down-stream gene(s) of CNR1-involved 
pathway(s), could also be considered. However, more studies and solid evidence 
are required to prove all above possibilities. 
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